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SUMMARY 
 
Thromboembolic events caused by implanted cardiovascular devices present serious 
challenges to surgeons and researchers alike. In particular bileaflet mechanical heart 
valves are prone to thrombus formation in the hinge region due to a combination of high 
shear stress and stagnation regions. Shear-induced platelet activation and aggregation is 
usually studied using viscometers, parallel plate flow, and other non-physiologic in vitro 
configurations. However, it is desirable to study this phenomenon in a more physiological 
environment. 
The research presented in this thesis addresses the hypothesis that models that isolate 
and mimic bileaflet mechanical heart valve (BMHV) hinge geometries can be used to 
quantitatively characterize procoagulant potential using a novel in vitro blood flow 
system. Furthermore, these results can be correlated with digital particle image 
velocimetry measurements detailing flow fields for the same models. To test this 
hypothesis, sensitive markers of platelet activation and the presence of activated thrombin 
were used to quantitatively measure these endpoints in a novel in vitro flow system 
utilizing the recalcification of citrated blood to enable propagation of the coagulation 
cascade. Simple round and slit orifices were used to model the hinge region and B-datum 
line, respectively, of BMHVs. Channels that approximated the different geometries of 
various BMHV hinge designs were also developed and evaluated in this flow system. As 
a final test, BMHVs were also studied using these same techniques to assess the influence 
on hinge gap width and hinge geometry on platelet activation and procoagulant potential. 
Lastly, the jets originating from these orifices and channels were studied using digital 
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particle image velocimetry (DPIV), and the velocity data were analyzed to determine 
differences in these jets that may increase the propensity for coagulation as a result of 
flow through the different orifices and channels. 
 The significant findings were that: 1) recalcification of recirculating citrated blood 
markedly increases the magnitude of thrombus forming reactions and the sensitivity for 
their detection; 2) a shear-dependent threshold for thrombin generation and coagulation 
exists, suggesting that clotting in a BMHV is most likely due to leakage flow through the 
hinge area and not through the B-datum line; 3) platelet activation, and the presence of 
adequate platelet numbers, may be essential for the activation of coagulation under 
conditions of high shear; and 4) thrombin formation can be inhibited by blocking the 
platelet receptors that facilitate platelet aggregation. 
The results from the DPIV studies give some insight into why the different 
channels resulted in varying propensities for coagulation as measured by TAT 
concentration. The channel geometries that induced significantly higher levels of TAT 
also formed jets that were subject to increased entrainment of the stagnant fluid in the 
chamber. This entrainment resulted in more rapid jet decay for the channel jets with more 
abrupt diameter changes relative to the channel jets with smoother transitions. 
Additionally, entrainment enables more mixing of the shear-activated platelets with the 
surrounding flow, which can propagate the coagulation cascade, thus increasing the 
chance for thrombus formation. The channel geometries that produced these jets that 
were more susceptible to entrainment had abrupt changes in diameter with 90 degree 
angles. Thus, these abrupt changes in diameter engender flow fields that are more 
favorable for propagation of the coagulation cascade. 
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The influence of abrupt changes in diameter was also evident in the human blood 
studies designed to investigate the effect of BMHV hinge geometry. The MP valve, 
which has a tortuous pathway through the hinge channel, induced significantly more TAT 
formation than the SJM Standard valve with a smoother hinge channel. This increased 
coagulation potential for the MP valve was not accompanied by an increase in platelet 
activation relative to the SJM Standard valve. Thus, although platelet activation was 
similar for both of the valves, procoagulant potential was not. This result shows that it is 
not necessarily platelet activation that is important in determining whether or not a valve 
will induce thrombosis in vivo. It is the subsequent flow fields after platelet activation has 
occurred that determine procoagulant potential. Nevertheless this study does show that 
MHV hinge geometry should be as smooth and free of diameter changes as possible to 
eliminate circulation and stagnation regions that enable activated platelets to congregate 
and propagate the coagulation cascade.  
Leakage gap width also had a significant effect not only on procoagulant potential 
but also on platelet activation. Both the low and high leaker prototype valves had 
significantly higher levels of platelet activation compared to the SJM Standard valve, but 
only the low leaker valve demonstrated a higher propensity for coagulation. Since it is 
important to minimize both platelet activation and thromboemboli formation, an optimal 
gap width should be maintained for BMHVs that is similar to that of the SJM Standard 






Heart valve disease is a serious condition caused by congenital defects, rheumatic 
fever, calcification as a consequence of aging, myocardial infarction, and other 
cardiovascular disease. If the disease progression is serious enough, a bio-prosthetic or 
mechanical heart valve (MHV) must be implanted. Worldwide approximately 225,000 
prosthetic heart valves are implanted each year, and about 50% of these are MHVs. 
MHVs are chosen for their durability, but they are prone to complications due to 
thromboembolic events, and recipients must undergo lifelong anticoagulant therapy.  
Studies using laser doppler velocimetry (LDV) have implicated the hinge region of 
MHVs as the key region for thrombosis formation. In this region flow can stagnate, and if 
activated platelets and other thrombus components are not completely washed out, 
thombi can grow to obstruct leaflet movement or embolize, leading to a risk of strokes. 
The mechanism by which MHVs initiate thrombosis are unclear, but it is thought that 
platelets that travel through this high shear stress hinge region become activated by the 
shear and then aggregate in the subsequent low flow regions downstream of the hinge 
region. 
Fluid dynamics methods such as laser Doppler velocimetry (LDV) or digital particle 
image velocimetry (DPIV) used to evaluate MHVs have indicated areas of bileaflet 
mechanical valves and times during the cardiac cycle that are vulnerable to 
thromboemboli formation caused by elevated shear stress. Studies on the St. Jude 
Medical (SJM), Carbomedics, and Medtronic Parallel valves utilizing LDV to investigate 
 2 
the hinge area showed maximum Reynolds stress magnitudes of 7,200, 5510, and 8000 
dynes/cm2, respectively, during the leakage phase. Additionally, leakage flow studies on 
the Medtronic Parallel valve using markers for platelet activation and platelet damage 
showed that platelets were activated and damaged in a time dependent fashion with 
activation and damage increasing with time. Similar studies performed with SJM 
standard prototype valves with higher and lower leakage values than normal and found 
that there were differences in platelet activation, and that the high leaker valve had 
significantly more platelet activation than the standard valve.  
These LDV measurements as well as the platelet activation studies imply that hinge 
geometry and leakage magnitude do have a significant effect on turbulent shear stresses 
and subsequent clot formation. However, there is difficulty in isolating the hinge region 
during blood studies because of the presence of the sewing ring, valve surface, and 
leakage through the periphery of the leaflets. In this study models were developed that 
isolate the hinge area so that hinge geometries can be directly compared without the 
complications introduced by the rest of the MHV.  A novel in vitro flow loop that utilizes 
the recalcification of citrated blood to enable propagation of the coagulation cascade was 
also developed. This system allowed us to quantitatively assess procoagulant potential as 
a result of flow through these model geometries as well as through the bileaflet MHVs. In 
addition, this study correlated differences in the flow fields through these models 
measured using DPIV with propensity for coagulation as a result of flow through these 
different model geometries. 
The results of these studies can be used to focus the efforts of bileaflet mechanical 
heart valve designers on the aspects of valve design that govern flow during the leakage 
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phase of the cardiac cycle. In addition, the novel in vitro flow system and recalcification 
strategy can be used in conjunction with the assays developed to investigate coagulation 
and platelet activation to assess these factors for other types of vascular devices that 
expose the blood to high or variable shear stresses. 
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CHAPTER 2 
BACKGROUND AND LITERATURE REVIEW 
 
2.1. Heart valves 
The function of the heart is to pump blood throughout the body to transport 
oxygen and nutrients to all of the organs and tissues. The right side of the heart pumps 
blood through the lungs to be oxygenated, and the left side pumps the oxygenated blood 
through the body. Each side is divided into two chambers, an atrium and a ventricle, as 
shown in Figure 2.1.1.  
 




Valves separate these chambers from each other and from the exiting vessels to prevent 
backflow of the blood.  
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Blood flows from the vena cavae and the pulmonary vein into the right and left 
atria, respectively. Figure 2.1.2 shows typical pressure and flow waveforms for the aortic 
and mitral valves. Approximately 75% of this blood flows directly into the ventricles 
before atrial contraction, and the subsequent contraction expels the rest of the blood into 
the ventricles. 
 
FIGURE 2.1.2 Typical pressure and flow waveforms and EKG during the cardiac cycle 
(Nichols and O’Rourke). 
 
During ventricular systole the atrio-ventricular (A-V) valves are closed allowing blood to 
accumulate in the atria. When the ventricular pressure falls during diastole these valves 
open causing this accumulated blood to rush into the ventricles. This rapid filling stage 
lasts for the first third of diastole and is followed by a phase characterized by only a small 
amount of blood flow into the ventricles. During the last third of diastole, the atria 
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contract thus forcing the remaining 25% of the blood into the ventricles. Atrial 
contraction is followed by ventricular contraction. Immediately after the onset of 
ventricular contraction, the pressure in the ventricles increases causing the A-V valves to 
close. During this time all of the valves are closed so this is termed the isovolumic 
contraction period. About 0.02 to 0.03 seconds after these valves close, the pressure in 
the left and right ventricles rises to above 80 and 8 mmHg, respectively, and the aortic 
and pulmonary valves open expelling blood into the aorta and pulmonary arteries, 
respectively. About 70% of this ejection occurs during the first third of the period of 
ejection, or period of rapid ejection. The remaining 30% is expelled during the last two-
thirds of ejection, or period of slow ejection. After systole the ventricles relax suddenly 
so that the intraventricular pressures decrease rapidly. The elevated pressure in the large 
arteries pushes blood backwards towards the ventricles resulting in immediate closure of 
the aortic and pulmonary valves. During this time all of the valves are closed so this is 
termed the isovolumic relaxation period. Ventricular relaxation continues for another 
0.03 to 0.06 second, and during this time the intraventricular pressures decrease rapidly 
back to diastolic levels. The A-V valves then open to begin a new cardiac cycle [1].  
Heart function is a delicate balance of contraction, relaxation, filling, and ejection 
with consequent pressure changes that control valve opening and valve closure to monitor 
blood flow. Thus, any malfunction in the muscular or valvular function of the heart can 
have serious implications in overall health. Under normal conditions all of these valves 
open and close passively in response to changes in pressure to prevent backflow of the 
blood from the ventricles to the atria during systole and from the aorta and pulmonary 
arteries into the ventricles during diastole. The A-V valves are connected to papillary 
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muscles located inside the ventricles by the chordae tendinae. These muscles contract 
when the ventricular walls contract to prevent the leaflets from bulging too far backward 
toward the atria during contraction. Chordae tendinae rupture or papillary muscle damage 
can result in valve leakage that can cause severe or even lethal cardiac incapacity. The 
aortic and pulmonary valves function differently with the main difference being the 
instant closure of these valves caused by the high arterial pressures compared to the softer 
closure of the A-V valves. Additionally, because of the smaller openings, the velocity of 
blood ejection through the aortic and pulmonary valves is much greater. The combination 
of the rapid closure and ejection subjects these valves to higher mechanical forces than 
those experienced by the A-V valves [1].  When closed the pulmonary and tricuspid 
valves must withstand a pressure of 30 mmHg [2]. However, the closed aortic valve must 
withstand a pressure of 100 mmHg, and the mitral valve closes against a pressure of up to 
150 mmHg. Thus the left side of the heart is particularly predisposed to heart valve 
disease. 
The aortic valve is composed of three semilunar leaflets contained within a 
connective tissue sleeve. The aortic sinus is located superior to the annulus ring and is 
comprised of three bulges at the root of the aorta that lead to either the left or right 
coronary arteries or to a blind, or empty, sinus. This valve varies in size and also 
translates along the axis of the aorta as the heart contracts and relaxes. The peak velocity 
of flow through the open aortic valve is approximately 1.35 m/s for adults and 1.5 m/s for 
children. The velocity profile at the orifice plane is almost flat with flow skewed slightly 
toward the septal wall [2]. During systole vortices develop in the sinuses behind the 
leaflets that help to close the valve quickly and efficiently [2]. At the end of systole there 
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is a small amount of reverse flow that can be measured with Doppler ultrasound. This 
closing volume has been estimated to be less than 5% of the forward flow.  
 
2.2. Heart valve disease 
 Valvular heart disease is any dysfunction or abnormality of one or more of the 
heart’s four valves. In the United States approximately 5 million people are diagnosed 
with heart valve disease each year. According to the American Heart Association’s 2004 
Heart and Stroke Statistical Update, valvular heart disease is responsible for nearly 
20,000 deaths each year in the United States and is a contributing factor in about 42,000 
deaths [3]. Aortic and Mitral valve dysfunction caused a majority of these deaths with 
63% and 14.5% of the total, respectively. Aortic valve dysfunction usually results from 
valve stenosis in which the valve does not fully open, thus impeding blood flow into the 
aorta. Aortic valve stenosis occurs in approximately 5 out of every 10,000 people. The 
main causes of aortic valve stenosis are age-related calcification, rheumatic fever, 
endocarditis, and congenital heart valve problems. Mitral valve dysfunction can result 
from either valve stenosis or mitral regurgitation in which the valve does not close 
properly, thus allowing blood to leak back into the left atrium during ventricular systole. 
In less severe cases of valve dysfunction, the valve can be repaired, but if the 
stenosis or regurgitation is severe enough the valve must be replaced. Every year 
surgeons perform over 250,000 heart valve operations worldwide. The choices for heart 
valve replacement include bioprosthetic valves made from porcine heart valves, bovine 
pericardial, or human cadaver tissue, mechanical heart valves, polymeric heart valves, 
and in the future tissue-engineered heart valves made from human-derived cells. 
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Mechanical heart valves are currently used in about 55% of all valve replacements with 
bioprosthetic valves making up the rest. Although mechanical heart valves (MHVs) have 
excellent durability, the flow characteristics of the valves subject the blood to high shear 
stresses that may damage blood elements or activate platelets leading to thromboembolic 
complications that can be fatal. Thus, MHV recipients must undergo lifelong 
anticoagulant therapy. Despite the risk of complications from MHVs, there is no doubt 
that their use has and still does improve the lives of many who face valvular disease. 
 
2.3. Prosthetic heart valves 
In October 1952 Dr. Charles Hufnagel implanted the first mechanical heart valve 
in humans to treat aortic valve insufficiency [4]. It was implanted in the descending aorta 
of patients. The design of the valve was a methacrylate ball contained in a methacrylate 
tube. During diastole the ball  is passively positioned at the proximal end of tube 
effectively stopping blood regurgitation. In total over 200 patients received this prosthesis 
with no anticoagulant therapy. These valves were recovered up to 30 years after 
implantation with no obvious wear [4].  
The advent of the heart-lung machine enabled surgeons to perform open-heart 
surgery, and in 1955 the first mechanical heart valve, a ball and cage design, was 
implanted in the aortic position in England by Judson Chesterman [5]. Unfortunately this 
patient survived only 14 hours, and long term survival was not achieved until 1961 when 
Charles Hufnagel implanted ball and cage valves into 8 patients and 6 survived [5]. Also 
during this time some work was being done to design fabric and fabric-coated valves and 
silicone rubber valves, but this work was ultimately unsuccessful [4]. The Harken ball 
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valve and the widely used Starr-Edwards ball valve (Figure 2.3.1a) were both introduced 
in 1960. Both valve designs incorporated a ball of silicone rubber held in place by a cage. 
The Harken valve initially had an additional cage to shield the valve from incursions into 
the aortic wall, but this was proved to be unnecessary and subsequently removed [4]. This 
type of valve functions on the principle that when downstream pressure increases, the ball 
is forced into the valve orifice thus stopping blood flow and preventing regurgitation. The 
cage holds the ball in place during forward flow when the upstream pressure is higher. 
Some innovations were introduced to improve the Starr-Edwards ball valve after 1960, 
but the valve has remained unchanged in the mitral position since 1965 and in the aortic 
position since 1968 [6].  
Improvements to the ball and cage valve were attempted by changing the 
materials and altering the cage design; however, the next big innovation in valve design 
did not occur until the introduction of the tilting disc valve in 1963 by Lillehei, Cruz, and 
Kaster. Although this valve was unsuccessful in making it to the market due to an area of 
stasis between the open disc and the aortic wall it did mark an important turning point in 
valve design [4]. The ball and cage design had good characteristics as far as closing with 
little or no regurgitation, but the forward flow hemodynamics were not optimal. The ball 
was located along the center of the orifice jet during forward flow resulting in increased 
pressure drops and reduced flow efficiency. Also, the cage could become thromobosed 
and eventually occluded. Thus, the tilting disc valve was designed to provide a more 
central flow field and, consequently, better hemodynamics. The valve was designed with 
a disc held in place in a round orifice by struts that restrict its movement. During the 
forward flow phase the disc is tilted like a door so that it juts through the downtsream 
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side of the valve and two asymmetric orifices are created through which blood can flow. 
As the downstream pressure increases, the disc is tilted in the other direction until it is 
flush with the orifice thus stopping the flow.  
Another major contribution to mechanical heart valve construction was provided 
by Jack Bokros in 1969 in the form of a new biologically compatible and highly durable 
material called pyrolite carbon. This coating revolutionized mechanical heart valves 
because it improved both their durability and their biocompatibility. Thus, two successful 
tilting disc valves, the Bjork-Shiley and Lillehei-Kaster valves, introduced in 1969 and 
1970, respectively, were both constructed of this material [4]. The only tilting disc valve 






FIGURE 2.3.1. (a) The Starr-Edwards caged-ball valve, (b) Medtronic-Hall tilting disc 
valve, and (c) St. Jude Medical bileaflet valve 
 
The bileaflet valve was introduced in 1978 with the St. Jude Medical (SJM) valve 
(Figure 2.3.1c) that is still in use today. This design consists of two semicircular, hinged 
occluders, or leaflets, that minimize flow disturbance in open position. The leaflets pivot 
within grooves in the valve orifice housing. The main differences between different 
bileaflet valves are in the valve opening angle and the hinge design. The SJM valve has 
an opening angle of 85° and the CarboMedics (CM) valve, which is also used 
a b c
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extensively, has an opening angle of 78°. Both of these valves have butterfly-shaped 
recesses machined into the housing into which the leaflets are inserted. The Medtronic 
Parallel (MP) valve, which was not successfully introduced into the market due to 
thrombosis in clinical trials, was designed with an opening angle of 90°. However, the 
hinge design resulted in flow fields that lead to thrombosis in these areas.  
 







FIGURE 2.3.2. Hinge geometries and flow pathways for the SJM, CarboMedic, and 
Medtronic Parallel bileaflet MHVs. 
 
 
During the leakage phase of the cardiac cycle, which occurs at the beginning of diastole 
for the aortic valve, some degree of leakage is built into the hinge region of bileaflet 
MHVs to wash out any entrapped blood elements. The geometry of this region has been 
shown to be very instrumental in the occurrence of thromboembolic complications. The 
hinge geometries for these three valves are shown in Figure 2.3.2 as well as the flow 
pathway through the hinge when the valve is closed. The SJM valve has a smooth hinge 
channel with minimal change in diameter while the Carbomedics valve has a somewhat 





a very angular pathway with 90 degree steps leading to several changes in diameter and a 
larger internal diameter. 
 
2.4. Valve-related complications 
Recipients of MHVs are prone to complications including tissue overgrowth, 
thromboembolic complications, hemorrhaging, infection, paravalvular regurgitation, and 
hemolysis. After implantation, the body immediately begins to respond to the MHV. The 
exposure of blood to artificial surfaces initiates a series of events including protein 
adsorption, adhesion and activation of platelets and leukocytes, and the initiation of the 
coagulation cascade [7]. Initially, plasma proteins are adsorbed onto the valve surface and 
the sewing ring. These proteins are thought to mediate the blood interactions with the 
device. Platelets have been shown to attach to MHV’s in studies with the Bjork-Shiley 
valve with the largest percentage on the sewing ring. Thrombus deposition on the sewing 
ring leads to the formation of either avascular fibrous tissue or granulation tissue 
accompanied by capillary growth to form vascular fibrous tissue [8]. Avascular tissue is 
most frequently seen covering the sewing ring while vascular tissue extends into the 
spaces in the sewing ring between the fibers. Eventually an uneven layer of endothelium 
covers parts of the tissue. If this tissue growth is completed satisfactorily a relatively non-
thrombogenic surface is produced. However, in some cases a pathological overgrowth of 
this tissue, or pannus formation, occurs that can impair movement of the valve leaflets 
rendering it non-functional. The exact mechanism of this pathogenesis is uncertain, but it 
does appear to be related to low cardiac output leading to lower levels of shear stress. 
Other potential causes may be sporadic anticoagulant use leading to the buildup of layers 
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of thrombus deposition, overproduction of collagen, or excessive foreign body reaction to 
tissue adjacent to the sewing ring leading to the formation of successive layers of fibrous 
tissue [8]. 
Thrombosis caused by mechanical heart valves can also lead to the formation of 
emboli that detach from the valve or from a larger clot. These emboli can become lodged 
in smaller blood vessels, especially in the brain, causing occlusion of these vessels and 
subsequent strokes or other ischemic events. To prevent these complications implant 
patients undergo lifelong anti-coagulant therapy. However, along with the therapuetic 
benefits of anticoagulants come the risk of hemorrhage. Because anticoagulants affect 
people differently, their outcomes are difficult to predict. The same dosage can affect 
each person differently and the same person differently from day to day. Because of this 
difficulty in determining the optimal anticoagulant dosage, patients must be monitored 
closely to minimize the risk of hemorrhage.  
 
2.5. Bileaflet MHV flow fields 
Bileaflet MHVs tend to have better bulk flow hemodynamics than tilting disc or 
caged ball valves with lower transvalvular pressure drops. Flow profiles for various 
MHVs are shown in Figure 2.5.1. In bileaflet MHVs the leaflets divide the forward flow 
into 3 regions consisting of 2 lateral orifices and a central orifice. The primary 
differences between different bileaflet valve designs exist in the hinge design, opening 
angle and leaflet curvature. Hinge design variations control the opening angle, thus 
influencing local fluid mechanics, washout, and flow patterns in the hinge area. In 
general the three jets formed during forward flow by the lateral and central orifices have 
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similar peak velocities independent of valve design. There is more flow through the 
lateral orifices, and these jets are crescent-shaped in contrast to the planar shape of the 
central jet as seen from the side. The wakes from these jets persist several centimeters 
downstream, but the central jet is encompassed by the lateral jets 2-3 cm downstream. 
 
FIGURE 2.5.1. Flow profiles for various MHVs [9]. 
 
 
Velocity and turbulent shear stress (TSS) profiles for the SJM valve at peak systole are 
shown in Figure 2.5.2 to illustrate the features of these jets [10]. The flow is generally 
well-ordered during the early acceleration phase of the cardiac cycle, but becomes 
turbulent prior to peak systole. Separated regions with flow reversal are observed around 
the perimeter of the housing, and these regions of separation tend to be asymmetric with 
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larger spatial dimensions near the hinge than adjacent to the lateral jets. This asymmetry 
may lead to increased thrombogenicity in the hinge region since asymmetry usually leads 
to flow separation and consequent higher shear stresses. Bileaflet valves typically have 
lower turbulent shear stresses than tilting disc or caged ball valves during forward flow 
with peak aortic values from 1000-1500 dyn/cm2. 
 
FIGURE 2.5.2. (a) Velocity profile on the centerline 13 mm downstream of the SJM 
valve at peak systole; (b) Velocity profile across the centerline 13 mm downstream of the 
SJM valve at peak systole; (c) TSS profile on the centerline 13 mm downstream of the 
SJM valve at peak systole; (d) TSS profile across the centerline 13 mm downstream of 
the SJM valve at peak systole [10]. 
 
However, regurgitant flow through bileaflet MHVs is generally higher than that of other 
valve types with leakage flow occurring mainly through the hinge pivots and around the 
periphery and gap between the leaflets. The major leakage jets have mean velocities of 2-
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3 m/s with turbulent shear stresses (TSS) of over 3000 dyn/cm2. These high TSSs 
coupled with stagnant flow can lead to thrombus formation since the shear stress may 
activate the platelets and the stagnant flow then affords the activated platelets sufficient 
residence time to interact with the necessary proteins to form clots [11]. Previous 
research utilizing LDV has further detailed the flow fields and turbulence characteristics 
of different bileaflet MHVs. Except where noted all studies described below are with the 
valve in the aortic position in physiologic pulsatile flow.  Studies performed using a 27 
mm SJM standard MHV with data collection at locations 8 and 13 mm downstream of 
the valve showed that peak velocities and TSS occurred during peak systole at 6.25 mm 
above centerline corresponding with the lateral jet. These values were 220 cm/s and 2000 
dyn/cm2, respectively. As expected high TSS occurred at locations of high velocity 
gradients and immediately distal to the leaflets. Regions of flow separation were 
observed around the jets adjacent to the flow channel wall resulting in flow separating 
from the orifice ring. This flow separation adjacent to the sewing ring could potentially 
lead to tissue overgrowth or thrombus formation, which has been reported in the 
literature. In addition, the region adjacent to the pivot region could also be vulnerable to 
thrombus formation due to high TSS and flow separation [12]. Studies by Ellis et. al. 
showed similar forward flow hemodynamics for the 17 mm SJM regent valve, which 
differs from the SJM standard in that it has  ‘thumbnail’ regions downstream of the 
hinges that serve to expand the internal orifice. They characterized the central orifice as 
having a parabolic flow profile with the lateral jets having a more plug-like appearance. 
Because these measurements were made closer to the valve, facilitated by optically 
transparent leaflets, flow patterns influenced by the hinge region could be observed. 
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Interestingly, secondary flow patterns within the aortic sinus adjacent to the hinge region 
directed from the central orifice jet outward were downstream of and in the same radial-
circumferential direction as flow in the thumbnail region. This behavior shows that even 
in forward flow the hinge region influences the near-field flow [13].  
In a study comparing the downstream turbulence characteristics of the 25 mm 
SJM standard and CM MHVs, differences between the forward flow profiles and 
resulting Reynolds shear stresses were found. The flow profiles of the lateral jets in the 
SJM valve were parallel to the orifice jet at peak systole due the larger opening angle 
while the flow profile of the CM valve lateral jets were oriented toward the wall. The 
smaller opening angle of the CM valve resulted in a larger wake due to increased 
disturbance from the leaflets intruding upon the flow. There was also less recirculation 
flow at the lateral sides in the CM valve. Additionally, Reynolds normal stresses for the 
CM valve were larger in the central orifice at a maximum value of 1780 dyn/cm2 
compared to the largest Reynolds normal stress for the SJM valve in the lateral orifice of 
1250 dyn/cm2 [14]. The integral, Taylor, and Kolmogorov time and length scales 
corresponding to the largest, intermediate, and smallest eddies created by the flow were 
found to be similar for both valves with the smallest length scale between 20 and 70 μm. 
Based on these calculations, the smallest eddy at 20 μm would potentially damage and/or 
activate RBCs and platelets with diameters of 8 and 4 μm, respectively [14]. Studies 
focusing on the leakage jets that are produced when the valve is closed have shown that 
these jets can reach relatively high velocities and generate sufficient shear stresses to 
damage RBCs and platelets. Ellis et al showed that in the mitral position Reynolds 
stresses can reach levels as high as 3600 dyn/cm2 in both the Medtronic Parallel and SJM 
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standard valves [13] [15]. Steegers et al analyzed the leakage jets of the SJM and CM 
valves immediately proximal to the hinge leakage gaps. They determined the velocities of 
the jets with LDV and pulsed Doppler ultrasound, and used this data combined with a 
mixing length model to estimate the Reynolds shear stresses in the jets. They found 
Reynolds stresses greater than 800 dyn/cm2 [16]. Travis compared the blood damage 
potential of jets derived from forward and leakage flow based on the magnitudes of the 
Reynolds shear stresses and the exposure time of the blood. Theses studies with SJM 
standard, HP, and Regent MHVs indicated that in the aortic position forward flow creates 
higher Reynolds shear stresses and had longer exposure times than leakage flow. 
Exposure time to high Reynolds stresses incurred by the leakage jets reached a maximum 
of 3.7 ms with an average of 2 ms. Reynolds shear stresses in these jets ranged from 24 to 
274 dyn/cm2. However, during forward flow exposure time was as high as 8.9 ms in the 
27 mm SJM standard valve with Reynolds shear stresses reaching 4400 dyn/cm2. 
Kolmogorov scales for forward flow were between 20 and 96 μm and for leakage flow 
were between 36 and 73 μm [17]. Thus, these studies imply that forward flow is more 
damaging to blood elements than leakage flow for bileaflet MHVs in the aortic position. 
Flow through mechanical heart valves has also been investigated using Doppler 
ultrasound both in vitro and in vivo. The most useful application for this technique is to 
assess regurgitation through both faulty native heart valves and MHVs in vivo. This 
technique utilizes the application of conservation of momentum principles in the 
turbulent regurgitant jet to centerline velocity measurements to quantitatively measure the 
regurgitant volume [18]. This method has been verified both in vitro [19] and in vivo in a 
canine model [20]. However, since the jets through bileaflet MHVs are more eccentric in 
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nature and can be very long compared to their width, this technique was modified to 
include these planar jets [21]. Furthermore, the time-varying nature of bileaflet MHV jets 
necessitated the extension of the calculation to total regurgitant volume by including a 
time velocity integral. This technique proved to have good accuracy with both steady and 
pulsatile flow through a bileaflet valve in the mitral position. More recently an in vivo 
ultrasound technique has developed using a pig model with a 29 mm SJM valve 
implanted in the mitral position [22]. This particular ultrasound transducer measured 
regurgitant velocities within 6 mm 2 interrogation areas. The obtained leakage patterns 
agreed well with previously reported in vitro experiments with LDV; however, the 
velocity magnitudes were somewhat higher. Tendencies for Doppler ultrasound to 
measure higher centerline velocities than those measured by LDV have been reported 
[10]. The turbulent shear stresses estimated in this study were over an order of magnitude 
less than those measured previously with LDV and appeared to be particularly dependent 
upon the analysis technique [22]. 
LDV has also been used to look into the hinge regions of valves to discern the 
differences in flow patterns imparted by different hinge geometries. Interest in the hinge 
area began after clinical trials with the Medtronic Parallel (MP) valve showed 
unacceptable numbers of explanted valves with thrombus deposition in the hinge region. 
These results were unexpected since the MP valve had performed well in forward flow 
hemodynamic studies. The MP valve also performed well in animal studies using sheep; 
however, the coagulation cascade in sheep differs significantly from that in humans. The 
hinge area of the MP valve differs from the SJM and CM valves in that the hinge 
mechanism consists of a projection from the leaflets that fits into an angular recess in the 
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valve housing instead of butterfly type recesses with less angular shapes. These 








FIGURE 2.5.3. From left to right, hinge region of a SJM regent and MP MHV. Inset on 
left shows the different shape of the CM hinge recess. 
 
clinical quality 27 mm MP valve, Ellis et. al. and Gross et. al. showed in both steady and 
pulsatile flow that the MP valve hinge geometry leads to flow within the hinge region 
that is generally unsteady with complex flow structures.  The highest regurgitant jet 
velocity was observed at the inflow channel near the housing wall and was 2.5 m/s. High 
turbulent shear stresses were also seen at this region oscillating between 700 and 2900 
dyn/cm2.  At this point of maximum TSS, the corresponding maximum turbulent normal 
stress was 17,000 dyn/cm2 with a Kolmogorov length scale of 7.1 μm, which is on the 
order to damage and/or activate RBCs and platelets. The abrupt angular reduction in flow 
area in the inflow channel leads to vortical flow, and the abrupt enlargement prior to this 
reduction leads to low velocity reverse flow and consequent stagnation zones. Thus the 
high TSS can damage or activate platelets and/or RBCs, and the stasis region can entrap 
them [15] [23]. Additionally, the leaflet movement does not physically sweep the hinge 
region as it does in the SJM and CM designs. 
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A similar hinge study using a 23 mm SJM regent valve model with clear housing 
to expose the hinge region and delrin leaflets shows the differences between the flow 
fields of the MP valve and the SJM valves. A rotating structure is seen in the inflow 
hinge pocket during forward flow, but this rotating structure was abolished when the 
leakage jet traveled through the hinge during the leakage phase. In contrast to the MP 
valve the maximum leakage velocity was 1.5 m/s, and the maximum turbulent shear 
stress was 2600 dyn/cm2. The highest velocities and TSS occurred in the region where 
the leaflet impacts the hinge walls during valve closure at which time a strong backflow 
jet is created. These results indicate that the leaflet action and subsequent jet formation 
does have a part in washing out the hinge area thereby eliminating stagnation zones [13]. 
Leo et al conducted hinge studies with a clear housing 23 mm CM valve showing that it 
also has a dynamic washout flow pattern that minimizes the formation of vortex 
structures and complex flows similar to the SJM valve. Additionally, the peak TSS and 
velocity values of 5640 dyn/cm2 and 3.17 m/s for this valve also occurred the moment 
after valve closure. The more angular shape of the CM hinge recess does not allow the 
leaflets to completely sweep to the edge of the hinge geometry, thus regions of ‘unmated’ 
space are left at each corner during the fully open and fully closed positions. This more 
angular geometry may lead to higher leakage flow rates because of the unmated space as 
well as increased TSS due to greater flow disruption [24].  
 Differences in hinge flow fields due to variance in the size of the hinge leakage 
region were investigated using a 27 mm SJM standard valve with a clear housing and 
prototype low leaker and high leaker valves in the mitral position [25]. The diameters of 
the hinge channels for these valves was estimated by microCT to be 100 μm, 50 μm, and 
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200 μm for the Standard, low, and high leaker valves, respectively. The main differences 
in the flow fields were found during the leakage phase. The high leaker valve had the 
largest leakage jets corresponding with its higher leakage flow rate as well as an 
additional strong leakage jet at the lateral corner of the hinge. 
 Studies have also been performed to investigate differences in the hinge flow 
fields of the 23 mm SJM Standard and CM valves in the aortic and mitral position [26]. 
In general the peak forward flow velocities were higher in the aortic position for both 
valve designs, which is consistent with the difference in the cardiac flow rate at these 
positions. More dynamic flow was noticed under aortic conditions with a strong forward 
flow jet developing in the outflow pocket and a swirling structure in the inflow pocket 
inside the hinge recess. Higher peak RSS were also recorded in the aortic position than in 
the mitral position for both valves. 
 
FIGURE 2.5.4. Diagram showing the differences between the Medtronic Advantage and 
SJM hinges [27]. 
 
Saxena et al [27] took hinge measurements of the Medtronic Advantage bileaflet 
MHV prior to clinical trials comparing its hinge flow dynamics to those of the SJM 
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the SJM standard with a recessed butterfly hinge design, a thumbnail region downstream 
of the hinge, and a cylindrical housing that allows the leaflets to seat entirely within the 
housing during valve closure. The main difference is that the Advantage valve has a 
secondary flat area downstream of the hinge region that is intended to decrease the 
resistance that flow encounters as it enters and exits the hinge area by channeling the 
flow through the hinge recess (Figure 2.5.4). Measurements were taken in the mitral 
position using LDV with valve models manufactured with clear, clinical-quality housings 
that exposed the flow in the hinge area. The measurement levels taken for each valve 
were the same to allow for direct hydrodynamic comparisons. The results of this study 
indicated that the hinge flow was similar for both valves with regard to velocity and 
turbulence measurements. The velocities were somewhat higher in the SJM valve, but 
these differences were not significant. Additionally, the forward flow through the 
Advantage hinge when the valve was open was more dynamic in nature, but it is not 
known what kind of effect, if any, this more dynamic flow will have on washout patterns 
in vivo [27].  
Computational fluid dynamics (CFD) is also being used increasingly to 
investigate flow through MHVs, and can be particularly useful in the future for assessing 
changes in flow fields induced by changes in MHV design. After the abrupt removal of 
the Medtronic Parallel (MP) valve from clinical trials, CFD was performed on the hinge 
area of this valve. This study found areas of stagnation within the hinge region that 
compared well to LDV studies on this valve [28] [23]. CFD studies were also performed 
to look at flow through the hinge region of a bileaflet MHV with a protruded hinge and 
another with a recessed hinge similar to the SJM valve under steady, forward flow with 
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the leaflets fixed in the open position [29]. Wang et al found that although low velocity 
vortices developed downstream of the protruded hinge, overall the hinge area appeared to 
be well washed. Vortices were also found in the recessed hinge design escpecially at 
higher Reynolds numbers. In general flow structures in the resessed hinge were 
dominated by reverse flow whereas flow through the protruded hinge was mainly forward 
flow with some reverse flow behind the stopper [29]. 
Digital particle image velocimetry (DPIV) has also been used to study the 
hemodynamics of MHVs, although to a lesser extent. Historically, PIV has not been 
thought to have sufficient resolution to capture in detail the dynamic flow fields 
associated with MHVs; however, advances in DPIV technology are bridging this gap. 
Additionally, DPIV can be a good companion to LDV since it enables researchers to have 
more qualitative views of flow fields. Kini et. al. used a combination of LDV and DPIV 
to characterize the flow fields of a 27 mm Bjork-Shiley monostrut valve during the 
closure and leakage phases of the cardiac cycle [30]. They showed that DPIV is better for 
visual displays of data while LDV is still inherently better for acute point measurements 
of velocity. Another study using an optically clear model of a 25 mm standard SJM MHV 
obtained instantaneous velocity fields at the fully open, closing, fully closed, and opening 
phases of the cardiac cycle in pulsatile flow. In addition to obtaining velocity vectors, 
they were also able to see the valve leaflets in the images and their opening and closing 
behavior while also showing flow fields within the lumen of the valve. The flow 
structures visualized in this study did not differ from what has been elucidated using 
LDV, but it does show the feasibility of using DPIV to obtain detailed mapping of MHV 
flow fields in pulsatile flow [31].  
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The characterization of flow fields through MHVs enables researchers to better 
understand the mechanisms behind the thromboembolic complications that plague MHV 
recipients. The RSS levels measured in all MHVs is well above that necessary to activate 
platelets, but all MHVs do not have the same thromboemobolic complication rates. Thus, 
more than jet velocity and subsequent RSS levels must dictate the formation of thrombus. 
The natural accompaniment to these conditions is stagnation regions that form and enable 
activated platelets to aggregate and to recruit more platelets and other blood elements into 
the clot. Therefore, thrombus formation is a combination of shear stress activation of 
platelets followed by regions flow separation and stagnation. 
 
2.6. Coagulation cascade 
 Clot initiation caused by the presence of MHVs can occur via three basic 
pathways: phospholipid and/or tissue factor exposure to blood during cell damage caused 
by excessive shear stress; platelet activation caused by exposure to excessive shear stress; 
and contact activation by foreign materials. Clotting occurs in three steps: initiation, 
amplification, and propagation. In the tissue factor pathway, a cell or cells are ruptured 
during the initiation phase to expose tissue factor (TF) to the blood. Factor (f) VII in the 
plasma binds to TF, thus activating it to fVIIa. As shown in Figure 2.6.1, this complex 
activates fX and fIX, and fXa can activate fV. On the cell surface fXa can bind with fVa, 
which activates prothrombin to produce small amounts of thrombin, which can activate 
platelets, fVIII, and fXI during amplification. During amplification, platelets adhere to 
the damaged tissue and are activated. The thrombin generated earlier enhances platelet 






















FIGURE 2.6.1. Simplified diagram of haemostasis. 
 
 
propagation phase large-scale thrombin generation takes place leading to the formation of 
fibrin, which enmeshes the platelets and stabilizes the clot [32]. 
Contact activated clotting (Figure 2.6.2) is initiated by the binding of fXII to a 
negatively charged surface, thus forming fXIIa. The proteins prekallikrein (PK), fXI, and 
high molecular weight kininogen (HK) are then activated by fXIIa, and PK and fXIa bind 
to the foreign surface through HK. On the surface fXIIa cleaves PK to kallikrein and fXI 
to fXIa, and kallikrein generates additional fXIIa. Kallikrein also hydrolyzes HK into its 

















FIGURE 2.6.2. Simplified diagram of contact-activated coagulation. 
 
 
formed on the surface near to fXIIa. During amplification fXIIa acts on these complexes 
to form surface bound Hka-kallikrein and Hka-fXIa complexes. The Hka-fXIa complex 
activates fIX to fIXa, which acts in a cascade to form thrombin, and thrombin activates 
platelets. Kallikrein is released to activate more fXIIa and convert existing fXIIa to fXIIf, 
which is still activated, but is no longer bound to the surface so that it can activate more 
PK. In addition, fibrinogen is adsorbed to the material surface. A buildup of a layer of 
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proteins on the material helps mediate platelet adhesion and subsequent tissue growth 
[33]. 
Shear stress can lead to thromboemboli formation by inducing blood cell damage 
thus exposing tissue factor to the plasma and/or by activating the platelets directly. The 
shear stress magnitudes shown to cause damage to both red blood cells (RBCs) and 
platelets have been quantified. RBCs are vulnerable to lethal damage at shear stresses of 
1500 to 4000 dynes/cm2 and by as little as 10 to 100 dynes/cm2 in the presence of foreign 
surfaces. Sublethal damage occurs at 500 dynes/cm2 [11]. Shear stress initiated 
coagulation begins with the activation of the platelets by mechanical forces. Studies using 
cone and plate viscometers have shown that platelet activation can occur at shear stresses 
as low as 60 to 80 dynes/cm2. Platelets have been shown to undergo damage after 
exposure to 100 to 500 dynes/cm2 [11]. Platelet damage is also dependent upon the 
duration of the shear stress; however, platelet damage increases linearly with time during 
exposure to a constant shear stress implying that shear induced platelet damage is 
cumulative [11]. Shear-induced platelet activation has been studied in viscometers and is 
also a function of magnitude and duration [11]. At 150 dynes/cm2 platelet aggregates are 
formed after 300 seconds. At 600 dynes/cm2 aggregates form after 30 seconds, and at 
6500 dynes/cm2 in less than 5 milliseconds. These studies also show that as the 
magnitude increases, formed aggregates tend not to separate when the force is 
discontinued [11]. This behavior points to a different mechanism for platelet activation at 
higher levels of shear stress. 
Although the exact mechanism of activation and initiation of the coagulation 
cascade by shear stress is not known, studies have shown that in the presence of purified 
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vWF multimers platelets exposed to fluid shear stresses of 90 and 120 dynes/cm2 have an 
increase in intracellular calcium (Ca2+) and aggregation [34]. Since the chelation of the 
extracellular Ca 2+ abolished this response, the intracellular increase is due to a 
transmembrane influx of extracellular Ca2+. Additionally, inhibition of the GPIb platelet 
receptor completely abolished these responses while inhibition of the GPIIb/IIIa platelet 
receptor only partially inhibited these responses [34]. Thus, vWF binding to GPIb is 
essential for shear stress-induced increase in platelet Ca2+ and aggregation, and vWF 
binding to GPIIb/IIIa potentiates platelet responses, but is not essential. This influx of 
Ca2+ activates the platelet, and leads to the amplification phase during which GPIIb-IIIa 
interacts with adhesive proteins to mediate platelet-platelet interaction and subsequent 
aggregation. GPIIb-IIIa usually binds to fibrinogen, but under high-shear conditions it 
binds to vWF to mediate platelet aggregation [35]. Thus, this pathway may not be 
dependent upon fibrinogen since vWF both activates the platelets as well as supports 
platelet cohesion. However the GPIIb/IIIa receptor on activated platelets can bind with at 
least four different ligands (fibrinogen, vWF, fibronectin, and vitronectin) and only 
immobilized fibrinogen when not activated. However, the GPIb receptor can bind with 
immobilized vWF in the absence of shear stress and only soluble vWF in the presence of 
shear stress. Based on this knowledge, it is apparent that these two platelet receptors 
represent different pathways of platelet activation and aggregation under shear stress 
conditions [35]. The mechanism by which the vWF binding function of GPIb is activated 
has been shown to be via a dissociation of this receptor from the membrance skeleton 
caused by actin filament rearrangement [36]. This mechanism supports previous studies 
pointing to shear stress as a mechanical initator for binding to this receptor. Furthermore, 
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Shankaran et al [37] have shown that platelet activation by shear stress occurs via a two-
step process in which fluid shear and vWF are required for the first step when vWF-GPIb 
binding occurs, and subsequent platelet activation requires fluid forces but not vWF. 
Thus, vWF-GPIb binding is separable from platelet mechanotransduction. Although the 
exact target of the fluid forces is still unknown, they may be applied to the vWF-GPIb 
complex. This is supported by a study showing that although platelets interact with vWF 
over a range of shear stresses, interacting cells only exhibit calcium fluxes at the higher 
shear stresses [38].  
There is also evidence that vWF and fibrin have a cooperative effect on platelet 
adhesion and aggregation under high shear conditions. These studies indicate that resting 
platelets under flow conditions at high shear stresses adhere to immobilized vWF via the 
GPIb platelet receptor and are consequently slowed down and activated. This activation 
turns on the GPIIb/IIIa receptor an allows it to bind to vWF since this adhesive reaction 
appears to take longer than the reaction between vWF and GPIb. This step is necessary 
for thrombus formation since the vWF-GPIb interaction is characterized by a fast 
dissociation rate and reversible bonds, and the vWF-GPIIb/IIIa interaction is irreversible. 
After immobilization by the vWF-GPIIb/IIIa interaction, fibrinogen binding to the 
GPIIb/IIIa receptor may function to recruit more platelets and to stabilize the clot [39] 
[40] [41] [42].  Thus, the vWF-GPIb interaction is crucial to initiating platelet arrest and 
activation, but the vWF-GPIIb/IIIa interaction is necessary for permanent thrombus 
formation and increasing the size of the clot. In addition to simple development of the 
clot by fibrinogen binding to GPIIb/IIIa, fibrinogen may also gradually replace the vWF 
that initially constructed the thrombi under high flow conditions [43].  
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A role for RBCs in platelet aggregation has also been explored because of the 
relatively large size of RBCs and their consequent role in transport of coagulative factors. 
In vitro RBCs are concentrated in the center of the blood stream thus colliding with 
platelets and pushing them to the periphery of the blood stream near the vessel walls 
where shear rate and shear stress are highest. In studies with a cone and plate viscometer, 
platelets in the presence of RBCs exhibited a hematocrit-dependent increase in both 
adhesion and aggregation with an increase in hematocrit from 0 to 30%. Test with active 
and inactive RBCs showed that this effect is mediated partly by chemical effects of RBCs 
and partly by physical effects of RBCs, with physical effects being more important in 
adhesion and chemical effects being more important in aggregation [44]. These results 
show the importance of the presence of RBCs in in vitro studies designed to explore 
shear-induced thrombosis. 
Detailing the kinetics of thrombus formation is critical in determining whether or not 
a thrombus will form under various flow conditions, especially in regions of high velocity 
such as MHV leakage jets. Studies done using a 10-micron filter to retain platelet 
aggregates while applying a predetermined pressure leading to elevated shear stress have 
shown that activation and aggregation can occur with 8 milliseconds [45]. Thus, activated 
platelets, if brought together could aggregate in a very short time period. Another study 
investigating the cytosolic calcium flux that occurs with platelet activation and 
subsequent thrombus formation found that interactions between a resting and a preformed 
thrombi containing activated platelet undergoing sustained calcium flux oscillations must 
occur within a temporal window of less than 0.6 seconds in order for the signal to be 
propagated [46]. This activation was dependent upon the platelets coming into contact 
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when the activated cell was expressing its peak calcium flux. Therefore, calcium flux 
propogation appears to be dependent upon timely and intimate platelet interactions 
between activated and resting platelets.  
In a model of a stenosis with a subsequent enlargement, radiolabeled platelets were 
used to determine the locations of highest adhered platelet density at different 
physiological flow rates [47]. In this model the stenosis generates a region of high shear 
stress in which platelets are activated, and the enlargement induces flow separation and 
consequent recirculation regions [47]. As expected, this study showed that net platelet 
density was elevated in areas of flow recirculation and reattachment. Furthermore, the 
extent of the platelet density correlated with the length of the recirculation region. Thus, 
under the effect of shear stress alone, emboli are most likely to develop in recirculation 
areas, and they may or may not attach in areas of stagnant flow to become thrombi. In the 
immediate vicinity of MHVs in the aortic and mitral positions, similar recirculation 
regions are observed. These regions of recirculation allow platelets to aggregate with the 
primary adhesion occurring downstream. Under the influence of tissue overgrowth or an 
exposed sewing ring, platelets may also attach at these locations due to contact activation 
or shear stress activation and subsequent adhesion. 
 
2.7. Blood flow studies 
Many studies have been done to better elucidate the shear stress-activated thrombosis 
pathway and relate it to physiologic stress levels and flow patterns seen in flow through 
stenoses and MHVs. In vitro blood studies with both porcine and human blood have 
correlated blood damage with both forward and leakage flow through MHVs. In a study 
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with porcine blood using a Bjork Shiley monostrut disc valve, hemolysis was shown to 
increase with time during both forward and leakage flow for the mitral and aortic 
positions. Furthermore, in comparisons of hemolysis between the aortic and mitral 
position, the mitral position was shown to be more damaging than the aortic valve during 
forward flow while the aortic position was more damaging during leakage flow [48]. 
Cavitation was also studied, and it was found that its contribution increases depending 
upon the duration of the cavitation, and that if the duration was long enough it became 
the dominant hemolysis mechanism. The hemolysis contributions during forward and 
leakage flow were about the same, but considering that leakage flow only affects 2-5% of 
the total blood volume, this contribution is significant [48]. Leakage flow studies on the 
Medtronic Parallel valve and SJM standard, high leaker and low leaker prototype valves 
using markers for platelet activation and blood element damage in human blood, showed 
that platelets were activated and damaged in a time dependent fashion with activation and 
damage increasing with time. Additionally, the high leaker prototype valve showed more 
platelet activation and blood damage than the SJM standard valve [49]. This result shows 
the effect of leakage magnitude on blood damage and platelet activation. Although a 
larger leakage area results in lower shear stresses during the leakage phase, a higher 
leakage volume through the valve exposes more of the blood to high shear stresses 
encountered during leakage flow. Thus, an optimal leakage area exists that minimizes 
blood damage. 
Flow-induced platelet activation for two Bjork-Shiley monoleaflet MHVs was 
investigated using a modified prothrombinase method with washed platelets [50]. In this 
assay the amount of acetylated thrombin generated correlates with the activation state of 
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the platelet sample. This study found that in a physiologic flow loop powered by a 
pulsatile pump, platelet activation was dependent upon the restriction of the valve with 
the free valve resulting in no significant platelet activation and the severely restricted 
valve resulting in significantly platelet activation. 
Clinical studies have found high incidences of circulating platelet/leukocyte 
aggregates in patients with MHVs, which may be an indication of platelet activation [51]. 
However, no correlations were found between valve type or implant location. Platelet 
dysfunction has also been detected in patients with heart valve replacement [52]. This 
dysfunction was not isolated to a particular position of valve type and was manifested by 
impaired function in a high shear environment. This dysfunction may be related to 
repeated activation by the MHV and subsequent increased susceptibility to damage by 
normal flow through the body. This damage may render a great number of the platelets 
refractory to further shear stress activation. Thus, after the initial risk of thromboembolic 
complications perhaps this platelet dysfunction compounds the risk of hemorrhage 
imposed by anticoagulant therapy. 
Studies focusing on the fluid mechanics properties of the SJM bileaflet valve, and the 
CarboMedics bileaflet valve have correlated areas of high shear stress, stagnation, and 
flow separation to thrombus formation [10]. Bileaflet valves are also vulnerable to high 
turbulent shear stresses during both forward and leakage flows They also exhibit 
asymmetric separated regions with flow reversal around the perimeter of the housing with 
larger spatial dimensions near the hinges adjacent to the lateral jets as well as high 
regurgitant flow volumes that lead to high shear stresses [10]. Coupled with adjacent 
stagnant flow, these high shear stresses could lead to thrombus formation in the hinge 
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area. The Medtronic Parallel valve demonstrated such thrombus formation in clinical 
trials. It passed all pre-clinical trials including animal blood studies with sheep in forward 
flow; however, once implanted in clinical trials, many patients experienced 
thromboembolic complications, and valve explants showed thrombus deposition in 
inflow region of the hinge area [10]. The St. Jude and CarboMedics bileaflet valves have 





Presently, vascular prostheses undergo rigorous testing before they can be placed 
in clinical trials. These in vitro tests include fluid dynamics studies to gain insight into 
whether or not a device will damage blood cells or activate platelets to initiate 
thromboemboli formation as well as tests with bovine blood to investigate hemolysis. 
After these in vitro tests have been completed satisfactorily, the device is then implanted 
into an animal model, such as an ovine model, to assess propensity for thromboembolic 
complications in this setting. After these tests are passed, the device can then be placed in 
clinical trials. However, this system is imperfect. The animal models available for use in 
these studies do not have the same biochemistry as humans with respect to haemostasis 
and thrombosis. Thus, these models cannot predict thromboembolic complications in all 
cases. Indeed, the Medtronic Parallel valve was one such case in which it passed all the 
preliminary tests, but failed in clinical trials. To minimize such events, it is desirable to 
develop an in vitro flow system that can test for procoagulant potential of devices without 
such dire consequences. Such was the aim of this research using bileaflet mechanical 
heart valves as a test case. 
In addition to illuminating the importance of the hinge geometry and gap width on 
platelet activation and propensity for coagulation, this study also describes a system that 
can be used to investigate these parameters for other vascular devices that expose the 
blood to high or varying shear stresses. This methodology has the sensitivity to detect 
changes in both platelet activation and procoagulant potential based on changes in the 
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hinge geometry. It also has a small volume requiring only relatively small amounts of 
human blood that can be drawn from one donor. Thus, this study provides a simple yet 
powerful methodology to investigate various vascular devices for both platelet activation 





HYPOTHESIS AND SPECIFIC AIMS 
 
Heart valve disease is a life-threatening condition that can be caused by rheumatic 
fever, ischemic heart disease, infection, connective tissue disorders, trauma, malignant 
carcinoma, and congenital defects. Patients with severe heart valve disease in which 
repair is not an option must undergo heart valve replacement or face a reduced quality of 
life and ultimately death. Because of their significantly better durability than the other 
prosthetic choices, mechanical heart valves (MHVs) are most often used to replace native 
valves. Unfortunately, the design of bileaflet MHVs, particularly the hinge area, produces 
flow fields that may impart damage upon blood elements. This damage can activate 
platelets leading to initiation of the coagulation cascade and subsequent thromboembolic 
events. Thus, lifelong anticoagulant therapy is necessary to reduce the risk of thrombosis. 
However, even with anticoagulant therapy many patients still have thromboembolic 
complications leading to emboli formation, which may cause strokes or valve thrombosis 
that impairs valve function. Since the advent of MHVs in 1952, researchers have been 
making improvements to MHVs to reduce the adverse hemodynamic effects of valves 
that cause damage to blood elements or activate platelets. An important part of this 
improvement is the understanding of the hemodynamic effects produced by different 
valve designs, and how the consequent flow fields affect thromboemboli formation. 
Shear stress can lead to thromboemboli formation in vitro by inducing blood cell 
damage thus exposing Tissue Factor (TF) to the plasma and/or by activating the platelets 
directly via von Willebrand Factor (vWF) and thrombin. The shear stress magnitudes 
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shown to cause damage to both red blood cells (RBCs) and platelets in vitro have been 
quantified using both flow and viscometer studies. RBCs are vulnerable to lethal damage 
at shear stresses as low as 1500 to 4000 dyne/cm2 and by as little as 10 to 100 dyne/cm2 
in the presence of foreign surfaces. Sublethal damage occurs at 500 dyn/cm2 [11]. 
Platelets have been shown to undergo damage after exposure to between 100 and 500 
dyne/cm2. Platelet damage is also dependent upon the duration of the shear stress such 
that platelet damage increases linearly with time during exposure to a constant shear 
stress implying that shear induced platelet damage is cumulative. This cumulative 
damage is especially relevant in recirculating systems. Shear-induced platelet activation 
has been studied in viscometers and is also a function of magnitude and duration. At 150 
dyne/cm2, platelet aggregates are formed after 300 seconds. At 600 dyne/cm2, aggregates 
form after 30 seconds, and at 6500 dyne/cm2, they form after less than 5 milliseconds. 
These studies also show that as the magnitude increases, formed aggregates tend not to 
separate when the force is discontinued [11]. 
Experimental fluid mechanics techniques such as laser Doppler velocimetry 
(LDV) or digital particle image velocimetry (DPIV) can be used to measure velocities in 
areas of MHVs and at times during the cardiac-cycle that are characterized by elevated 
shear stresses that exceed the levels capable of inducing thromboemboli formation.  LDV 
studies performed on the St. Jude Medical (SJM), Carbomedics, and Medtronic Parallel 
valves in the vicinity of the hinge area [15] [23] [24] showed maximum Reynolds stress 
magnitudes of 7200, 5510, and 8000 dyne/cm2, respectively, during the leakage phase. 
Additionally, leakage flow studies on the Medtronic Parallel valve using markers for 
platelet activation and damage [49] showed that platelets were activated and damaged in 
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a time dependent fashion with activation and damage increasing with time. Similar 
studies performed with prototype valves with hinge leakage values that were higher (230 
μm) and lower (80 μm) than the normal tolerances for the SJM standard valve (100 μm) 
found that there were differences in platelet activation, and the high leaker valve had 
significantly more platelet activation than the standard valve. These LDV measurements 
as well as the platelet activation studies imply that hinge geometry and leakage 
magnitude do have a significant effect on shear stresses and subsequent thrombus 
formation. However, there is difficulty in isolating the hinge region during blood studies 
because of the confounding presence of the sewing ring, valve surface, and leakage 
around the periphery of the leaflets.  
The objective of this study is to design a system to assess quantitatively platelet 
activation and thrombosis in models that approximate different mechanical heart valve 
hinge geometries as well as flow through the valves themselves. Models are developed 
that isolate the hinge area so that geometries can be directly compared without the 
complications introduced by the rest of the MHV such as the sewing ring and b-datum 
line. In addition, the fluid shear stresses through these model geometries are calculated 
and measured using DPIV to correlate platelet activation and thrombosis with wall-shear 
stress and Reynolds stress.  
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Hypothesis:  Thrombus formation in models that isolate and mimic mechanical 
heart valve hinge geometries can be characterized quantitatively using a novel in 
vitro blood flow system, and these results can be correlated with digital particle 
image velocimetry measurements detailing flow fields for the same models.  This 
hypothesis will be addressed by investigating the following specific aims: 
 
SPECIFIC AIM 1:  Develop a system in which thrombi can be initiated at locations that 
are vulnerable to thrombus formation.  A steady flow system is developed in which 
thrombogenic areas are minimized so that thrombosis formation is contained within the 
area of interest.  Anticoagulant and a reversing agent are balanced so that the coagulation 
cascade can be initiated without inducing gross thrombosis in the entire loop.  The 
anticoagulated blood is returned to as normal a state as possible by continuously infusing 
the reversing agent so that the coagulation cascade can proceed in response to activating 
factors such as shear stress. 
 
SPECIFIC AIM 2:  Develop orifice models that validate this shear-mediated steady flow 
system and models that mimic MHV hinge geometries to characterize quantitatively 
coagulation and platelet activation induced by these geometries.  To accomplish this 
specific aim, simple orifice models as well as more complicated hinge channel models 
are placed in the steady flow loop to test the correlation between thrombus formation and 
shear stress levels. Human blood experiments are used to assess platelet activation and 
thrombus formation, and wall shear stress calculations and DPIV Reynolds stress and 
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shear stress measurements are correlated with quantitative biological endpoints for the 
different models that indicate platelet activation, thrombus formation, and hemolysis. 
 
SPECIFIC AIM 3:  To show a difference in coagulation and platelet activation for 
different valve designs of the same size.  To accomplish this specific aim, 27 mm SJM 
standard, and 27 mm Medtronic Parallel (MP) bileaflet valves are placed in a steady flow 
loop in the leakage position.  The hinge designs of these valves are different with the 
SJM valve having a more curved design versus the more angular designs of the MP and 
CM valves. Human blood experiments are used to assess quantitatively platelet activation 
and thrombus formation for each of these valves. 
 
SPECIFIC AIM 4:  To show a difference in coagulation and platelet activation for valves 
with the same design and size, but with different leakage magnitudes.  To accomplish this 
specific aim, 27 mm SJM standard, high leaker, and low leaker valves are used in a 
steady flow loop in the leakage position.  The high leaker and low leaker valves are 
specifically designed to have higher (200 μm) and lower (50 μm) leakage, respectively, 
than the standard valve (100 μm) during the leakage phase of the cardiac cycle. Human 
blood experiments are used to assess quantitatively platelet activation and thrombus 
formation for each of these valves. 
 
SPECIFIC AIM 5:  To correlate digital particle image velocimetry (DPIV) flow field 
data with procoagulant potential for the orifices and channels.  To accomplish this 
specific aim, the orifices and channels developed in Specific Aim 2 were placed in the 
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steady flow loop with a blood analog solution consisting of water, glycerine, and sodium 
iodide to match both the kinematic viscosity of blood and the refractive index of the 
orifice chamber. DPIV was then used to characterize the flow field through the orifices 
and channels. The acquired velocity vectors were used to calculate shear stress, Reynolds 
stress, and vorticity for these different jets. These data were analyzed to illuminate 











The methods section is divided into two sections: the blood experimental design and 
the digital particle image velocimetry (DPIV) experimental design. Each section will 
detail the rationale and methods for the development of these experiments as well as 
the general protocols. Detailed protocols for the blood are in Appendix A. 
 
5.1. Blood experimental design 
The experimental design for the blood experiments is a culmination of bench tests 
and preliminary experiments that were performed to determine the proper protocols 
and assays to quantitatively assess platelet activation and procoagulant potential of 
different MHVs, orifices and channels. This section will detail these preliminary 
experiments and the detailed protocols that were subsequently developed. 
 
5.1.1. System development and validation 
For the development of a reversible anticoagulant system, bench tests were first 
performed to determine the best reversible anticoagulant to use as well as the optimal 
ratio of anticoagulant to reversing agent to enable thrombus formation without causing 
gross thrombosis of the entire flow loop. The two anticoagulants tested for their 
feasibility in these studies were heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) and sodium 
citrate (Sigma, St. Louis, MO) with their respective reversing agents, protamine (CP 
Pharmaceuticals, UK) and Ca2+ found in calcium chloride (Sigma, St. Louis, MO). Bench 
 46 
tests with sodium citrate and calcium chloride were performed by measuring whole blood 
clotting times with different concentrations of calcium chloride. In these experiments 
blood was drawn into a 3.2% citrate solution in a blood:citrate volume ratio of 9:1, and 
the fluid mixture was placed into glass test tubes with various amounts of 100 mM 
calcium chloride The tubes were sealed and placed in a rocker to continuously invert the 
tubes. The glass in the test tubes acted as the agonist to initiate the coagulation cascade. 
The time at which a thrombus formed was recorded as the whole blood clotting time. The 
optimal citrate:Ca2+ ratio was defined at the time just before the clotting time decreased 
to the minimum clotting time. Figure 5.1.1.1 shows that the clotting time decreased 
quickly from infinity to 200 seconds at a molar citrate:calcium ratio of  approximately 6.5 
and then remained constant before rising again. Thus, an initial ratio of 7 was used for the 
steady flow blood experiments that will be discussed in a later section. 

















































FIGURE 5.1.1.1 Plots of bench tests done with (a) citrate/Ca2+ and (b) heparin/protamine. 
 
For bench tests with heparine and protamine, the activated partial thromboplastin 
time (APTT) was used to measure the clotting time. The APTT test could not be used for 
the citrate/calcium bench tests because it utilizes the addition of calcium as an agonist. 
a b
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The APTT was determined for whole blood by adding 100 μl of 20 mM calcium chloride 
to 200 μl of platelet poor plasma obtained from blood heparinized with one unit of 
heparin per ml of blood and then measuring the length of time before the blood clotted 
using a fibrometer. By adding different amounts of protamine to the heparinized blood, 
the optimal ratio of heparin to protamine was determined. The results of these bench tests 
are shown in Figure 5.1.1.1. From these bench tests it was determined that the 
heparin/protamine system was too sensitive to be used for these experiments. The 
addition of just a small amount of protamine resulted in APTTs of 30 seconds, which is 
too low and would probably result in a grossly thrombosed flow loop. Thus, this system 
would be too difficult to regulate. Additionally, heparin and protamine are known to 
interact with blood components in many different ways whereas the sole anticoagulant 
mechanism of citrate is to reversibly chelate the extracellular calcium. Thus, the 
simplicity of the citrate/calcium system also makes it a more attractive option. 
 
5.1.2. Steady flow loop development 
After determining that the citrate/Ca2+ system could be used and beginning with a 
final molar citrate:Ca2+ ratio of 7, the system was tested in a steady flow loop in which a 
thrombogenic surface, a 6.35 mm OD glass tube, was inserted. This flow loop consisted 
of 6.35 mm ID silicone tubing (VWR, Bridgeport, NJ) connected to a bypass pump and 
the glass tube by forcing the tubing over the entrances to the pump head and the glass 
tube. The glass tube was designed to fit snugly into the silicone tubing without leaking, 
and the tubing also fit snugly around the entrance and exit of the pump head without 
leaking. The loop was filled with anticoagulated human blood, and the blood was pushed 
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through the loop using a Model 540E Bioconsole Medtronic centrifugal pump 
(Biomedicus, Eden Prairie, MN). The reversing agent was continuously infused into the 
flow loop with a syringe pump (Harvard Apparatus, Holliston, MA) for 30 minutes until 
the predetermined citrate:Ca2+ ratio was reached. At this time the glass tube was isolated 
from the rest of the loop, removed, rinsed with saline, and then inspected for thrombus 
formation. Two flow rates were used in these experiments, 1 l/min and 2 l/min, with 
slightly different results at each of the flow rates. At 1 l/min thrombi were found in each 
case at both the inflow and outflow sides of the glass tube where the silicone tubing 
meets the glass tube, but at 2 l/min thrombi were only found at the inflow edge of the 
glass tube. Thrombi were not found in any other part of the flow loop. Two-dimensional 
computational fluid dynamics (CFD) simulations of the flow fields induced by the inflow 
and outflow regions of the glass tube at these flow rates showed that the vortices formed 
at the outflow region were much larger at 2 l/min than at 1 l/min. Thus, these larger 
vortices may have dislodged the thrombi formed at 2 l/min, which explains why thrombi 
were not found at this flow rate.   
Once reproducible thrombus formation was demonstrated using a glass tube as the 
agonist, a 17 mm SJM Regent MHV was inserted in place of the glass tube, and inspected 
in the same way for thrombi. As shown in Figure 5.1.2.1, this steady flow loop was also 
connected with 6.35 mm ID silicone tubing, and the valve was placed in an acrylic valve 
chamber designed to approximate the geometry of the aortic sinus. The valve was placed 
in the leakage position so that it was closed at all times while flow went through it, and 
the upstream pressure was set at 120 mmHg to approximate the upstream pressure during 
leakage flow across the aortic valve. The experiments with the 17 mm MHV served 
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mainly to aid in refinement of the citrate:Ca2+ ratio for a shear-mediated system. The 
resulting value found to enable reproducible thrombus formation without gross 
thrombosis of the entire flow loop was a citrate:Ca2+ ratio of 5.8:1. Quantitative assays 
were not performed so these results were only qualitative.  
 
FIGURE 5.1.2.1 Picture of the steady flow loop setup for a MHV. 
 
 
FIGURE 5.1.2.2 Pictures of clots on the inflow and outflow sides of a 17 mm SJM MHV 
set in the leakage position. 
 
Pictures were taken of the thrombi while they were on the valve (Figure 5.1.2.2), then 
these thrombi were removed from the valve, fixed in formalin, and stained with a 
standard Hematoxylin and Eosin (H & E) stain for cell nuclei and membranes or with a 
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Carstairs stain specific for fibrin, platelets, and RBCs. These results are shown in Figures 
5.1.2.3a and 5.1.2.3b. These histology results showed that the thrombi produced had 
normal morphology with RBCs and platelets enmeshed in fibrin strands. The presence of 
fibrin showed that the coagulation cascade was initiated, and that the thrombi formed 















FIGURE 5.1.2.3. (a) Microscopy pictures of clots stained with a hemotoxylin and eosin 
stain. viewed under 40X . (b) Microscopy pictures of clots stained with a Carstairs stains. 
viewed under 40X 
 
5.1.3. Orifice/Channel experiments 
For the final experiments the orifice plates and channels were placed in the 
chamber as shown in Figure 5.1.3.1 and connected to a Biomedicus centrifugal bypass 
pump using 6.35 mm ID silicone tubing as shown in Figure 5.1.3.2. The total volume of 
the loop was approximately 77 ml. The flow loop was rinsed with saline and then filled 
with human blood drawn into 3.2% sodium citrate at a 10:1 blood to citrate ratio. Air was 
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 FIGURE 5.1.3.2. Diagram of the steady flow loop used for this study. 
 
Simultaneously, to partially reverse the citrate anticoagulation, 100 mM calcium chloride 
was infused into the loop with a steady flow syringe pump at a rate of 17.3 μL/min. 
Calcium chloride was injected just prior to the pump head since experiments with dye 
injection showed complete mixing of substances injected at this point by the centrifugal 
action of the pump head. This infusion rate resulted in an end calcium chloride volume in 
the flow loop of 1.04 ml. The dilution effect from this addition was accounted for in the 
calculations of TAT, PF4, and plasma hemoglobin concentrations.  
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The calcium infusion rate was chosen based on initial bench tests in which the 
whole blood clotting times in response to glass-mediated clotting were measured using 
different ratios of sodium citrate to calcium chloride. In response to calcium chloride 
addition, the whole blood clotting times were decreased from infinity to approximately 
200 seconds. Based on these results an initial molar citrate to Ca2+ ratio was chosen at 6:1 
for contact-activated thrombosis which was adjusted to meet the current shear stress-
mediated clotting conditions. The citrate:Ca2+ ratio for these studies was fixed at an end 
molar ratio of 8.3:1 at 60 minutes after initial experiments with the 400 μm round orifice 
at the predetermined ratio resulted in gross thrombosis of the entire flow loop. 
Apparently, initiation of the coagulation cascade by contact activation with glass required 
more Ca2+ than initiation by shear stress. Based on direct interactions of this added Ca2+ 
with citrate+, this end molar ratio was not sufficient for the Ca2+ to bind with all of the 
citrate+. In fact, by the end of the experiment, the added Ca2+ would only remove 24% of 
the citrate+ by direct binding. 
To further test whether or not TAT formation, or thrombus formation, was due to 
contact activation instead of shear stress, samples were removed at the end of the 
experiments to test the whole blood clotting times in response to contact with glass. Since 
the clotting times were infinite, it was concluded that the TAT formation was due to shear 
stress and not contact activation.  
During the experiment the pressure upstream of the orifices was monitored using 
the pressure transducer on the pump and maintained at 120 mmHg (+/- 5 mmHg) 
resulting in flow rates of 0.01, 0.045, 0.19, and 0.32 l/min for the 200, 400, 800, and 1200 
μm orifices, respectively. These flow rates were measured using a blood analog fluid at a 
 53 
pump speed of 2000 RPM and upstream pressure of 120 mmHg. The flow rate was also 
monitored during the experiment with an inline flow meter and flow transducer supplied 
with the Biomedicus centrifugal pump (Biomedicus TX50, Minneapolis, MN). Two 0.5 
ml samples were withdrawn at 0, 15, 30, and 45 minutes and also at the end of the 60-
minute experiment and placed in 3 ml EDTA Vacutainer tubes (Becton Dickinson, 
Franklin Lakes, NJ) for the TAT and hemolysis assays and in a mixture of aspirin 
(Sigma, St. Louis, MO), acid citrate dextrose (ACD) (Sigma, St. Louis, MO), and 
Prostaglandin E1 (EMD Biosciences, San Diego, CA) for the PF4 assay (Detailed mixture 
recipe in Appendix A). This volume was replaced with 1 ml of saline after each sample 
was withdrawn. These samples were centrifuged at 14,000 RPM for 15 minutes at room 
temperature to obtain platelet poor plasma. The plasma was frozen at 4 °C until it was 
assayed for TAT, PF4, and hemoglobin concentrations. At the end of each experiment, 
the chamber was isolated from the rest of the loop and rinsed with saline. After 
disassembly the orifice plate was removed and visually inspected for gross clotting. Any 
thrombi were carefully removed and placed in 10% neutrally buffered formalin (VWR) 
for later histological observation. 
 
5.1.4. Blood collection 
These studies were approved by the Institutional Review Board for human subject 
research at the Georgia Institute of Technology. Blood was collected by venipuncture 
using a 19-gauge needle into 60 ml syringes filled with 3.2% sodium citrate to prevent 
clotting. Volunteers were randomly selected from a population of healthy individuals 
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both male and female who had not taken aspirin for at least two weeks. Ages ranged from 
20 to 50 years old with an average age of 24. Blood was used within 3 hours of drawing.  
 
5.1.5. Orifice plate construction 
The orifice plates were constructed from 25.4 mm diameter, 400 μm thick acrylic 
plates with central round orifices or rectangular slits. The fabrication was done by a 
machinist using precision drill bits (McMaster Carr, Atlanta, GA) for the round orifices 
and thin saw blades (McMaster Carr, Atlanta, GA) for the rectangular slits. All entrances 
and exits to the orifices and slits were 90-degree solid edges that were polished to 
minimize burrs. The geometries used for this study were 200 μm, 400 μm, 800 μm, and 
1200 μm round orifices, and slits, which were 200 μm, 400 μm and 800 μm wide by 12.7 
mm long. The round orifices were designed to simulate the hinge area of the bileaflet 
MHV and the slits to simulate the b-datum line of the MHV during valve closure. The 
average diameter of the hinge region through which blood flows is approximately 100 to 
200 μm, and the width of the b-datum line is approximately 200 μm. Thus, the orifice 
and slit sizes were chosen to characterize the upper and lower limits for these leakage 
regions. The 1200 μm round orifice served as a control to demonstrate that thrombin-
antithrombin III (TAT) concentration was not increased by the flow loop. The measured 
flow rates, cross-sectional areas, estimated bulk velocities, Reynolds numbers, and 
calculated wall shear stresses are listed in Table 5.1.5.1. The wall shear stress for the 
round orifices was calculated as the dynamic viscosity, ν, times the magnitude of the 
partial derivative with respect to the radial direction, r, of the laminar pipe entrance 























































where u is the instantaneous velocity, U is the bulk velocity through the orifice, a is the 
radius, x is the axial distance from the inlet, Jo is the zeroth order Bessel function, and αi 
is the ith root of the second order Bessel function, J2. The Reynolds number was based on 
U and a. The resulting wall shear stress equation is: 
( )





































For the slit orifices, the wall shear stress was calculated as the dynamic viscosity, ν, times 
the magnitude of the partial derivative with respect to the transverse direction, y, of the 


























































where h is the channel halfwidth and αi is the ith root of the equation tan αi = αi. The 



































For all of the wall shear stress calculations, the derivative was calculated 50 μm 







TABLE 5.1.5.1. Flow rate, Cross-sectional area, bulk velocity, Reynolds number 
(Re=aU/ν for the round orifices, Re= hU/ν for the slit orifices), and estimated wall shear 
stress for the orifices used in this study. Bulk velocity was calculated based on the cross-
sectional area and measured flow rate, and wall shear stress was estimated using a 
laminar pipe entrance flow profile for the round orifices and a parallel plate channel 
















200 μm round 
orifice 
0.01 0.0314 5.31 150 21,700 
400 μm round 
orifice 
0.045 0.126 5.97 340 19,100 
800 μm round 
orifice 
0.15 0.503 5.0 570 9,200 
1200 μm round 
orifice 
0.32 1.13 4.72 810 6,000 
200 μm slit orifice 0.90 2.54 5.91 170 24,200 
400 μm slit orifice 1.7 5.08 5.58 320 21,100 
800 μm slit orifice 3.06 10.16 5.02 570 15,800 
 
 
5.1.6. Channel construction 
The channels were constructed from 25.4 mm diameter, 1.5 mm thick acrylic 
plates. Four different geometries were studied with small (400 μm) and large (800μm) 
diameters as shown in Figure 5.1.6.1. The channels were designed to represent different 
nuances that could be present in hinge geometries to test the efficacy of the system at 
detecting these differences in geometry. Channels 1 and 2 were constructed using 400, 
800, and 1200 μm precision drill bits. The smaller inner orifices were drilled straight 
through while the angled inlet portion was constructed by inserting a 130° micro drill bit 
into the orifice only until the main portion of the bit touched the outside of the plate. 
Thus, an angled opening with a 130° opening was created. The inner orifices of Channels 
3 and 4 were also drilled through in the same way as those of Channels 1 and 2. 
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However, the entrance and exit to these channels were constructed using 800 and 1200 
μm end mills (McMaster Carr, Atlanta, GA) that created 90° angles to the plate. 
Channel 1-400
μm ID and 800
μm OD
Channel 2-800
μm ID and 1200
μm OD
Channel 3-400
μm ID and 800
μm OD
Channel 4-800
μm ID and 1200
μm OD
1.5 mm 1.5 mm
Channel 5-400











1.5 mm 1.5 mm
FIGURE 5.1.6.1. Channel diagrams. 
 
Channels 5 and 6 were constructed from two pieces that were made the same way as 
Channels 1 and 2. These pieces were then glued together with acrylic glue. Similarly, 
Channels 7 and 8 were constructed from two pieces that were made in the same manner 
as Channels 3 and 4 that were then glued together with acrylic glue. 
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5.1.7. Valve experiments 
For the final experiments the valves in Table 5.1.7.1 were placed in the chamber shown 
in Figure 5.1.7.1 and connected to a centrifugal bypass pump (Biomedicus Bioconsole 
Pump, Minneapolis, MN) using 6.35 mm ID silicone tubing as shown in Figure 5.1.7.2.  
TABLE 5.1.7.1. Valves used in this study with measured flow rates and approximate 
hinge geometries and minimum diameters. Diameters for the SJM standard and low and 
high leaker prototype valves are estimated from CT scans of similar valves scaled by the 
respective leakage flows for the valves used in this study. 
Valve type Leakage flow rate, 
l/min 
Hinge geometry Approximate min. 
hinge diameter, μm 
27mm SJM Standard 0.37 +/- 0.06 100 
 
27mm low leaker 
prototype 
0.13 +/- 0.05 80 
27mm high leaker 
prototype 






0.41 +/- 0.07 
 












FIGURE 5.1.7.1. Diagram of the orifice/channel chamber used for this study. 
 
The total volume of the flow loop was approximately 160 ml. The flow loop was rinsed 
with saline and then filled with human blood drawn into 3.2% sodium citrate at a 10:1 
blood to citrate ratio. Air was purged from the system, and the bypass pump was operated 
at 2000 RPM. Simultaneously, to partially reverse the citrate anticoagulation, 100 mM 
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calcium chloride was infused into the loop with a syringe pump at a rate of 38.6 μL/min. 
This infusion rate resulted in an end calcium chloride volume in the flow loop of 2.3 ml. 
The dilution effect from this addition was accounted for in the calculations of TAT, PF4, 
and plasma hemoglobin concentrations. Calcium chloride was injected just prior to the 
pump head since experiments with dye injection showed complete mixing of substances 
injected at this point by the centrifugal action of the pump head. The citrate:Ca2+ ratio for 














 FIGURE 5.1.7.2. Diagram of the steady flow loop used for this study. 
 
During the experiment the pressure upstream of the orifices was monitored using 
the pressure transducer on the pump and maintained at 120 mmHg (+/- 5 mmHg). Flow 
was also monitored during the experiment. Two 0.5 ml samples were withdrawn at 0, 15, 
30, and 45 minutes and also at the end of the 60-minute experiment and placed in 3 ml 
EDTA vacutainer tubes for the TAT and hemolysis assays and in a mixture (detailed 
protocol in Appendix A) of aspirin, acid citrate dextrose (ACD), and Prostaglandin E1 for 
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the PF4 assay. This sample volume was replaced by 1 ml saline at each sample time. 
These samples were centrifuged at 14,000 RPM for 15 minutes to obtain platelet poor 
plasma, which was subsequently assayed for TAT, PF4, and hemoglobin concentrations. 
At the end of each experiment, the chamber was isolated from the rest of the loop and 
rinsed with saline. After disassembly the orifice plate was removed and inspected for 
gross clotting. 
 
5.1.8. Biological assays 
Once the recalcification system was set up, the next step was to develop 
reproducible assays to quantitatively assess thrombus formation. Different methods were 
investigated to measure this endpoint. RBC quantification and the d-dimer ELISA assay 
are two of these preliminary assays discussed briefly here. The final assays, Thrombin-
Antithrombin III (TAT) and platelet factor 4 (PF4) ELISAs and plasma hemoglobin, used 
for quantitative analyses in these studies will then be discussed in detail. 
 
5.1.8.1. Preliminary assays 
For the RBC quantification assay, gross thrombosis and loose blood was removed and 
then the valve was soaked in Drabkin’s reagent (Ricca Chemical Company, Arlington, 
TX) to lyse the RBCs to release the hemoglobin. The absorbance of the resulting solution 
was measured with a spectrophotometer (SpectraMax Plus 384, Molecular Devices, 
Sunnyvale, CA) and correlated with the amount of RBCs on the valve. The problem with 
this method of quantification was that RBCs became attached to the sewing ring, despite 
coating the fabric with silicone to reduce this likelihood. Because these cells contributed 
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to the final number, the sensitivity of this method was dependent upon very few or no 
RBCs attaching to the sewing ring. Due to this lack of sensitivity and the high standard 
deviations, this method was not the best for determining thrombus size. 
The d-dimer ELISA (American Diagnostica, Stamford, CT) assay is routinely used 
for diagnosis of venous thromboemobolism, pulmonary embolism or other conditions 
that result in clot lysis in vivo [55]. These assays are commercially available and measure 
reliably the amount of D-dimer present in a patient’s plasma. D-dimer is one of the 
degradation products of cross-linked fibrin that is only present in clots. Soluble fibrin 
found in the bloodstream does not form d-dimers. Thus, d-dimer is only a measure of clot 
lysis, not of soluble fibrin. For the purposes of this study, the amount of D-dimer found 
on the valve or orifice/hinge model after each run was measured using the ELISA test. 
First the orifice plates were removed at the end of the experiment, rinsed, and then 
incubated with tissue plasminogen activator (TPA, Biosciences, Inc., La Jolla, CA). The 
TPA activates the plasminogen in the sample to plasmin, which degrades the fibrin into 
its base monomers. In this assay d-dimer was attached to a monoclonal antibody fixed to 
wells in the test plate by adding the mixture to the plate, incubating for a period then 
rinsing off any unbound proteins. A dye conjugated with a secondary antibody was then 
added to the wells to bind to the primary antibody for d-dimer. In this way the d-dimer 
was labeled with a colored substance that could be detected and quantified with a 
spectrophotometer. The excess dye was rinsed from the plate, and the color magnitude 
was quantified. A calibration curve was then used to determine the sample 
concentrations. Assuming that the mixture obtained from the dissolution and degradation 
of the sample was well mixed, this number was converted from a concentration to an 
 62 
actual quantity of fibrin in the entire clot. However, because of the unpredictability of 
thrombus formation and embolization in these studies, the d-dimer assay proved to have 
poor reproducibility and was thus not suitable for quantitative assessment of thrombus 
formation for these studies. 
 
5.1.8.2. Final assays 
Thrombin is an essential agonist for the formation of thrombi containing both 
platelets and fibrin. Accordingly, to assess the thrombus forming potential of MHV 
geometries, the present study focused on the generation of thrombin as measured by the 
TAT assay. The TAT complex is formed when the inhibitory molecule, Antithrombin III 
(ATIII), binds to active thrombin, consequently preventing it from propagating the 
coagulation cascade.  Thus, TAT formation is a positive indication of cumulative 
thrombin generation. This assay is limited, however, because all thrombin and 
antithrombin present may not be bound in a TAT complex. The presence of TAT in the 
samples was measured using an Enzygnost TAT micro assay (Dade Behring, Deerfield, 
IL). In this assay (detailed protocol in Appendix A), a primary antibody for thrombin was 
affixed to the bottom of each well of a 96 well plate. Duplicates of each sample were 
inserted into these wells and incubated. Unbound proteins were then rinsed, and a 
peroxidase-conjugated ATIII antibody was added to bind with the unbound ATIII 
constituent of the complex. The unbound ATIII antibodies were then rinsed, and 
chromogen was added to initiate a reaction with hydrogen peroxide. This reaction was 
stopped by the addition of sulfuric acid. For this chromogenic assay, color intensity was 
measured with a microtiter absorbance plate reader (SpectraMax Plus 384, Molecular 
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Devices, Sunnyvale, CA) at a wavelength of 492 nm. The intensity was proportional to 
concentration based on a standard curve in the range from 2 to 60 μg/L. Samples with 
higher concentrations were diluted with plasma prior to the start of the assay. 
PF4 was measured using a Zymutest PF4 (Hyphen Biomed, Neuville sur Oise, 
France) micro assay (detailed protocol in Appendix A). Once again the antibody specific 
for human PF4 was affixed to the bottom of each well in a 96 well plate. The samples 
were inserted into the wells and incubated. Unbound proteins were then rinsed, and the 
secondary antibody, an immunoconjugate to the unbound PF4 epitope coupled to 
horseradish peroxidase, was added, and the mixture was incubated. The unbound 
secondary antibody was then rinsed off, and a peroxidase substrate, Tetramethylbenzidine 
(TMB), was added, which in the presence of hydrogen peroxide developed a blue color. 
Upon termination of the reaction by the addition of sulfuric acid the color became yellow. 
Absorbance was determined using a SpectraMax Plus 384, (Molecular Devices, 
Sunnyvale, CA) at a wavelength of 450 nm. Concentration of the samples was 
determined using a standard curve ranging from 0.5 to 10 μg/l. Samples with higher 
concentrations were diluted with sample diluent prior to the start of the assay. 
Hemolysis in the samples was determined using a microplate assay (detailed 
protocol in Appendix A). The plasma samples were mixed with Drabkins reagent (Ricca 
Chemical Co., Arlington, TX) in a 1:3 ratio of plasma to Drabkins, and 100 μL of the 
mixture was added to each of the wells. The resulting color intensities of the samples 
were measured with a microtiter absorbance plate reader (SpectraMax Plus 384, 
Molecular Devices, Sunnyvale, CA) at a wavelength of 540 nm. A standard curve was 
constructed with known amounts of whole blood and Drabkins reagent, and from the 
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standard curve the concentration of hemoglobin in each of the samples was determined. 
The standards were prepared by measuring the RBC count and hemoglobin concentration 
of the whole blood using a cell counter (CoulterMAX). This whole blood was then mixed 
with different amount of Drabkins reagent to obtain a range of hemoglobin 
concentrations from 0 to 0.55 mg/ml. 
 
5.1.9. Experimental variations 
5.1.9.1. 400 μm round orifice 
Variations of the normal experiments were performed with the 400 μm round orifice 
as a positive control to assess important variables in TAT generation and platelet 
activation. These experiments were performed only with the 400 μm round orifice since 
the normal blood experiments with this orifice showed reproducible and significant 
increases in TAT at all sample times. The role of platelets was assessed by removing 
platelets from the blood prior to the experiments, and experiments were performed 
without calcium chloride addition to assess the effect of this variable. The role of the 
GpIIb/IIIa platelet receptor in the aggregation of activated platelets was assessed by 
blocking this receptor using Aggrastat (Merck & Co., Inc. East Point, PA), a drug that 
binds to this platelet receptor thus rendering it inactive. The role of vWF binding to the 
platelet GpIb receptor was assessed by blocking the CD42 region of vWF using the 
commerically available AN51 antibody (Dako, Carpinteria, CA). 
To assess the role of platelets in thrombin generation and thrombosis in the 
model, platelets were removed from blood by first centrifuging 33 ml aliquots of blood in 
60 ml Taylor tubes at 4000 RPM to prepare platelet poor plasma (PPP), a buffy layer, and 
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RBCs. The PPP was largely removed and set aside. The remaining PPP, the buffy layer, 
and about 2.5 ml of the RBCs were removed and discarded. The PPP was then 
centrifuged for 5 minutes at 4000 RPM and added back to the remaining RBCs. Blood 
cell counts were taken before and after centrifugation to determine the efficiency of 
platelet removal and to ensure that the blood counts were still in the range of normal 
blood (Coulter Multisizer III, Beckman Coulter, Fullerton, CA). In normal blood, platelet 
counts averaged 170,000 +/-65,000 cells per μl, while in platelet-depleted blood the 
counts averaged 20,000 +/- 6,000 cells per μl. The hematocrit was modified by this 
protocol from 41 +/- 14 to 32 +/- 5, which was still in the acceptable range. 
Runs without calcium chloride addition were performed as a control. These runs 
were identical to previous runs except that no calcium chloride was infused.  
Aggrastat ( Merck & Co., Inc. East Point, PA) was used to block the platelet 
GPIIb/IIIa receptor binding to fibrin. The amount of Aggrastat necessary was determined 
to be 2.17 μg/ml in preliminary steady flow tests with the 400 μm round orifice. This 
amount is tenfold the concentration used clinically to block 90% of ADP aggregation. 
Aggrastat was added to the blood prior to filling the loop to ensure that it was well mixed. 
AN51 (Dako, Carpinteria, CA) was selected to block the platelet GPIb receptor 
binding of vWF thereby preventing platelet aggregation via this pathway. The amount of 
AN51 necessary was initially estimated from the literature [56] and confirmed in 
preliminary steady flow tests with the 400 μm round orifice to be 0.25 μg/ml. AN51 was 
added to the blood prior to filling the loop to ensure that it was well mixed. 
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5.1.9.2. 800 μm round orifice 
Variations of the normal experiments with the 800 μm round orifice with different 
flow rates were performed to investigate the effect of shear stress and flow rate on 
platelet activation and thrombus formation. Table 5.1.9.2.1 shows these different 
conditions along with the estimated wall shear stress and Reynolds numbers for the 
variations. For these experimental variations with the 800 μm round orifice, the flow rate 
was varied to change the shear stress. The volume and run time were also varied to 
maintain the same number of passes for the low, normal, and high flow experiments. The 
passes were calculated as the number of times a single volume would pass through the 
orifice during the experiment assuming a homogeneous distribution. The total number of 
passes was approximately 100, and samples were withdrawn at times corresponding to 0, 
25, 50, 75, and 100 passes. 
 
Table 5.1.9.2.1. Flow rate, bulk velocity, Reynolds number (Re=aU/ν), and estimated 
wall shear stress for the variations on the 800 μm round orifice experiments. Bulk 
velocity was calculated based on the cross-sectional area and measured flow rate, and 
wall shear stress was estimated using a laminar pipe entrance flow profile for the round 









Estimated Wall Shear 
Stress Magnitude 
(dynes/cm2) 
800 μm round orifice-low 
flow 
0.09 3.0 340 5,300 
800 μm round orifice-
normal 
0.15 5.0 570 9,200 
800 μm round orifice-high 
flow 
0.19 6.6 750 12,400 
 
5.1.10. General histology 
Two basic stains were used to better elucidate the morphology of the thrombi. A 
Hematoxylin and Eosin (H & E) stain was used to show the cell membranes and nuclei of 
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the cells. A Carstairs stain was used to positively identify the platelets and fibrin in the 
thrombus. A perfused rat heart section was used a positive control for the Carstairs stain 
to show the presence of fibrin, platelets, and RBCs in an artificially induced thrombus in 
the rat heart. 
 
5.1.10.1. Tissue preparation 
For all of the stains the tissue was fixed in 10% neutrally buffered formaldehyde 
(VWR, 3323-1) overnight then transferred to 70% alcohol and stored at 4°C before 
tissure processing. The fixed tissue was then placed into plastic cassettes and placed in a 
tissue processor (Shandon Pathcentre Tissue Processor, Shandon, Pittsburgh, PA) for 
routine overnight tissue processing. There are three steps in tissue processing: 1. Tissue is 
dehydrated by successive incubation in graded alcohol from low to high concentrations; 
2. The tissue is cleared of alcohol using xylene; 3. The tissue was infiltrated with liquid 
paraffin. The block of paraffin with the tissue embedded in it is then sliced using a 
microtome (Rotary microtome HM 355S, Microm International GmbH) into 5 μm thick 
sections. The tissue was then affixed to positively charged glass slides and placed in a 
drying oven at 37°C overnight. Prior to staining the slides were deparaffinized in a Leica 
Autostainer (Leica, #74710254). Removal of the paraffin is necessary so that the stains 
can penetrate the tissues.  
 
5.1.10.2. Basic staining 
Hematoxylin and Eosin (H and E) staining is a common staining method for 
tissue structure visualization. Hematoxylin is a basic dye that stains acid structures, such 
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as chromatin in the cell nuclei, purple or blue. Eosin is an acidic dye that stains basic 
structures, such as RBCs, red. The H and E stain (detailed protocol in Appendix A) was 
performed automatically by the autostainer up to the point at which the slides were ready 
to be coverslipped.  
The Carstairs stain is a three color stain used specifically to look for platelets, 
RBCs, fibrin, and collagen. This stain allowed us to see the thrombus morphology more 
clearly and to disinguish the different components. For this stain (detailed protocol in 
Appendix A) the slides were first incubated with 5% ferric alum then stained in order 
with hematoxylin, picric acid-orange G solution, ponceau fuchsin, and aniline blue 
solution. Differentiation with 0.25% acid alcohol and 1% phosphotungstic acid was 
performed to ensure the proper uptake of the stain in the different tissues. The timing of 
these different steps and incubation periods was optimized to achieve the colors that best 
matched the scheme outlined in the initial protocol. 
 
5.1.11. Immunohistochemistry 
Immunohistochemistry (IHC) is the localization of proteins in tissue sections with 
labelled antibodies as specific reagents through antigen-antibody interactions. Protein 
localization can be visualized uisng fluorescent dyes, enzymes, radioactive elements, 
colloidal gold, or colorimetric dyes. The Avidin-Biotin-Complex (ABC) method was 
used for this particular IHC, and both fluorescent and colorimentric dyes were used. 
Avidin is a large glycoprotein that can be labelled with enzymes or fluorophores and has 
a high affinity for Biotin. Biotin can be conjugated to a variety of antibodies. Thus the 
ABC IHC technique involves three layer placed on the tissue section. The first layer is an 
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unlabeled primary antibody, the vWF antibody in this case. The second layer is a 
biotinylated secondary antibody that will bind to the primary antibody, and the third layer 
is a complex of avidin-biotin conjugated peroxidase. The peroxidase is then developed by 
diaminobenzidine (DAB) or other substrate to produce different colored end products. 
Briefly, the steps for the IHC (detailed protocol in Appendix A) were to first block the 
endogenous peroxidase using 3% H202, followed by blocking of nonspecific binding 
using a 1% gelatin/PBS mixture. The primary vWF antibody was then added to the slides 
and incubated. A biotinylated secondary antibody was then added to the slides and 
incubated. Finally, the slides were incubated with diaminobenzidine (DAB) to bring out 
the color, and then counterstained with hematoxylin to show the nuclei. All incubation 
steps were carried out in a humid chamber to prevent drying of the slides. 
 
5.1.12. Scanning electron microscopy 
Scanning electron microscopy (SEM) provides high resolution imaging of surface 
morphology and was used in this study to evaluate thrombus morphology. SEM produces 
a highly magnified image by using electrons instead of light to form an image. The 
sample is placed in a vacuum chamber and is then bombarded with a beam of electrons 
that is focused on the area on interest by a series of electromagnetic fields and lenses. 
Once the beam hits the sample surface, electrons and X-rays are ejected from the sample, 
and an image is obtained using these secondary electrons. The orientation of the sample 
surface influences the number of electrons that reach the seconday electron detector, thus 
creating variation in image contrast that represents the surface topography of the sample.  
 70 
Since the SEM is performed in a vacuum, all water must be removed from the 
sample to prevent the water from vaporizing under the vacuum conditions. The sample 
surface must also be made conductive by coating it with a thin layer of conductive 
material. The orifice plates were fixed in 10% neutral buffered formalin overnight then 
placed in 70% ethanol. For SEM preparation (detailed protocol in Appendix A) [20] the 
samples were placed in 2.5% glutaraldehyde (Electron Microscopy Science: 16019) in 
cacodylate buffer (pH 7.2, Electron Microscopy Science: 11652) for 1-2 hours. The 
samples were then rinsed in 0.2M cacodylate buffer and dehydrated in increasing 
concentrations of alcohol. In place of critical point drying, the sample was dried with 
hexamethyldisilazane (HMDS, Electron Microscopy Science: 16700) using the following 
protocol: 100% ethanol, 2:1 ethanol:HMDS, 1:1 ethanol:HMDS, 1:2 ethanol:HMDS, and 
100% HMDS. The samples were then rinsed three times in HMDS and then left 
overnight in the fume hood in the last wash to allow the HMDS to evaporate. After 
overnight drying the samples were adhered to an aluminum stub (SPI: 01506-BA) using 
conductive, double sided carbon tape (SPI: 05081-AB) and then sputter coated with gold 
to a thickness of about 100 Angstroms. After sputter coating, the samples were kept 




 Because the data for the biological endpoints was not normally distributed and the 
samples sizes (as low as 6) were small, non-parametric tests were used to determine the 
statistically significance of the data. These non-parametric tests place no restriction on 
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the distribution of sample size. Instead of specific parameters of a population, the non-
parametric tests compare the relative locations of the probability distributions of the 
sampled populations. Many of these tests use the relative ranks of the sample 
observations rather than their actual numerical values.  
The Kruskal Wallace test was used to initially determine the influential variables 
that affected the end quantitative measures. Statistical significance between the samples 
was determined using the Mann-Whitney test with a sample size of 6 for all experiments. 
Comparisons were made to the 400 and 1200 μm round orifices as positive and negative 
controls, respectively. The Kruskal-Wallis test is a nonparametric method of testing the 
hypothesis that several populations have the same continuous distribution versus the 
alternative that measurements tend to be higher in one or more of the populations. To 
apply the test, we obtain independent random samples of sizes n1, n2, . . , nm from m 
populations. Assume that there are N observations in all. We rank all N observations and 
let Ri be the sum of the ranks of the ni observations in the ith sample. The Kruskal-
Wallace statistic is: 
 















12 2   Equation 5.1.13.1 
 
When the sample sizes are large and all m populations have the same continuous 
distribution, then H has an approximate chi-square distribution with (m – 1) degrees of 
freedom. When H is large, creating a small right-tail probability (p-value), then we reject 
the null hypothesis that all populations have the same distribution.  
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The Mann-Whitney test compares medians rather than means. In the two-tailed 







H0 μ1 = μ2 η 1 = η 2 
HA μ1 ≠ μ2 η 1 ≠ η 2 
 
where η stands for the median and μ stands for the mean. For either case, you reject the 
null-hypothesis if the p-value is below a specified level (perhaps .01, .025, or .05 
depending on the situation). Specifically, in the Mann-Whitney test the observations from 
both samples are listed together in increasing order and each observation is given a rank 
showing its position in this combined listing (1 for the lowest and n1+n2 for the highest).  
An adjustment has to be made if there are ties.  One of the groups is chosen and its “rank-
sum” is computed.  If there is no difference between the populations the groups are 
sampled from, then each group should have about the same “rank-sum” proportional to 
its sample size. If there is a difference between the population medians, then one sample 
will have a lower-than-expected rank-sum (because disproportionately many of the lower 
observations are in that sample) and the other will have a higher-than-expected rank-sum 
(because disproportionately many of the higher observations are in that sample). There is 
also a confidence interval associated with the Mann-Whitney test, as there is for the t-test, 
which includes likely values for differences between population medians. 
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5.1.14. Ex vivo experiments 
The ex vivo experiments were performed using an arterio-venous shunt from the 
femoral artery to the femoral vein of a baboon. The animals for these experiments were 
chosen to have similar platelet counts (400+/-17.2 million/ml) that were above 375 
million/ml since this was determined to be an important factor in thrombus formation on 
the orifice plate. For the platelet radiolabeling (detailed protocol in Appendix A), blood 
was initially removed from the baboon and the platelets were isolated and labeled with 
111Indium. The blood was then mixed with the plasma and RBCs that had been removed, 
and re-injected into the animal. After allowing the labeled platelets to circulate at least 
overnight, the ex vivo experiments were performed.  
Prior to beginning the experiments, Heparin was first administered as a bolus in 
60 IU/kg quantities until the APTT time was between 75 and 100 seconds. Heparin was 
then administered during the experiment at a rate of 50 IU/kg/hr. This heparinized blood 
traveled from the arterial side of this shunt through the 800 μm slit orifices in the orifice 













Figure 5.1.14.1 Diagram of ex vivo shunt flow loop with orifice chamber. 
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of 60 minutes. During the experiment the buildup of radiolabeled platelets on the orifice 
plate was measured at either 3 or 5 minute time intervals using a gamma camera. Flow 
and APTT times were also measured at 0, 15, 30 and 60 minutes. After the experiment 
the chamber was isolated from the ex vivo shunt and rinsed with saline. An image of the 
rinsed chamber was then acquired to quantify the platelets that were bound to the 
chamber and the orifice. Subtraction of the measured radioactivity from the rinsed 
chamber from that in the last image acquired prior to isolating the chamber yields the 
background radioactivity emitted from the flowing platelets. This background 
radioactivity is subtracted from all of the images to calculate the net platelet deposition 
on the plate and chamber during the experiments. After rinsing with saline, the orifice 
was removed and placed on the gamma camera to allow better visualization and 
quantification of the areas in which platelets are present. An image of the entire orifice 
was first acquired. Then the proximal side of the orifice was scraped, and second image 
was acquired. In this way the thrombus formation could be quantified on each side of the 
plate. During data processing the previously determined relationship between radiation 
and platelet count was used to calculate platelet count at each time step. 
 
5.2. Digital Particle Image Velocimetry (DPIV) 
Planar DPIV is a non-invasive velocity measurement technique that can be used to 
measure the in-plane velocity field component in a planar region of interest. The 
instantaneous fluid velocity field is determined by estimating the displacements of 
neutrally buoyant particles that are seeded in the flow. A double pulsed laser combined 
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with optics produces two pulses of uniform laser light that illuminates the particle-laden 
flow in the region of interest. Paired images corresponding to the respective laser pulses 
are captured using a digital camera and stored on a computer in real time. The image data 
is subsequently analyzed to obtain particle velocities by estimating the particle 
displacement over the known time interval between laser pulses using a cross correlation 
scheme applied over small interrogation regions between the image pair. The output from 
this analysis is the in-plane vector field measurement corresponding to the velocity in the 
axial direction, u, and the velocity in the transverse direction, v. 
 
5.2.1. Materials 
The working fluid used for the DPIV experiments was a solution of saturated 
sodium iodide, glycerin, and deionized water in a volumetric ratio of 79/20/1. The 
kinematic viscosity of this solution was measured with a viscometer to be 3.5 cSt, and the 
refractive index was measured with a refractometer to be 1.49. Although the density of 
this blood analog solution (1.62 g/cm3) differs from that of blood (1.05 g/cm3), its 
kinematic viscosity (3.5 cSt) matches that of blood under normal physiological 
conditions. Based on this similarity of kinematic viscosity between blood and the blood 
analog under Newtonian conditions, dynamic similarity was assumed between the fluid 
flow through the orifices and channels in the DPIV setup and the blood flow through 
them in the in vitro flow loop. The refractive index of the blood analog (1.49) was mixed 
to match that of the acrylic orifice plate/channel mounting chambers so as to minimize 
optical distortion in these studies.  
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A typical batch of NaI saturated solution has a life span of approximately 6-8 
months depending on the frequency of usage because of the oxidation of the NaI 
constituent of the blood analog, which turns dark brown after contact with the 
atmosphere, thereby interfering with the accuracy of the velocity measurement. To 
prolong the life of the solution, it was periodically filtered with a 5μm carbon 
impregnated filter cartridge (US Filter, Plymouth Products, MD) to deoxidize the solution 
and also to remove any contaminants. Additionally, the viscosity and refractive index of 
the solution had to be corrected occasionally by incrementally adding components of the 
solution to account for the evaporation of the water in the solution.  
 Fluorescent polymer particles (FPP-RhB-10, Dantec Dynamics, Denmark) based 
on melamine resin were used in all of the PIV experiments to seed the flow. The 
introduction of these fluorescent particles was to reduce the unwanted laser glare 
reflected from the surface of the chamber or orifice plate/channel surface and to improve 
the signal to noise characteristics of the raw images. The fluorescent particles, which had 
a diameter range of 1 – 20 μm, were delivered in suspension with water. The particles 
absorb the laser light at a wavelength of 532 nm and emit light at above 560 nm. An 
orange cutoff filter (Edmund Optics) mounted on the chamber permitted only light with 
wavelengths in the range of 560 – 600 nm to pass through it for detection by the camera. 
This filter ensured that only the fluorescent particles, which emitted light in response to 
excitation by the laser sheet at a wavelength of 560 nm, would be detected by the camera. 
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5.2.2. Experimental setup 
For the DPIV experiments the orifice plates and channels were placed in the 
chamber as shown in Figure 5.2.2.1 and connected to a Biomedicus centrifugal bypass 
pump using 6.35 mm ID silicone tubing as shown in Figure 5.2.2.2. The total volume of 
the loop was approximately 77 ml. The flow loop was filled with the blood analog fluid 
seeded with the fluorescent particles. Air was purged from the system, and the bypass 
pump was operated at 2000 RPM. During the experiment the pressure upstream of the 
orifices/channels was monitored using the pressure transducer on the pump and 
maintained at 120 mmHg (+/- 5 mmHg) resulting in flow rates of 0.01, 0.045, 0.15, and 
0.32 l/min for the 200, 400, 800, and 1200 μm orifices, respectively. These flow rates 
were measured using a blood analog fluid at a pump speed of 2000 RPM and upstream 
pressure of 120 mmHg. The flow rate was also monitored during the experiment with an 
inline flow meter and flow transducer supplied with the Biomedicus centrifugal pump. 
 
Orifice Plate
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6.4 mm
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FIGURE 5.2.2.2. Diagram of the steady flow loop used for this study. 
 
5.2.3. DPIV system 
The DPIV system (Figure 5.2.3.1) consists of two Nd:YAG lasers (Model 
MiniLaser-I, New Wave Research, CA) that have an energy of 17 mJ per pulse and a 
maximum repetition rate of 15 Hz, and a light arm (Model 610015, TSI, MN) to transfer 
the laser beam to the area of investigation. A 12-bit 1600X1200 grey scale CCD camera 
(Model 1101MPRO, LaVision, Germany) equipped with a 1-5X fixed focal length zoom 
lens (Edmund Optics) was used for image acquisition. A programmable timing unit 
(Model 1108013, LaVision, Germany) was used to synchronize image capture with the 
laser pulse illumination of the particles, and an A/D converter (Model 1108033, 
LaVision, Germany) to integrate sampling control and data logging of the images. All of 
these components were connected to a host computer, which controlled the measurement 




















FIGURE 5.2.3.1 Diagram of DPIV system. 
 
The basis of velocity measurement using DPIV is the simple tracking of particle 
displacement using paired images taken over a fixed time interval. The particles in the 
flow are illuminated for about 50 ns by a pulsed laser light sheet of approximately 1 mm 
in width. The width of this laser sheet was produced by diffracting the laser beam with a 
cylindrical lens combined with a spherical lens mounted at the end of the articulated light 
arm. At the instant of illumination by the first laser sheet, the CCD camera, which is 
placed orthogonal to the light sheet, captures an image. After a set time interval, termed 
the pulse separation, the second laser pulse illuminates the particles, and a second image 
is acquired. The pulse separation is prescribed based on the expected particle velocity, 
seeding density, and interrogation region size. As a rule a particle should be displaced by 
no more than ¼th the size of the interrogation region during the pulse separation. 
Preliminary analysis, however, determines the optimal pulse separation. These paired 
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images are stored in the RAM of the host computer and quickly transferred to the hard 
drive, and the procedure is repeated. The velocities in the field of investigation was 
subsequently calculated from the acquired paired images and the known pulse separation 
using a correlation algorithm, The final DPIV results are planar velocity fields, which 
describe the flow fields in the area of interest. With the known velocity field, it is 
possible to calculate quantities such as the total kinetic energy, the vorticity, and the 
viscous dissipation. The following section will describe in detail the components of the 
PIV system, which can be separated into several subsystems: 
1) Solid state YAG laser 
2) Laser transmitting articulated arm  
3) Receiving camera 
4) Velocity calculation software 
 
 
5.2.3.1. Solid state YAG lasers  
The two solid state Nd:YAG or Neodimium Doped Yttrium Aluminum Garnet 
(LaserPulse Mini YAG 12) lasers are mounted on a Breadboard (SA series, Newport, 
CA). Each laser consists of a flash lamp and a YAG crystal placed inside a mirrored 
elliptical cavity to maximize the energy transfer from the flash lamp to the crystal. The 
flash lamp in the laser has an excitation duration of approximately 250 µs, and a 
repetition frequency of 15 Hz. Each YAG laser is equipped with a Q-switch, which acts 
as a shutter to quickly open and close the laser cavity. The Q-switch is used to control the 
duration of the laser emission from the cavity so that the cavity is closed for the majority 
of the time and is only allowed to open for a brief period. The Q-switch mechanism 
allows the YAG rod to build up the lasing energy so that a high-energy pulse can be 
released. The laser also contains a harmonic generator device to divide the wavelength of 
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the emitted YAG laser light in half to 532 nm to improve the efficiency of the cameras, 
which are more sensitive to the blue-green spectrum. An additional advantage of having a 
visible light beam is to facilitate the alignment of the beam path. The double-pulsed laser 
beams pass through an exit port unit, which consists of a series of mirrors used to align 
the two beams to ensure that they overlap.  
 
5.2.3.2. Laser transmitting articulated arm 
The articulated arm assembly was coupled to the exit port of the YAG lasers. The 
assembly consists of a series of mirrors and joints connected by hollow tubes to direct the 
laser beams from one mirror to the next irrespective of the orientation of the joint. At the 
end of the arm assembly is an output ring, which enables the coupling of various optical 
configurations. In these experiments, a cylindrical lens (f = –25.4 mm) and a spherical 
lens (f = 500 mm) were mounted in series to the arm assembly to produce a laser sheet 
with a thickness of approximately 1 mm.  The output end of the arm was mounted on a 
traversing mechanism to enable movement of the laser sheet. 
 
5.2.3.3. Receiving camera  
The term CCD stands for charge-coupled device. A CCD camera is comprised of 
receiving chip consisting of an array of CCD detectors called pixels. Each pixel is a 
Metal Oxide Silicone (MOS) capacitor that is charged by converting incident photons of 
light into electrons, as in a photodiode. The charge falling on the individual pixels is 
transformed to a voltage during read-out of the CCD chip, and the value of the voltage is 
seen as a gray scale distribution on the PIV image map. Ideally, particles in the image 
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should have a high charge (i.e. appear white), and the background noise should have a 
low charge (i.e. appear dark). 
 
5.2.3.4. Velocity calculation software  
The cross correlation of the digital image pairs to calculate the velocity fields was 
performed using commercially available PIV software (DaVis 7.0, LaVision, Germany).  
In the cross correlation program, each of the camera images are divided into rectangular 
regions called interrogation areas, and for each of these interrogation areas the particle 
images captured during the first and second pulse of the light-sheet are correlated to 
produce an average particle displacement vector (Figure 5.2.3.4.1). The cross correlation 
function statistically measures the degree of match between the two samples. The highest 
value in the correlation plane can then be used as a direct estimate of the particle image 
displacement. During cross correlation it is assumed that all particles within one 
interrogation region move homogeneously between two laser pulses.  
 
 
FIGURE 5.2.3.4.1 Diagram of DPIV image processing steps. 
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This calculation is performed for all interrogation regions to produce a vector map 
of average particle displacements. The displacement vectors are divided by the known 
pulse separation time and thus converted into a map of raw velocity vectors. Fast Fourier 
Transform (FFT) processing is used to increase the speed of the cross correlation. It is 
important to note that with FFT processing there will always be an outcome whether the 
input is meaningful or not. Since PIV is an instantaneous measurement technique, all 
spatial information is sampled at the same time. Consequently, there is a finite statistical 
probability that there will be some regions where the input is not meaningful. Therefore, 
it is necessary to validate the PIV vector map. The validation algorithms in DaVis can be 
applied to the raw vector maps so that outliers can be detected and removed. To remove 
these outliers the vector files obtained from the cross correlation were filtered to remove 
vectors that were more than five standard deviations from the local mean velocity at each 
measurement location. 
 
5.2.4. Data Analysis 
The filtered vectors are then used to calculate the axial and transverse turbulence 
intensities, urms and vrms, the Reynolds shear stress, τxy, the Reynolds normal axial stress, 

























where u and v are the mean of the local velocity vector in the axial and transverse 
direction, respectively, and n is the number of velocity vectors. 
 
 ''vuxy ρτ =      Equation 5.2.4.3 
 
where u’ and v’ are the instantaneous velocity fluctuations acting in the x (axial) and y 
(transverse) directions. 
 
 2'' rmsxx uuu ρρτ ==     Equation 5.2.4.4 
 
 2'' rmsyy vvv ρρτ ==     Equation 5.2.4.5 
 
Once these quantities are calculated they are plotted on either contour or vector maps in 
which the contour colors correspond to the magnitudes of the values and the vector 
lengths and directions correspond to magnitude and net direction, respectively. 
 
5.2.5. DPIV experimental considerations 
Illumination of the particles is a critical aspect of the PIV setup. The laser sheet 
must be bright enough to illuminate the seed particles in the flow so that sufficient 
scattered light reaches the CCD camera. Ideally, the width of the light sheet should be as 
thin as possible to reduce the effect of out-of-plane particles. Thus, the test section should 
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be located where the light sheet is the thinnest; for these experiments, this region is 
approximately 500 mm from the lens. Another way to maximize the laser power is 
through the Q-switch control, which enables the opening and closing of the shutter to the 
laser cavity. The optimal firing time for maximum laser power is 186 μs, which 
corresponds to the time at the peak of the laser power (Figure 5.2.5.1). There is a trade-
off between allowing the energy to build up by the action of the flash lamp and the 
natural dissipation rate of the cavity so the Q-switch is normally fired 150-200 µs after 
the start of the flash lamp. The advantage of the Q-switch is that all of the energy is 
released in a high-energy pulse, and since the duration of the laser beam is short, the 
seeding particles move very little during illumination. Another consideration for the 
lasers is to be sure that both lasers have the same brightness, or that the paired images 
have the same brightness. If one of the images is considerably brighter than the other, 
particles that are illuminated in this image may not be shown in the dimmer image. 
Consequently, these images will not be correlated by the correlation software and could 
result in erroneous vectors or noise. Thus, to equalize the brightness in the images, it may 
be necessary to reduce the brightness of one of the lasers by adjusting the firing time of 
the Q-switch to a time past the optimal firing time of 186 μm. 
Particle size and seeding density is also a crucial consideration for accurate DPIV 
measurements. Larger particles have better light scattering properties; however smaller 
particles follow the flow more faithfully. In general particles used to represent the flow of 
a fluid continuum should be: (1) able to follow the flow faithfully; (2) scatter light well; 
(3) cheap and conveniently generated; and (4) chemically inactive and clean. Typical 
particle size ranges between 1- 100 μm, and these are considered sufficient for most PIV 
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applications. Fluorescent polymer particles with a mean diameter between 1 – 20 μm 
were used for these studies. Particles with less variation in the mean diameter are 
considerably more expensive. For the experiments with the 400 μm round orifice, the 
larger particles (>5μm) had a tendency to occlude the orifice within 30 minutes of 
beginning the experiment. Consequently, these particles were filtered with a 5 μm filter 
to yield 1-5 μm particles. 
 
FIGURE 5.2.5.1 Q-switch Control of the lasing cavity. 
 
The pulse separation between laser pulses is dependent upon the velocity of the 
flow and the particle density. It must be sufficiently long to enable determination of the 
particle displacement between image pairs with adequate resolution as well as short 
enough to prevent particles with an out-of-plane velocity component from leaving the 
light sheet between pulses. The complex flows encountered in the orifice/channel 
experiments complicated the pulse separation setting. For each image pair, there were 
both very high and low velocity flows. Thus, a choice had to be made as to what 
important structures were to be captured. For the jet, a pulse separation of 10-15 μs was 
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used, and to capture the stagnant and circulation regions beside the jet, a pulse separation 
of 50-100 μs was used.  
Besides the particle density and size and the camera resolution, the size of the 
interrogation area also affects the spatial resolution of the vector maps. In fluid flow 
experiments, 32 x 32 pixels is a typical interrogation window size. Studies have shown 
that, given a window side length of N, a maximum particle displacement of N/4 is 
recommended to ensure a reasonable signal-to-noise ratio. The recommended minimum 
number of particles within each interrogation area is about 7 particles/interrogation area 
to ensure a good signal-to-noise ratio for cross correlation calculations.   
The number of images can also affect the accuracy of the calculated velocity 
components. Even though an increased number of image pairs can invariably lead to 
improved signal-to-noise ratio and a lower percentage of error in the measured values, 
there must be a balance between the greater time and expense spent on data acquisition, 
processing, and storage space and measurement accuracy. Typical allowable percentage 
error in the measured velocity components is 5 to 6 percent in fluid flow experiments. 
Using the following relation: 
 







R  Equation 5.2.5.1 
 
where R is the principal Reynolds shear stress, an estimated number of images required to 
meet the error requirement can be calculated. The percentage error for the Reynolds shear 
stress obtained at a point with maximum turbulence intensity is showed in Figure 5.2.5.2. 
From this figure a percentage error of less than 6 percent in R can be achieved at 
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approximately 1000 image pairs. The number of image pairs acquired in these 
experiments was 1000 or 1500, resulting less than 6 or 3 percent error, respectively. 
 
Figure 5.2.5.2 Percentage error in principle Reynolds stress at a point with maximum 
turbulence intensity. 
 
In these studies, a 1600X1200 12-bit CCD camera (Model 1101MPRO, LaVision, 
Germany) was used with a frame rate of 30 frames/sec and a CCD size of 7.4 x 7.4 mm. 
The number of vectors in the vector map is dependent upon the number of pixels in the 
CCD camera and the size of the interrogation area. The array of totally independent 
vectors, Nv is determined by the following equation: 
 
intint
column CCDin  pixels of no.row CCDin  pixels of no.  
NN
Nv ×=   Equation 5.2.5.2 
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where Nint is the side of the interrogation area in pixels. 
In practice the number of independent vectors is greater than this because 
successive interrogation areas were overlapped to optimize the use of the information in 
the image map. Overlapping the interrogation regions by 50 percent of the side length is 
recommended. If a particle is near the outer edge of an interrogation area it may be 
displaced into the neighboring interrogation area so these particles would not contribute 
to the calculation of a velocity vector if there were no overlap. Therefore, overlapping 
interrogation areas can help maximize the use of the available information. With 50 
percent overlapping of the interrogation areas the number of vectors obtained is: 
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=   Equation 5.2.5.3 
 
The choice of Nint is constrained by both the velocity dynamic range and spatial 
resolution considerations. A smaller value provides better resolution, but also increases 
the risk of not capturing the higher velocity particles. Thus, the interrogation window size 
is a compromise between these two constraints. For these experiments an interrogation 





The results section is divided into two sections: the human blood study results, the 
digital particle image velocimetry (DPIV) study results, and the ex vivo baboon study 
results. Each section will present the results of these experiments. Detailed 
tabulations of the raw experimental data are in Appendix B for the blood study and 
Appendix C for the DPIV study. 
 
6.1. Human blood experimental results 
The human blood study results are separated into sections for the round and slit 
orifices, the channels, and the mechanical valves as well as the experimental variations 
using the 400 μm round (non-calcium infused, platelet-reduced, and Aggrastat and AN51 
addition) and 800 μm round (lower and higher than normal flow rates) orifices. In each 
section there is initially a plot to show all of the experimental results over time, and then 
the results that are statistically different from one another are broken down and discussed 
in detail to better elucidate the findings in these studies. The negative control for these 
experiments was the empty chamber without an orifice, channel, or valve inserted into it. 
Thus, blood flowed unimpeded through the chamber with little change in the shear stress 
and little or no stagnation or recirculation. 
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6.1.1. Round orifices 
The endpoints for the round orifices were plasma TAT and plasma hemoglobin 
concentrations. The clinical baseline values for TAT and plasma hemoglobin are 7 ng/ml 
and 2 mg/ml, respectively.  
 
6.1.1.1. TAT results 
The TAT results for all the round orifices over time are shown in Figure 6.1.1.1.1. 
This plot shows that there is a transition between the 400 μm and the 800 μm size at 
which TAT formation becomes significant.  
 
FIGURE 6.1.1.1.1. TAT concentration over time for all the round orifices. The 200 and 
400 μm round orifices show a significant increase in TAT formation over time whereas 
the 800 and 1200 μm round orifices show only a moderate increase in TAT formation. 
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As shown in Figures 6.1.1.1.2 and 6.1.1.1.3, at 45 and 60 minutes, respectively, 
TAT formation for the 800 μm and the 1200 μm round orifice was not significantly more 






















 FIGURE 6.1.1.1.2. TAT concentration for the round orifices at 45 minutes (N=6, 
*p<0.05). The 200 and 400 μm round orifices have significantly higher TAT 
concentrations than both the 800 and 1200 μm round orifices at 45 minutes. 
 
However, TAT formation for the 200 μm and the 400 μm round orifices was significantly 
above the baseline level (N=6, p<0.05) as well as significantly more than that for the 800 
μm and 1200 μm round orifices (N=6, p<0.05). Also, in Figure 6.1.1.1.4, it is interesting 
to note that at 15 minutes the TAT concentration for the 200 μm round orifice is 
significantly less than that for the 400 μm round orifice (N=6, p<0.05), despite the fact 
that they are nearly equal at all other sample times. This behavior implicates a 





passes through the orifice. At 15 minutes the estimated number of times that a blood 
volume passes through the 200 μm round orifice is 2, and the number of ‘passes’ through 
the 400 μm round orifice at 15 minutes is 10. Thus, cumulative blood damage may not be 
sufficient to initiate the coagulation cascade for the 200 μm round orifice until after the 
15 minute sample time.  
Observations after each experiment showed that the 200 μm round orifice was 
occluded at 60 minutes in every instance as shown in Figure 6.1.1.1.5. The 400 μm round 
orifice was occluded approximately 20% of the time, and the 800 μm and 1200 μm round 
























FIGURE 6.1.1.1.3. TAT concentration for the round orifices at 60 minutes (N=6, 
*p<0.05). The 200 and 400 μm round orifices have significantly higher TAT 








































 FIGURE 6.1.1.1.4. TAT concentration for the 200 and 400 μm round orifices over time 
(N=6, *p<0.05). The 400 μm round orifice has a significantly higher TAT concentration 
than the 200 μm round orifice at 15 minutes, but the TAT concentrations are 
approximately equal at all other time points. 
 
 
FIGURE 6.1.1.1.5. Picture of an occluded 200 μm round orifice. This orifice was 









 Further investigation into the 400 μm round orifice results shows that there is a 
linear relationship between time and the increase in TAT concentration. As shown in 
Figure 6.1.1.1.6, a linear equation can be obtained that describes the increase over time. 



































FIGURE 6.1.1.1.6. TAT concentration over time for the 400 μm round orifice. Trendline 
shows the linear increase in TAT during the experiment with a TAT production rate of 24 
ng/ml*min. 
 
6.1.1.2. Hemolysis results 
The results for the plasma hemoglobin concentration, which is an indication of 
hemolysis, are shown in Figure 6.1.1.2.1. From these results it is evident that only the 
200 μm round orifice exhibits significantly more hemolysis than the other round orifices 
at all time points (N=6, p<0.05). Furthermore, the 200 μm round orifice is the only one 
that induced hemolysis at levels significantly above the clinical baseline level of 2 mg/ml 
by the end of the experiment (N=6, p<0.05). Thus, this system did not damage the red 
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blood cells appreciably in the experiments with the 400 μm, 800 μm, or 1200 μm round 
orifices. 
 
FIGURE 6.1.1.2.1. Plasma hemoglobin concentration over time for all the round orifices 
(N=6, *p<0.05). Hemolysis was significantly more for the 200 μm round orifice than for 
all of the other round orifices. 
 
6.1.2. Slit orifices 
The endpoints for the round orifices were plasma TAT and plasma hemoglobin 
concentrations. The clinical baseline values for TAT and plasma hemoglobin are 7 ng/ml 
and 2 mg/ml, respectively. 
 
6.1.2.1. TAT Results 
As shown in Figure 6.1.2.1.1, the experiments with the slit orifices did not 
produce significant amounts of TAT over time. Thus, even though the wall shear stress, 
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dyn/cm2, for the 200 μm, 400 μm, and 800 μm slits, respectively, is sufficient to activate 
the platelets, the stagnation regions may not afford the activated platelets sufficient time 
to propagate the coagulation cascade. 
 
 
FIGURE 6.1.2.1.1. TAT concentration over time for all the slit orifices. TAT 
concentrations were below the clinical baseline level for all the slit orifices at all sample 
times. 
 
6.1.2.2. Hemolysis results 
The plasma hemoglobin results for the slit orifices are shown in Figure 6.1.2.2.1. 
Similar to the larger round orifices, the hemolysis for the slit orifices was not significant 
compared to the clinical baseline level (p>0.05). Thus, even with the higher flow rates, 
which result in an increased number of ‘passes’ through the orifice for each blood 
volume, the red blood cells did not experience significant damage. 
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FIGURE 6.1.2.2.1. Plasma hemoglobin concentration over time for all the round orifices. 
None of the slit orifices induced hemolysis that was significantly more than the clinical 
baseline level. 
 
6.1.3. 800 μm round orifice low and high flow rate experiments 
Experiments with the 800 μm round orifice were performed at different flow rates 
to assess the importance of shear stress in this system without a corresponding change in 
orifice size. Unfortunately, because of limitations imposed by the pump, these 
experiments were not successful at demonstrating the importance of high shear. At higher 
RPMs, the pump head became too hot, thus warming the blood to above physiological 
levels (up to 104 °F) consequently inducing unacceptable levels of hemolysis. 
Nevertheless, these results are presented below. To eliminate the variation in ‘passes’ for 
these experiments, the blood volume was varied, and the time was lengthened for the low 
shear experiments. The total number of passes for each experiment was 100. The sample 
Baseline Hemoglobin Level 
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times were chosen to represent the approximate number of ‘passes’ for each blood 
volume for standardization between the experiments. These sample times, which were 
measured in minutes during the experiments, equated to 0, 25, 50, and 100 passes. The 
biological endpoints studied for these experiments were TAT and plasma hemoglobin. 
The clinical baseline values for TAT and plasma hemoglobin are 7 ng/ml and 2 mg/ml, 
respectively. 
 
6.1.3.1. TAT results 
The TAT results for the varying shear experiments with the 800 μm round orifice 
are shown in Figure 6.1.3.1.1.  
 
FIGURE 6.1.3.1.1. TAT concentration over time for the varying shear experiments with 
the 800 μm round orifice. TAT concentrations for the 800 μm high and low flow rate 
experiments did not differ significantly from those for the 800 μm normal flow rate 
experiments (N=6, p>0.05). 
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There was no significant difference between any of the experimental variations, and the 
cumulative TAT formed was not significantly above the clinical baseline level (N=6, 
p>0.05). 
 
6.1.3.2. Hemolysis results 
The plasma hemoglobin results are shown in Figure 6.1.3.2.1. From this plot it is 
evident that the high shear experiments resulted in significantly more hemolysis than the 
low shear or normal 800 μm round orifice experiments (N=6, p<0.05). Furthermore, the 
cumulative plasma hemoglobin concentration is significantly above the clinical 
 
FIGURE 6.1.3.2.1. Plasma hemoglobin concentration over time for the varying shear 
experiments with the 800 μm round orifice. Only the high WSS, or high flow rate, 
experiments induced a significant amount of hemolysis, most likely due to increases in 
temperature above 104 °F. 
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baseline level (N=6, p<0.05). The error bars for the high shear experimental results also 
indicate that there is a large variation in the hemolysis levels between the experiments. 
This variation may be due to the increase in temperature (up to 104° F) that resulted from 
heat transfer from the pump head at the higher RPMs for the high shear experiments. This 
excessive increase in temperature and the concomitant hemolysis invalidate the high 
shear experiments. 
 
6.1.4. Experimental variations with the 400 μm round orifice 
In the initial experiments the 400 μm round orifice demonstrated reproducible 
TAT formation at levels significantly above the clinical baseline level. Furthermore, this 
orifice did not occlude in all cases, and when a thrombus did cause occlusion, the 
occurrence was usually after 45 minutes. Thus, this orifice was used to look at different 
variables to assess their importance in this system. In particular, the importance of 
calcium chloride (Ca2+) addition, platelets, the GPIIa/IIIb platelet receptor, and the GPIb 
platelet receptor were investigated. The flow rate, experimental duration, sample times, 
upstream pressure, sodium citrate concentration in the blood, and blood volume in the 
steady flow loop were maintained the same for all of the experiments with the 400 μm 
round orifice. To assess the importance of Ca2+ addition, experiments were performed 
without the continuous infusion of Ca2+. To investigate the importance of platelets in the 
system, platelets were removed from the blood (approximately 80% removal efficiency) 
prior to placing the blood in the flow loop. To assess the importance of the GPIIb/IIIa and 
GPIb platelet receptors, Aggrastat and AN51, respectively, were added to the blood prior 
to placing the blood in the flow loop. For the non-calcium infused and reduced platelet 
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experiments, TAT concentration was the only endpoint investigated. For the Aggrastat 
and AN51 experiments, TAT and PF4 concentrations were the assayed endpoints. The 
clinical baseline values for TAT and PF4 are 7 ng/ml and 20 ng/ml, respectively. 
 
6.1.4.1. TAT results 
The TAT results for all of the experimental variations with the 400 μm round 
orifice are shown in Figure 6.1.4.1.1. These results show that TAT formation for the 
normal 400 μm round orifice experiments was significantly greater than that for all of the 
experimental variations (N=6, p<0.05). Furthermore, the experimental variations did not 
exhibit TAT concentrations significantly above the clinical baseline level at any of the 
 
FIGURE 6.1.4.1.1. TAT concentration over time for the various experiments with the 
400 μm round orifice (N=6, *p<0.05). At all sample times, the normal 400 μm round 
orifice experiments resulted in significantly higher TAT concentrations than the 
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sample times. These results indicate that all of these variables are necessary for TAT 
formation and thus the propagation of the coagulation cascade in this system. 
To further investigate the importance of these variables in relation to one another, 
trendlines were used to determine the rate of increase in the TAT concentration over 
time. Figure 6.1.4.1.2 shows these trendlines, and they are summarized again in Table 
6.1.4.1.1. 
y = 1.2287x - 0.2929
R2 = 0.9363
y = 5.4233x - 3.8381
R2 = 0.9633
y = 5.5795x - 6.2122
R2 = 0.9794




























400r no added Ca2+
Linear (400r Aggrastat)
Linear (400r AN51)
Linear (400r platelet reduced)
Linear (400r no added Ca2+)
 
FIGURE 6.1.4.1.2. TAT concentration for the 400 μm round orifice experiments with 
Aggrastat, AN51, reduced platelet count, and no added Ca2+. Trendlines have been added 
to show the varying effectiveness of these experimental variations in suppressing TAT 
formation over time. 
 
Based on the results in Table 6.1.4.1.1 and Figure 6.1.4.1.2, the most important variable 
appears to be the GPIIb/IIIa receptor. Blocking this receptor with Aggrastat resulted in 
the lowest cumulative TAT concentration as well as the lowest rate of TAT increase. 
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Reducing the platelet count seems to have a similar result to blocking GPIb with the 
AN51 antibody, since these two have similar cumulative TAT concentration and rates of 
TAT increase. The suspension of Ca2+ addition appears to be the least important of these 
factors, with the highest cumulative TAT concentration and rate of TAT increase. 
 
TABLE 6.1.4.1.1. Cumulative TAT increase and rate of TAT increase for the 
experimental variations with the 400 μm round orifice. 
 Cumulative TAT increase, 
ng/ml 
Rate of TAT increase, 
(ng/ml)/min 
400r normal 93.8 24.1 
400r w/out Ca2+ addition 25.2 7.7 
400r platelet reduced 16.9 5.6 
400r w/AN51 addition 16.6 5.4 
400r w/Aggrastat addition 4.9 1.2 
 
6.1.4.2. PF4 results 
The PF4 results for the Aggrastat and AN51 experiments shown in Figure 
6.1.4.2.1 indicate that blocking the GPIIb/IIIa and GPIb platelet receptors is not effective 
in suppressing platelet activation since the PF4 levels for the Aggrastat and AN51 
experiments is not significantly less than that for the normal 400 μm round orifice 
experiments (N=5, p>0.05). 
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FIGURE 6.1.4.2.1. PF4 concentration over time for the Aggrastat and AN51 experiments 
with the 400 μm round orifice. The AN51 experiments demonstrated significantly more 
PF4 release than either the normal or Aggrastat experiments with the 400 μm round 
orifice experiments (N=6, p<0.05). There was no significant difference in PF4 release 
between the Aggrastat and normal 400 μm round orifice experiments. 
  
Although the PF4 concentration is moderately less for the Aggrastat experiments 
than for the normal experiments, it is significantly more at 45 and 60 minutes for the 
AN51 experiments than for both the normal and Aggrastat experiments as shown in 
Figure 6.1.4.2.2. This moderate decrease in platelet activation for the Aggrastat 
experiments implies that although blocking the GPIIb/IIIa receptor does not inhibit initial 
platelet activation, it may suppress further feedback activation. The increase in platelet 
activation for the AN51 experiments may represent an artefactual release of PF4 that 
occurs when the AN51 antibody binds to the GPIb receptor. This release would be in 
addition to any PF4 release that occurs due to shear, which explains the elevation above 




























FIGURE 6.1.4.2.2. PF4 concentration for the 400 round orifice Aggrastat and AN51 
experiments over time (N=6, *=p<0.05). The AN51 experiments demonstrated 
significantly more PF4 release than either the normal or Aggrastat experiments with the 
400 μm round orifice experiments. There was no significant difference in PF4 release 
between the Aggrastat and normal 400 μm round orifice experiments. 
 
6.1.5. Channels 
The channel geometries used in these experiments were described in detail in 
Section 5.1.6. As shown in Figure 6.1.5.1, the channel geometries were chosen to mimic 
the different geometrical features of various MHV hinge pathways. The endpoints for 
these experiments were TAT, PF4, and plasma hemoglobin concentrations. The clinical 
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FIGURE 6.1.5.1. Channel diagrams. 
 
6.1.5.1. TAT results 
The TAT results for all of the channels are shown in Figure 6.1.5.1.1. This plot 
shows that all of the channels with a minimum diameter of 400 μm, or small channels 
(odd-numbered), have approximately the same TAT concentration at each sample time. 
However, the channels with a minimum diameter of 800 μm, or large channels (even-
numbered), do differ from one another. Figure 6.1.5.1.2 shows these differences more 
clearly at 60 minutes. This plot shows that Channel 4 has a significantly higher TAT 
concentration at 60 minutes than Channel 4 (N=6, p<0.05). These channels have similar 
geometries except that Channel 2 has a smoother transition to the smaller internal 
diameter, and Channel 4 has a 90 degree angle leading into the smaller internal diameter. 
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Similarly, Channel 8 has a significantly higher TAT concentration at 60 minutes than 
Channel 6 (N=6, p<0.05). Both of these channels have a larger internal diameter, but 
Channel 6 has a smoother transition than Channel 8, which has a 90 degree angle. 
Additionally, Channel 4 has significantly higher TAT than Channel 6, and Channel 8 has 
significantly higher TAT than Channel 2 at 60 minutes (N=6, p<0.05). 
 
FIGURE 6.1.5.1.1. TAT concentration over time for the channel experiments. TAT 
concentration appears to be lower for Channels 2 and 6 than for all of the other channels. 
 
 Figure 6.1.5.1.3 shows a comparison between all of the channels and the 400 μm 
round orifice at 60 minutes. The significance of this plot is that it shows that despite the 
fact that Channels 4 and 8 have a minimum diameter of 800 μm, they still produce 
approximately the same amount of TAT as the 400 μm round orifice. This is direct 
contrast to the results for Channels 2 and 6, which produce significantly less TAT than 
the 400 μm round orifice at 60 minutes (N=6, p<0.05). This result also differs from the 
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results with the 800 μm round orifice, which produced significantly less TAT than the 
400 μm round orifice at 60 minutes. Based on these results, it is evident that for the small 
channels, size is more important to TAT formation than the geometry, but for the larger 




























FIGURE 6.1.5.1.2. TAT concentration for the large (800 μm) channels at 60 minutes 
(N=6, *=p<0.05). Experiments with Channel 4 produced significantly more TAT than 
those with Channels 2 and 6. Experiments with Channel 8 also produced significantly 





































































 FIGURE 6.1.5.1.3. TAT concentration for the channels at 60 minutes compared with the 
400 μm round orifice (N=6, *=p<0.05). Experiments with channels 2 and 6 produced 
significantly less TAT than those with the 400 μm round orifice. However, TAT 
concentrations at 60 minutes for experiments with all of the other channels did not differ 
significantly from that for the 400 μm round orifice. 
 
6.1.5.2. PF4 results 
The PF4 results for all of the channels are shown in Figure 6.1.5.2.1. These results 
show that there is not a significant difference in PF4 concentration for the channels at any 
of the sample times. Furthermore, the cumulative PF4 concentration is well above the 
baseline level. Thus, all of the channels activate the platelets at about the same level with 







FIGURE 6.1.5.2.1. PF4 concentration over time for the channel experiments. There was 
no significant difference in PF4 release between any of the channels (N=6, p>0.05). PF4 
release was at least an order of magnitude higher than the baseline level (20 ng/ml). 
 
6.1.5.3. Hemolysis results 
The hemolysis results for the channel experiments are shown in Figure 6.1.5.3.1. 
There was no significant difference in plasma hemoglobin concentration for the channels 





FIGURE 6.1.5.3.1. Plasma hemoglobin concentration over time for the channel 
experiments. There was no significant difference in PF4 release between any of the 
channels (N=6, p>0.05). Hemolysis was not significantly above the baseline level. 
 
6.1.6. Mechanical heart valves 
The valves used in these experiments were described in detail in Section 5.1.7. 
These valves are the SJM Standard valve, a low leaker prototype valve, a high leaker 
prototype valve, and the MP valve. The endpoints for these experiments were TAT, PF4, 
and plasma hemoglobin concentrations. The clinical baseline values for TAT, PF4, and 
plasma hemoglobin are 7 ng/ml, 20 ng/ml, and 2 mg/ml, respectively. 
 
6.1.6.1. TAT results 
The TAT results for all of the valves are shown in Figure 6.1.6.1.1. This plot 
indicates that the SJM Standard valve produces a negligible amount of TAT. However, 
the high leaker, low leaker and MP valves do show an increase in TAT concentration.  
Baseline Hemoglobin Level 
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FIGURE 6.1.6.1.1. TAT concentration over time for the MHV experiments. TAT 
concentration was significantly higher for the low leaker prototype valve and the MP 
























FIGURE 6.1.6.1.2. TAT concentration for the different valves at 45 minutes (N=6, 
*=p<0.05). TAT concentration was significantly higher for the low leaker prototype 





























 FIGURE 6.1.6.1.3. TAT concentration for the different valves at 60 minutes (N=6, 
*=p<0.05). TAT concentration was significantly higher for the low leaker prototype 
valve and the MP valve compared to the SJM Standard MHV at 60 minutes. 
 
Figures 6.1.6.1.2 and 6.1.6.1.3 show the differences in TAT production between these 
valves more clearly at 45 and 60 minutes, respectively. At 45 minutes there is 
significantly more TAT produced in the experiments with the low leaker valve than with 
the SJM Standard valve, and at 60 minutes experiments with both the low leaker and MP 
valves resulted in significantly more TAT production than the SJM standard valve (N=6, 
p<0.05). These results indicate that the low leaker and MP valves have a higher 
thromboembolic potential than the SJM Standard valve, which is used clinically with low 






6.1.6.2. PF4 results 
The PF4 results for all of the valves are shown in Figure 6.1.6.2.1. This plot 
shows that all of the valves induced platelet activation at levels above baseline levels. 
However, the experiments with the SJM Standard valve did not result in an increase in 
PF4 concentration over time. The experiments with the MP valve resulted in a moderate 
increase, whereas the experiments with the low and high leaker prototype valves resulted 
in a significant increase over time (N=6, p<0.05).  
 
FIGURE 6.1.6.2.1. PF4 concentration over time for the MHV experiments. PF4 
concentration was significantly higher for the low and high leaker prototype valves 
compared to the SJM Standard MHV (N=6, p<0.05). 
 
Figures 6.1.6.2.2 and 6.1.6.2.3 show these differences in PF4 concentration between the 
different valves more clearly at 45 and 60 minutes, respectively. At 45 minutes, the low 















and the MP valves (N=6, p<0.05). However, at 60 minutes only the high leaker valve 
produced significantly more PF4 than only the SJM Standard valve because of the high 
standard deviations for the low leaker valve (N=6, p<0.05). These high standard 
deviations are due to the variability in different donor blood as well as to experimental 
variability associated with the PF4 assay. Additionally, the low leaker valve was more 
prone to thrombus formation, which led to valve occlusion in some of the experiments. 
This occlusion reduced the amount of platelet activation since the platelets were no 
longer flowing through the hinge region, but instead remained stagnant in the flow loop. 
This effect was more prominent at 60 minutes since the occlusion did not occur until after 

























FIGURE 6.1.6.2.2. PF4 concentration for the different valves at 45 minutes (N=6, 
*=p<0.05). PF4 concentration was significantly higher for the low leaker prototype valve 




























 FIGURE 6.1.6.2.3. PF4 concentration for the different valves at 60 minutes (N=6, 
*=p<0.05). PF4 concentration was significantly higher for the high leaker prototype valve 
compared to the SJM Standard MHV. 
 
6.1.6.3. Hemolysis results 
The plasma hemoglobin results for all of the valves shown in Figure 6.1.6.3.1 
indicate that hemolysis was not significant for the valve experiments. None of the valves 





FIGURE 6.1.6.3.1. Plasma hemoglobin concentration over time for the valve 
experiments. Hemolysis was not significantly above the baseline level for any of the 
valves (N=6, p>0.05). 
 
6.1.7. Scanning electron microscopy 
Scanning electron microscopy (SEM) was performed to closely investigate the 
morphology of the thrombus as well as the surrounding area of the orifice plate. Figures 
6.1.7.1a and 6.1.7.1b show the SEM results for an upstream and downstream thrombus. 
The pictures of the thrombi indicate that they have a normal clot morphology with RBCs 
and platelets enmeshed in a fibrous network. The fibers in the two thrombi appear to have 
different structure such that the fibers in the inlet thrombus are thicker and the fibers in 
the outlet thrombus are thinner and wispier. The histology in the next section will 
illuminate these types of fibers more clearly. 
Baseline Hemoglobin Level 
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FIGURE 6.1.7.1(a) SEM Pictures of the inlet thrombus under 1300X magnification and 
(b) the outlet thrombus under 1200X magnification. The SEM images show a normal 
thrombus morphology with platelets and RBCs enmeshed in fibers that are presumably 
either fibrin or vWF. 
 
Figure 6.1.7.2 shows a region of the orifice plate away from the outlet thrombus. It is 
evident from this figure that a small amount of RBCs and platelets do adhere to the 
orifice plate along with some fibrous strands, but there does not appear to be any 









FIGURE 6.1.7.2. SEM picture of the orifice plate region away from the downstream 
thrombus under 1200X magnification. This SEM image shows that platelets and RBCs 
attach only sparsely to the orifice plate. 
 
6.1.8. Histology results 
Three different staining methodologies were used to investigate the morphology 
of the thrombi formed in this system. The Hematoxylin and Eosin (H&E) staining was 
used to see the cell membranes and nuclei, the Carstairs stain was used to identify the 
platelets, fibrin, and RBCs, and immunostaining with an antibody to vWF was used to 
identify vWF in the thrombi. Representative images are presented in the following 
sections, and the rest of the images are in Appendix B. 
 
6.1.8.1. H&E staining results 
Figure 6.1.8.1.1 shows a representative H&E stained slice from an experiment 




and the blue shows cell nuclei. The deep red bodies are RBCs and the pink are platelets. 
The blue nuclei most likely belong to leukocytes since RBCs and platelets do not have 
nuclei. Although the proportion of RBCs to platelets varied somewhat between samples 
H&E staining was not used to detect these differences. Thus, this representative image 
shows the general thrombus morphology for all of the samples. 
 
FIGURE 6.1.8.1.1. H&E stain of a thrombus formed in an experiment with Channel 1. 
Red denotes cell membrane, and blue denotes cell nuclei. Magnification is 40X. 
 
6.1.8.2. Carstairs staining results 
The result of the Carstairs stain for the 200 μm round orifice is shown in Figure 
6.1.8.2.1. Red-orange denotes RBCs, navy blue denotes platelets, and red strands denote 
fibrin. In areas where platelets and fibrin are present the color is purple. As was the case 
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for the H&E stain for the Channel 1 thrombus, RBCs are abundant. Platelets are present 
in clusters, and fibrin can be seen co-localized with the platelets.  
 
FIGURE 6.1.8.2.1. Carstairs stain of a thrombus formed in an experiment with a 200 μm 
round orifice. Red-orange denotes RBCs, navy blue denotes platelets, and red strands 
denote fibrin. In areas where fibrin and platelets overlap, the strands appear purple. This 
image shows a homogeneous mixture of RBCs and platelets with some fibrin 
interspersed. Magnification is 40X. 
 
The Carstairs stain results for a Channel 1 thrombus are shown in Figure 6.1.8.2.2. This 
image looks similar to that for the 200 μm round orifice thrombus. However, the 
thrombus is less compact in the lower left, and there is a region in the lower right that is 
almost exclusively fibrin and platelets. Thus, instead of being a homogeneous mixture 
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like the thrombus collected from the 200 μm round orifice experiments, the Channel 1 
thrombus has areas that appear to be in different stages of development. 
 Figure 6.1.8.2.3 shows the Carstairs stain results for different regions from an 
elongated thrombus formed in the hinge of the low leaker prototype valve. These thrombi 
were extracted, as shown in Figure 6.1.8.2.4, beginning at the inlet (1) to the hinge region 
extending into the hinge recess (4). Thus, the last thrombus collected should represent the 
most mature thrombus. The first, second, and third thrombus regions are similar to one 
another in morphology. These regions all have RBCs enmeshed by fibrin with small,  
 
FIGURE 6.1.8.2.2. Carstairs stain of a thrombus formed in an experiment with Channel 
1. Red-orange denotes RBCs, navy blue denotes platelets, and red strands denote fibrin. 
In areas where fibrin and platelets overlap, the strands appear purple. This image shows a 
concentration of platelets enmeshed in fibrin with very few RBCs included. 
Magnification is 40X. 
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platelet-rich regions. However, the last image (4) is almost completely platelets with 
some fibrin and a few RBCs. During the thrombus extraction, this thrombus appeared to 
be all white whereas the other thrombi had some red color. Thus, if this does represent 
the most mature thrombus, it shows that the thrombus was indeed initiated by an 




FIGURE 6.1.8.2.3. Carstairs stain of a thrombus formed in an experiment with the low 
leaker prototype valve. The numbering refers to where in the hinge the thrombus was 
found: (1) The first thrombus region at the inflow area of the hinge and (4) Embedded 
inside the hinge recess. Red-orange denotes RBCs, navy blue denotes platelets, and red 
strands denote fibrin. In areas where fibrin and platelets overlap, the strands appear 
purple. The outermost thrombi appear to be a mixture of platelets, RBCs, and fibrin 
whereas the thrombus farthest inside the hinge is mostly platelets and fibrin. 





FIGURE 6.1.8.2.4. Diagram of the thrombus shown in Figure 7.8.1.2.3. Arrows denote 
regions of the thrombus as described in Figure 7.8.1.2.3 with region (1) at the inlet to the 
hinge, and region (4) inside the hinge recess. Arrow shows the leakage flow direction. 
 
Figure 6.1.8.2.5 shows two thrombi formed upstream and downstream of Channel 
3. The upstream thrombus is a homogeneous mixture of RBCs, platelets, and fibrin. 
However, the downstream thrombus is predominantly platelets and fibrin. Thus, based on 




FIGURE 6.1.8.2.5. Carstairs stain of a thrombus formed upstream (1) and downstream 
(2) of Channel 3. Red-orange denotes RBCs, navy blue denotes platelets, and red strands 
denote fibrin. In areas where fibrin and platelets overlap, the strands appear purple. The 
upstream thrombus appears to be a mixture of platelets, RBCs, and fibrin whereas the 







6.1.8.3. vWF immunostaining results 
A representative image of a colorimetric anti-vWF stain for a 200 μm round 
orifice thrombus is shown in Figure 6.1.8.3.1. The dark pink indicates the presence of 
vWF, and blue denotes cell nuclei. 
 
FIGURE 6.1.8.3.1. Colorimetric anti-vWF stain of a thrombus formed in an experiment 
with the 200 μm round orifice. Red denotes vWF and blue denotes cell nuceli. This figure 
shows that the vWF is interspersed throughout the thrombus with slightly higher 
concentrations at the edges where the thrombus may have been growing Magnification is 
40X. 
 
This figure shows that the vWF is interspersed throughout the thrombus with slightly 
higher concentrations at the edges where the thrombus may have been growing. Figure 
6.1.8.3.2 shows the fluorescent anti-vWF images for regions (1) and (4) of the low leaker 
prototype valve thrombus that was also stained with the Carstairs stain (Figure 6.1.8.2.3). 
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FIGURE 6.1.8.3.2. Fluorescent anti-vWF stain of a thrombus formed in an experiment 
with the low leaker prototype valve. The numbering refers to where in the hinge the 
thrombus was found: (1) The first thrombus region (Region 1) at the inflow area of the 
hinge and (2) Embedded inside the hinge recess (Region 4). The first thrombus appears to 
contain more cell nuclei than the embedded thrombus, which appears to contain more 
vWF. Green denotes the presence of vWF, and blue is cell nuclei. Magnification is 40X. 
 
As in Figure 6.1.8.3.1 with the colorimetric anti-vWF stain, the vWF is interspersed 
throughout the thrombi. Additionally, the edges appear to have a higher concentration of 
vWF. Region 4 shown in panel 2 of Figure 6.1.8.3.2 appears to have a greater 
concentration of vWF than region 1, which is shown in panel 1 of Figure 6.1.8.3.2. This 
correlates well with the higher concentration of platelets seen in the Carstairs stain for 
region 4, which is shown in panel 4 of Figure 6.1.8.2.3, compared to that in region 1 
shown in Figure 6.1.8.2.3. Since platelet aggregation can occur under high shear 
conditions via linkage with vWF this part of the thrombus found in the hinge recess of the 
low leaker valve may be held together via vWF binding. 
 Figure 6.1.8.3.3 shows the upstream and downstream thrombi formed in an 
experiment with Channel 3. These sections are from the same region of the thrombus as 
those shown in Figure 6.1.8.2.4 with the Carstairs stain. The upstream thrombus is 





FIGURE 6.1.8.3.3. Fluorescent anti-vWF stain of a thrombus formed upstream (1) and 
downstream (2) of Channel 3. Green denotes the presence of vWF, and blue is cell nuclei. 
The upstream thrombus appears to contain more cell nuclei and vWF than the 
downstream thrombus. Magnification is 40X. 
 
This result correlates well with the Carstairs stain result in Figure 6.1.8.2.4, which shows 
that the downstream thrombus contained more fibrin than the upstream thrombus. Thus, 
in the downstream thrombus fibrin may enable platelet aggregation and thrombus 
formation, and in the upstream thrombus this may be mediated by vWF linkage. 
 
6.2. Particle image velocimetry results 
The digital particle image velocimetry (DPIV) results are separated into sections for 
the different orifices and channels. Additional results are presented in Appendix C. PIV 
was not performed with the 200 μm round orifice because the seed particles aggregated 
and occluded the orifice before images could be acquired. In each section, figures are 
shown for the centerplane average velocity, the square of the root mean of the axial 
velocity (VRMS), principle Reynolds stress (PReS), and shear stress fields. VRMS is a 
measure of the velocity fluctuations in the flow field. Similarly, PReS is a standard 
measure of fluctuations in velocity that also incorporates the viscosity and density of the 
1 2 
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fluid in its calculation. These velocity fluctuations can be damaging to blood elements if 
the length scale of the fluctuations is small enough to affect these cells. Generally, the 
length scale must be on the order of the diameter of the blood element. Thus, for PReS 
values that are on this length scale and above a given threshold indicate that these 
velocity fluctuations are sufficient to damage blood cells or activate platelets. However, 
because most blood damage and platelet activation studies are performed under laminar 
flow conditions, this exact threshold is not known. Also, determining the length scale of 
the PReS is theoretical and these estimations may not be valid for the transitional and low 
Reynolds number turbulence studied here. For this reason, the shear stress (SS) data is 
also presented. This value is a measure of the velocity gradient with respect to the 
transverse direction of the flow. SS magnitudes of 80 dyn/cm2 have been implicated in 
platelet damage and activation leading to platelet aggregation.  
 
6.2.1. Round orifice results 
6.2.1.1. Average velocity fields 
The average velocity field for the 400 μm round orifice with a laser pulse 
separation time of 5 μs is shown in Figure 6.2.1.1.1. This pulse separation allows for the 
measurement of the highest velocity particles that are passively advected in the orifice jet. 
There were problems with occlusion of the 400 μm round orifice, but an adequate number 
of images could be taken for this orifice before the flow rate decreased significantly. The 
figure shows the measured jet downstream of the orifice plate along the centerplane 
through the orifice. The peak centerline velocity for the 400 μm round orifice is much 
lower than expected from the measured flow rate, of 0.05 L/min. Since the laser sheet 
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width was approximately 1 mm, and the orifice is only 400 μm in diameter, particles 
outside the center plane, moving much slower than the jet, were included in the raw PIV 
images. These slower moving particles could have resulted in a decrease in the measured 
velocity. Also, the particle density for the 400 μm round orifice experiments had to be 
lower to prevent almost instant occlusion at the higher particle densities used for the 
larger orifices. Figure 6.2.1.1.1 also shows that the jet is dissipated very quickly most 
likely because of the entrainment of the large volume of slower moving reverse flow. 
This reverse flow is evident in Figure 6.2.1.1.2, which was acquired with a pulse 
separation time of 50 μs. This pulse separation allows for the capture of the lower 
velocity particles while eliminating the higher velocity particles from the vector field.  
 
FIGURE 6.2.1.1.1. Average velocity vector field downstream of the 400 μm round 
orifice. The pulse separation was 5 μs, and the vector plot is an average of 1000 image 
pairs. Velocity in m/s is color coded according to the legend. 
 
Thus, in this image the recirculation zones on either side of the jet are apparent. It is clear 
from Figure 6.2.1.1.2 that the fluid that impinges on the chamber wall at the throat of the 
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chamber is directed back to the orifice jet resulting in mixing of this low flow fluid with 
the jet. This mixing could also contribute to the rapid dissipation of the jet. 
 
FIGURE 6.2.1.1.2. Average velocity vector field downstream of the 400 μm round 
orifice. The pulse separation was 50 μs, the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
 
FIGURE 6.2.1.1.3. Flow profiles at 1, 3, and 5 diameters downstream of the 400 μm 
round orifice. The pulse separation was 5 μs, the vector plot is an average of 1000 image 
pairs. Velocity in m/s is color coded according to the legend. 
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Figure 6.2.1.1.3 shows the velocity profiles at 1, 6, and 10 diameters downstream 
of the 400 μm round orifice. These flow profiles show the decay of the jet as the flow 
moves downstream of the orifice. It is evident from this plot that the profile flattens out 
very quickly indicating that the jet momentum diffuses very rapidly. Additionally, the 
profile is skewed, which shows the asymmetry of the jet. This asymmetry may be a result 
of seed particle accumulation at the orifice, which altered the shape of the orifice. 
The average velocity fields for the 800 μm round orifice with a pulse separation 
time of 10 μs is shown in Figure 6.2.1.1.4. This pulse separation allows for the tracking 
of the highest velocity particles that are entrapped in the orifice jet. The peak centerline 
velocity for the 800 μm round orifice of approximately 6 m/s corresponds with the 
measured flow rate of 0.15 l/min. The measurements for this orifice were more accurate 
compared to those for the 400 μm round orifice due to the higher particle density, larger  
 
 
FIGURE 6.2.1.1.4. Average velocity vector field downstream of the 800 μm round 
orifice. The pulse separation was 10 μs, the vector plot is an average of 1000 image pairs. 




FIGURE 6.2.1.1.5. Average velocity vector field downstream of the 800 μm round 
orifice. The pulse separation was 200 μs, the vector plot is an average of 1000 image 
pairs. Velocity in m/s is color coded according to the legend. 
 
orifice diameter, and higher flow rate, which reduced the amount of out of plane particles 
captured in the images as well as the tendency for particles to build up on the orifice. 
Figure 6.2.1.1.5 shows the average velocity field measured with a pulse 
separation of 200 μs. As was the case for the 400 μm round orifice, large recirculation 
regions are evident on both sides of the jet. However, for this larger diameter jet the 
reverse velocities are about twice those for the 400 μm round orifice jet. Figure 6.2.1.1.6 
shows the centerplane jet velocity profiles at locations 1, 3 and 6 diameters downstream 
of the 800 μm round orifice. Unlike the 400 μm round orifice jet, this jet maintains a 
Gaussian jet-like profile indicating that it is able to persist for a longer distance 




FIGURE 6.2.1.1.6. Flow profiles at 1, 3, and 6 diameters downstream of the 800 μm 
round orifice. The pulse separation was 10 μs, and the vector plot is an average of 1000 
image pairs. Velocity in m/s is color coded according to the legend. 
 
PIV measurements were also performed at a lower flow rate for the 800 μm round 
orifice corresponding to the low flow rate blood experiments. The flow rate for the low 
shear stress experiments was chosen to have the same Reynolds number as the 400 μm 
round orifice experiments. These results are shown in Figure 6.2.1.1.7 along with the 
results for the normal shear experiments. These images show that, as expected, the peak 
velocities for the low shear experiments are approximately 70% of the values for the 
normal shear experiments, which corresponds to the different bulk flow rates of 0.09 and 
0.15 l/min for the low and normal shear experiments, respectively. The low shear jet also 
appears to dissipate more rapidly. 
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FIGURE 6.2.1.1.7. Average velocity vector field downstream of the (a) low shear and (b) 
normal shear 800 μm round orifice experiments. The pulse separation was 10 and 8 μs, 
respectively, and the vector plots are an average of 1000 image pairs for both 
acquisitions. Velocity in m/s is color coded according to the legend. 
 
The average orifice centerplane velocity fields for the 1200 μm round orifice with 
a pulse separation time of 10 μs is shown in Figure 6.2.1.1.8. This pulse separation allows 
for the tracking of the highest velocity particles that are entrapped in the orifice jet. The 
peak velocity for the 1200 μm round orifice of approximately 6 m/s corresponds with the 
measured flow rate.  
 
FIGURE 6.2.1.1.8. Average velocity vector field downstream of the 1200 μm round 
orifice. The pulse separation was 10 μs, and the vector plot is an average of 1000 image 
pairs. Velocity in m/s is color coded according to the legend. 
a b
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Figure 6.2.1.1.9 shows the average velocity field measured with a pulse 
separation of 75 μs upstream and downstream of the orifice plate. As was the case for the 
400 and 800 μm round orifices, large recirculation regions are evident on both sides of 
the jet. However, for this larger diameter jet the reverse velocities are about 30% higher 
those for the 800 μm round orifice jet. Figure 6.2.1.1.10 shows the average velocity field 
upstream of the orifice plate measured with a pulse separation of 100 μs. This plot shows 
the flow field narrowing towards the orifice with an increase in velocity as it approaches 
the orifice.  
 
FIGURE 6.2.1.1.9. Average velocity vector field for the 1200 μm round orifice on both 
sides of the orifice. The pulse separation was 75 μs, and the vector plot is an average of 
500 image pairs. Velocity in m/s is color coded according to the legend. 
 
The general flow pattern is in the forward direction towards the orifice with very little 
reverse flow. The upstream flow profiles for the 1200 μm round orifice shown in Figure 
6.2.1.1.11 further illuminate this upstream flow field. These profiles clearly show the 
narrowing of the flow towards the orifice opening. They also show some skewing of the 
Orifice Plate
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flow, which is a result of the inlet flow that is not fully developed. However, this skewing 
is not reflected in the downstream jet as evidenced by the symmetric downstream flow 
profiles at 1, 2.5, and 4 diameters downstream of the orifice shown in Figure 6.2.1.1.12. 
These flow profiles indicate that the jet persists to this point with Gaussian flow profiles 
similar to those seen for the 800 μm round orifice jet. 
 
 
FIGURE 6.2.1.1.10. Average velocity vector field for the 1200 μm round orifice. The 
pulse separation used was 10 μs, and the vector plot is an average of 1000 image pairs. 




FIGURE 6.2.1.1.11. Flow profiles upstream of the 1200 μm round orifice. The pulse 
separation was 100 μs, and the vector plot is an average of 1000 image pairs. Velocity in 
m/s is color coded according to the legend. 
 
 
FIGURE 6.2.1.1.12. Flow profiles at 1, 2.5, and 4 diameters downstream of the 1200 μm 
round orifice. The pulse separation was 10 μs, and the vector plot is an average of 1000 
image pairs. Velocity in m/s is color coded according to the legend. 
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6.2.1.2. VRMS fields 
The VRMS fields corresponding to the jet average velocity fields presented in the 
previous section will be shown in this section. These plots show the magnitude of the 
velocity fluctuations present in the jets. The VRMS fields for the 400, 800, and 1200 μm 
round orifice jets are shown in Figures 6.2.1.2.1, 6.2.1.2.2, and 6.2.1.2.3, respectively. 
The rough contours and high apparent VRMS (between 0.6 and 1.4 m/s) in the low flow 
region in Figure 6.2.1.2.1 indicate the preponderance of velocity fluctuations present in 
the 400 μm round orifice jet flow field, even where the fluid should be relatively 
stagnant.  This plot shows that the highest VRMS is found in the core of the jet and has a 
peak value of approximately 2 m/s.  
 
 
FIGURE 6.2.1.2.1. VRMS field for the 400 μm round orifice jet. VRMS units are m/s. VRMS 




FIGURE 6.2.1.2.2. VRMS field for the 800 μm round orifice jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend.  
 
The VRMS field for the 800 μm round orifice jet in Figure 6.2.1.2.2 is more homogenous 
with smoother contours. The highest VRMS is still found in the core of the jet, but the peak 
value is roughly 1.75 times that for the 400 μm round orifice jet at 3.5 m/s. The VRMS 
field for the 1200 μm round orifice jet in Figure 6.2.1.2.3 is slightly different from those 
for the smaller round jets. Instead of the peak VRMS being concentrated in the jet core, 
they are on either side of the core near the orifice. In addition, the peak values are lower 




FIGURE 6.2.1.2.3. VRMS field for the 1200 μm round orifice jet. VRMS units are m/s. 
VRMS magnitudes are color coded according to the legend. 
 
6.2.1.3. Reynolds stress fields 
The principal Reynold stress (PReS) fields corresponding to the jet average 
velocity fields presented in the previous section will be shown in this section. These plots 
give an indication of the velocity fluctuations that can cause blood element damage 
and/or platelet activation. The Reynolds stress fields for the 400, 800, and 1200 μm round 
orifice jets are shown in Figures 6.2.1.3.1, 6.2.1.3.2, and 6.2.1.3.3, respectively. 
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FIGURE 6.2.1.3.1. Principal Reynolds stress (PReS) field for the 400 μm round orifice 
jet. PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
The rough contours and high apparent PReS (approximately 1000 dyn/cm2) in the low 
flow region in Figure 6.2.1.2.1 indicate the preponderance of velocity fluctuations present 
in the 400 μm round orifice jet flow field, even where the fluid should be relatively 
stagnant. This plot shows that the highest PReS is found in the core of the jet and has a 
peak value of approximately 5,000 dyn/cm2. The PReS field for the 800 μm round orifice 
jet in Figure 6.2.1.2.2 is more homogenous with smoother contours. The highest PReS is 
still found in the core of the jet, but the peak value is roughly 3 times that for the 400 μm 
round orifice jet at 15,000 dyn/cm2. 
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FIGURE 6.2.1.3.2. Principal Reynolds stress (PReS) field for the 800 μm round orifice 
jet. PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.1.3.3. Principal Reynolds stress (PReS) field for the 1200 μm round orifice 
jet. PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
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The PReS field for the 1200 μm round orifice jet in Figure 6.2.1.3.3 is slightly different 
from those for the smaller round jets. Instead of the peak PReS being concentrated in the 
jet core, they are on either side of the core near the orifice. In addition, the peak values 
are lower than they are for the 800 μm round orifice jet at 9,500 dyn/cm2.   
 
6.2.1.4. Shear stress fields 
The shear stress (SS) fields corresponding to the jet average velocity fields 
presented in the previous section will be shown in this section. These plots give an 
indication of the magnitude of the velocity gradients between the different shear layers in 
the flow that can cause blood element damage and/or platelet activation. The shear stress 
fields for the 400, 800, and 1200 μm round orifice jets are shown in Figures 6.2.1.4.1, 
6.2.1.4.2, and 6.2.1.4.3, respectively.  
 
FIGURE 6.2.1.4.1. Shear stress (SS) field for the 400 μm round orifice jet. SS units are 
dyn/cm2. SS magnitudes are color coded according to the legend. 
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Figure 6.2.1.4.1 shows that the highest SS is found on either side of the 400 μm round 
orifice jet core and has a peak value of approximately 20 dyn/cm2. The location of these 
higher SS values coincides with the mixing of the higher velocity jet and the lower 
velocity recirculation regions near the orifice. Thus, these areas may be vulnerable to 
inducing platelet activation, and the subsequent recirculation may enable these activated 
platelets to aggregate. 
The SS field for the 800 μm round orifice jet in Figure 6.2.1.4.2 is more 
homogenous than that for the 400 μm round orifice, and the low flow region has SS 
values at or near zero. The highest SS is still found on either side of the jet core, but they 
occur farther downstream of the orifice. Also, the peak value is somewhat higher than 
that for the 400 μm round orifice jet at 90 dyn/cm2. respectively. The location of these 
higher SS values coincides with the mixing of the  
 
FIGURE 6.2.1.4.2. Shear stress (SS) field for the 800 μm round orifice jet. SS units are 
dyn/cm2. SS magnitudes are color coded according to the legend. 
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The SS field for the 1200 μm round orifice in Figure 6.2.1.3.3 is similar to that for 
the 800 μm round orifice. However, the peak value for this orifice jet is lower than that 
for the 800 μm round orifice jet at 80 dyn/cm2. 
 
 
FIGURE 6.2.1.3.3. Shear stress (SS) field for the 1200 μm round orifice jet. SS units are 
dyn/cm2. SS magnitudes are color coded according to the legend. 
 
6.2.2. Slit orifice results 
The PIV measurements for the slit orifices were taken only at the centerline of the 
narrow part of the orifice since this narrow cross-section is where the highest Reynolds 
stresses and shear stresses would be seen. These results are presented below. 
 
6.2.2.1. Average velocity flow fields 
The average velocity field for the 200 μm slit orifice with a pulse separation time 
of 10 μs is shown in Figure 6.2.2.1.1. This pulse separation allows for the tracking of the 
highest velocity particles that are entrapped in the orifice jet. This jet is similar to those  
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FIGURE 6.2.2.1.1. Average velocity vector field downstream of the 200 μm slit orifice. 
The pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
 
FIGURE 6.2.2.1.2. Flow profiles at 1, 5, and 10 hydraulic diameters downstream of the 
200 μm slit orifice. The pulse separation was 10 μs, and the vector plot is an average of 
1000 image pairs. Velocity in m/s is color coded according to the legend. 
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for the 800 and 1200 μm round orifice except that the flow profiles downstream of the jet 
shown in Figure 6.2.2.1.2 appear to broaden out more quickly than those for the round 
orifice jets. However, using the hydraulic diameter of 400 μm to characterize the number 
of diameters downstream of the jet shows that the flow profile at 10 hydraulic diameters 
downstream still has a Gaussian profile indicating that it has not dissipated. 
 
 
FIGURE 6.2.2.1.3. Average velocity vector field downstream of the 400 μm slit orifice. 
The pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
The average velocity field for the 400 μm slit shown in Figure 6.2.2.1.3 is similar 
to that for the 200 μm slit orifice except that it is significantly skewed to one side of the 
chamber. The initial skewing is most likely due to the orifice chamber not being level 
relative to the camera, but the progressive skewing may be due to excessive curvature of 
the inlet tubing. Despite the skewing of the jet, comparisons between this and the other 
jets can still be made. The peak velocity in this jet is approximately 35% higher than that 
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for the 200 μm slit orifice jet at 5.5 m/s. Similar recirculation regions are present, and this 
jet also appears to broaden quickly as it progresses downstream of the orifice. Figure 
6.2.2.1.4 show the flow profiles at 1, 3 and 5 hydraulic diameters downstream of the 
orifice. This plot indicates that at 5 diameters downstream of the orifice, the profile is 
almost the same as that 10 diameters downstream of the 200 μm slit orifice. Thus, this jet 
appears to dissipate more rapidly than the narrower jet. This dissipation may be due to the 
higher velocity recirculation regions for the 400 μm slit orifice jet which had a peak 
reverse velocity of -0.5 m/s compared to -0.35 for the 200 μm slit orifice jet. 
 
 
FIGURE 6.2.2.1.4. Flow profiles at 1, 3, and 5 hydraulic diameters downstream of the 
400 μm slit orifice. The pulse separation was 10 μs, and the vector plot is an average of 
1000 image pairs. Velocity in m/s is color coded according to the legend. 
 
The average velocity field for the 800 μm slit shown in Figure 6.2.2.1.5 is similar 
to that for the other slit orifice jets. The peak velocity of 4.8 m/s falls between those for 
the other two slit orifice jets, and the flow profiles shown in Figure 6.2.2.1.6 broaden 
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quickly as the jet flows downstream of the orifice indicating rapid dissipation. The more 
rapid dissipation of the slit orifice jets into the bulk flow as compared to the round orifice 
jets is most likely due to the narrowing of the chamber downstream of the orifice plate. 
Since the slit orifice jet is much wider in one direction than in the other, and this width is  
 
FIGURE 6.2.2.1.5. Average velocity vector field downstream of the 800 μm slit orifice. 
The pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
wider than the neck of the chamber, the jet flow impinges on the chamber wall inducing 
high velocity recirculation regions. In contrast, the recirculation regions for the round 
orifice have a maximum reverse velocity of -0.18 m/s. These higher velocity recirculation 
regions dissipate the jet more rapidly as well as transport activated platelets away from 
the orifice plate before they can aggregate. 
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FIGURE 6.2.2.1.6. Flow profiles at 0.5, 1, 2, and 2.5 hydraulic diameters downstream of 
the 800 μm slit orifice. The pulse separation was 10 μs, and the vector plot is an average 
of 1000 image pairs. Velocity in m/s is color coded according to the legend. 
 
6.2.2.2. VRMS fields 
The VRMS fields corresponding to the jet average velocity fields presented in the 
previous section will be shown in this section. These plots show the magnitude of the 
velocity fluctuations present in the jets. The VRMS fields for the 200, 400, and 800 μm slit 
orifice jets are shown in Figures 6.2.2.2.1, 6.2.2.2.2, and 6.2.2.2.3, respectively. Figure 
6.2.2.2.1 shows that the highest VRMS values are found in the core of the 200 μm slit 
orifice jet near the orifice and has a peak value of approximately 3.4 m/s. This peak value 
is as high as those for the 800 and 1200 μm round orifices. However, unlike the round 
orifice jets, these VRMS values decay rapidly, which corresponds to the rapid dissipation 
evident in the average velocity fields presented in the previous section. 
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FIGURE 6.2.2.2.1. VRMS field for the 200 μm slit orifice jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.2.2.2. VRMS field for the 400 μm slit orifice jet. VRMS units are m/s. VRMS 




FIGURE 6.2.1.2.3. VRMS field for the 800 μm slit orifice jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
 
The VRMS field for the 400 μm slit orifice jet in Figure 6.2.2.2.2 is skewed in the 
same manner as the velocity field. The highest VRMS is found on one side of the jet with a 
peak value of only 1.6 m/s. The VRMS field for the 800 μm slit orifice jet in Figure 
6.2.2.2.3 is more homogenous than that for the 400 μm slit orifice. The peak PReS values 
are located symmetrically on either side of the jet core downstream of the orifice. The 
peak values are also approximately 1.6 m/s. However, relatively high VRMS values (0.5 
m/s) extend out to the edges of the measurement plane. 
 
6.2.2.3. Reynolds stress fields 
The principal Reynold stress (PReS) fields corresponding to the jet average 
velocity fields presented in the previous section will be shown in this section. These plots 
give an indication of the velocity fluctuations that can cause blood element damage 
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and/or platelet activation. The Reynolds stress fields for the 200, 400, and 800 μm round 
orifice jets are shown in Figures 6.2.2.3.1, 6.2.2.3.2, and 6.2.2.3.3, respectively.  
Figure 6.2.2.3.1 shows that the highest PReS is found in the core of the 200 μm 
slit orifice jet near the orifice and has a peak value of approximately 12,500 dyn/cm2. 
This peak value is somewhat less than that for the 800 μm round orifice. However, unlike 
the round orifice jets, these PReS values decay rapidly, which corresponds to the rapid 
dissipation evident in the average velocity fields in the previous section.  
 
FIGURE 6.2.2.3.1. Principal Reynolds stress (PReS) field for the 200 μm slit orifice jet. 
PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
The PReS field for the 400 μm slit orifice jet in Figure 6.2.2.3.2 is skewed and has 
relatively high PReS values in the low flow region between 750 and 1000 dyn/cm2 with 
rough contours and asymmetry. The highest PReS is found on only one side of the jet 
with a peak value of only 3000 dyn/cm2. The PReS field for the 800 μm slit orifice jet in 
Figure 6.2.2.3.3 is more homogenous than that for the 400 μm slit orifice. The peak PReS 
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values are located symmetrically on either side of the jet core downstream of the orifice. 
The peak values are also approximately 3000 dyn/cm2. 
 
FIGURE 6.2.2.3.2. Principal Reynolds stress (PReS) field for the 400 μm slit orifice jet. 
PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.2.3.3. Principal Reynolds stress (PReS) field for the 800 μm slit orifice jet. 
PReS units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
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6.2.2.4. Shear stress fields 
The shear stress (SS) fields corresponding to the jet average velocity fields 
presented in the previous section are shown in this section. These plots give an indication 
of the magnitude of the velocity gradients between the different shear layers in the flow 
that can cause blood element damage and/or platelet activation. The shear stress fields for 
the 200, 400, and 800 μm slit orifice jets are shown in Figures 6.2.2.4.1, 6.2.2.4.2, and 
6.2.2.4.3, respectively.  Figures 6.2.2.4.1 shows that the highest SS levels for the 200 μm 
slit orifice jet are found on either side of the jet core and have peak values of 
approximately 75 dyn/cm2. The location of these higher SS values coincides with the 
mixing of the higher velocity jet and the lower velocity recirculation regions near the 
orifice. The SS field for the 400 μm slit orifice jet in Figure 6.2.2.4.2 is skewed but like 
the 200 μm slit orifice, the highest SS values are still found on either side of the jet core. 
However, the peak SS values on either side of this jet are 140 and 180 dyn/cm2. This 
inequality in the magnitude of these SS values indicates that the skewing of the jet 
induces more interaction between the shear layers on the side that the jet is leaning 
towards. The SS field for the 800 μm slit orifice in Figure 6.2.2.4.3 is similar to that for 
the other slit orifices. However, the peak SS values have moved farther downstream of 
the orifice, which corresponds approximately to the same amount of hydraulic diameters 
downstream of the orifice as the other slit orifices. The peak SS values are about 130 
dyn/cm2. For all of the slit orifice jets, the location of the higher SS values coincides with 
the mixing of the higher velocity jet and the lower velocity recirculation regions as the jet 
begins to dissipate downstream of the orifice. The main difference between SS fields for 
the slit orifice jets and the round orifice jets is that the high SS regions for the slit orifice 
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jets diverge more than those for the round orifice jets, which corresponds to the more 
rapid broadening of the flow profiles downstream of the slit orifices. 
 
FIGURE 6.2.2.4.1. Shear stress (SS) field for the 200 μm slit orifice jet. SS units are 
dyn/cm2. SS magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.2.4.2. Shear stress (SS) field for the 400 μm slit orifice jet. SS units are 




FIGURE 6.2.2.4.3. Shear stress (SS) field for the 800 μm slit orifice jet. SS units are 
dyn/cm2. SS magnitudes are color coded according to the legend. 
 
6.2.3. Channel results 
PIV was not performed with the channels with a smallest diameter of 400 μm 
because the seed particles aggregated and occluded the orifice. Thus, the following 
section includes PIV data only for Channels 2, 4, 6, and 8 (minimum diameter of 800 
μm). 
 
6.2.3.1. Average velocity flow fields 
The average velocity field for Channel 2 with a pulse separation time of 10 μs is 
shown in Figure 6.2.3.1.1. The flow field looks similar to that for the 800 μm round 
orifice with the same peak velocity of 6 m/s. Figure 6.2.3.1.2 shows the velocity profiles 
at 1, 3, 5, and 7 diameters downstream of Channel 2. These flow profiles show the decay 
of the jet as the flow moves downstream of the orifice. Since the field of view does not  
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FIGURE 6.2.3.1.1. Average velocity vector field downstream of Channel 2. The pulse 
separation was 10 μs, and the vector plot is an average of 1000 image pairs. Velocity in 
m/s is color coded according to the legend. 
 
 
FIGURE 6.2.3.1.2. Flow profiles at 1, 3, 5, and 7 diameters downstream of Channel 2. 
The pulse separation was 10 μs, and and the vector plot is an average of 1000 image 
pairs. Velocity in m/s is color coded according to the legend. 
 
 160 
extend beyond 7 diameters, the fully developed, self-similar, jet profile cannot be seen in 
this plot. However, it is evident from this plot that the profile flattens out very quickly 
indicating that the jet dissipates very rapidly. These jet profiles appear to be similar to 
those for the 800 μm round orifice. 
The average velocity field for Channel 4 with a pulse separation time of 10 μs is 
shown in Figure 6.2.3.1.3. The flow field also looks similar to that for the 800 μm round  
 
FIGURE 6.2.3.1.3. Average velocity vector field downstream of Channel 4. The pulse 
separation was 10 μs, and the vector plot is an average of 1000 image pairs. Velocity in 
m/s is color coded according to the legend. 
 
orifice except that the peak velocity of 5 m/s is somewhat lower. This decrease 
corresponds to the lower flow rate through Channel 4 that may be due to the more abrupt 
geometry of Channel 4. Figure 6.2.3.1.4 shows the velocity profiles at 1, 3, and 6 
diameters downstream of Channel 4. These flow profiles show the decay of the jet as the 
flow moves downstream of the orifice. Since the field of view does not extend beyond 6 




FIGURE 6.2.3.1.4. Flow profiles at 1, 3, and 6 diameters downstream of Channel 4. The 
pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
 
FIGURE 6.2.3.1.5. Average velocity vector field downstream of Channel 6. The pulse 
separation was 10 μs, and the vector plot is an average of 1000 image pairs. Velocity in 
m/s is color coded according to the legend. 
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However, it is evident from this plot that the profile flattens out very quickly indicating 
that the jet dissipates very rapidly. These jet profiles appear to flatten out more quickly 
than those for the 800 μm round orifice and Channel 2, which may indicate that the 
Channel 4 jet dissipates more rapidly, perhaps because of the lower core velocity. 
 
 
FIGURE 6.2.3.1.6. Flow profiles at 1, 3, 5, and 7 diameters downstream of Channel 6. 
The pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
The average velocity field for Channel 6 with a pulse separation time of 10 μs is 
shown in Figure 6.2.3.1.5. The flow field looks similar to that for the 800 μm round 
orifice with a same peak velocity of 5.5 m/s, which is between that of Channels 2 and 4. 
Figure 6.2.3.1.6 shows the velocity profiles at 1, 3, 5, and 7 diameters downstream of 
Channel 6. These flow profiles show the decay of the jet as the flow moves downstream 
of the orifice. Since the field of view does not extend beyond 7 diameters, the fully 
developed, self-similar, jet profile cannot be seen in this plot. However, it is evident from 
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this plot that the profile flattens out very quickly indicating that the jet dissipates very 
rapidly. These jet profiles appear to be similar to those for the 800 μm round orifice and 
Channel 2. 
The average velocity field for Channel 8 with a pulse separation time of 10 μs is 
shown in Figure 6.2.3.1.7. The flow field spreads out much more quickly than that for 
any of the other channels or for the 800 μm round orifice. Additionally, the peak velocity 
of 3.6 m/s is lower than that for the Channels 2 and 6, which have a smoother geometry, 
and for the 800 μm round orifice. It is also lower than that for Channel 4, which has a 
larger exterior diameter compared to the larger internal diameter of Channel 8.  This 
larger internal diameter may influence the jet flow due to recirculation regions inside the 
channel. The jet is also skewed, which may indicate that the chamber was not level 
relative to the camera.  
 
FIGURE 6.2.3.1.7. Average velocity vector field downstream of Channel 8. The pulse 
separation was 10 μs, and the vector plot is an average of 1000 image pairs. Velocity in 
m/s is color coded according to the legend. 
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Figure 6.2.3.1.8 shows the velocity profiles at 1, 3, 5 diameters downstream of Channel 
8. These flow profiles show the decay of the jet as the flow moves downstream of the 
orifice. Since the field of view does not extend beyond 5 diameters, the fully developed, 
self-similar, jet profile cannot be seen in this plot. However, it is evident from this plot 
that the profile flattens out very quickly indicating that the jet dissipates very rapidly. 
These jet profiles appear flatten out more quickly than those for the other channels or the 
800 μm round orifice. The Channel 8 jet may dissipate more quickly because of the lower 
velocity and recirculation regions inside the channel. 
 
 
FIGURE 6.2.3.1.8. Flow profiles at 1, 3, and 5 diameters downstream of Channel 8. The 
pulse separation was 10 μs, and the vector plot is an average of 1000 image pairs. 
Velocity in m/s is color coded according to the legend. 
 
 
6.2.3.2. VRMS fields 
The VRMS fields corresponding to the channel jet average velocity fields presented 
in the previous section will be shown in this section. These plots show the magnitude of 
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the velocity fluctuations present in the jets. The VRMS for the Channel 2, 4, 6, and 8 jets 
are shown in Figures 6.2.3.2.1, 6.2.3.2.2, 6.2.3.2.3 and 6.2.3.2.4, respectively. 
 
FIGURE 6.2.3.2.1. VRMS field for the Channel 2 jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
 
The Channel 2 jet VRMS field in Figure 6.2.3.2.1 is similar to that for the 800 μm round 
orifice jet except that the peak values are distributed on either side of the jet core instead 
of concentrated in the center. The peak VRMS value for the Channel 2 jet is approximately 
3.4 m/s compared to 3.5 m/s for the 800 μm round orifice jet. The VRMS field for the 
Channel 4 jet in Figure 6.2.3.2.2 is similar to that for Channel 2 and the 800 μm round 
orifice jets. The peak value of 3 m/s is lower than that for Channel 2 and the 800 μm 
round orifice. The peak VRMS values are also concentrated in the core of the jet as they 
are for the 800 μm round orifice indicating that the abrupt transition to the larger exit 
diameter of Channel 4 may concentrate these velocity fluctuations in the jet core whereas 
the smoother transition in Channel 2 may spread out these fluctuations thus stabilizing 
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the jet core. This result corresponds with the flatter jet profile downstream of Channel 4 
compared to Channel 2. 
 
FIGURE 6.2.3.2.2. VRMS field for the Channel 4 jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.3.2.3. VRMS field for the Channel 6 jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
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The Channel 6 jet VRMS field in Figure 6.2.3.2.3 is similar to that for the 800 μm round 
orifice jet. Like the 800 μm round orifice jet peak values are concentrated in the core of 
the jet; however, higher VRMS values also extend to either side of the jet core. The peak 
VRMS value for the Channel 6 jet is approximately 3.2 m/s compared to 3.5 m/s for the 
800 μm round orifice jet and 3.4 m/s for the Channel 2 jet. The VRMS field for the 
Channel 8 jet in Figure 6.2.3.2.4 is similar to that for the Channel 4 and the 800 μm round 
orifice jets. The peak value of 2.6 m/s is lower than that for the other channels. The peak 
VRMS values are also concentrated in the core of the jet as they are for the 800 μm round 
orifice. 
 
FIGURE 6.2.3.2.4. VRMS field for the Channel 8 jet. VRMS units are m/s. VRMS 
magnitudes are color coded according to the legend. 
 
 168 
6.2.3.3. Reynolds stress fields 
The principal Reynold stress (PReS) fields corresponding to the jet average 
velocity fields presented in the previous section will be shown in this section. These plots 
give an indication of the velocity fluctuations that can cause blood element damage 
and/or platelet activation. The Reynolds stress fields for the Channel 2, 4, 6, and 8 jets are 
shown in Figures 6.2.3.3.1, 6.2.3.3.2, 6.2.3.3.3 and 6.2.3.3.4, respectively. 
 
FIGURE 6.2.3.3.1. Principal Reynolds stress (PReS) field for the Channel 2 jet. PReS 
units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
The Channel 2 jet PReS field in Figure 6.2.3.3.1 is similar to that for the 800 μm round 
orifice jet except that the peak values are distributed on either side of the jet core instead 
of concentrated in the center. The peak PReS value for the Channel 2 jet is approximately 
12,500 dyn/cm2 compared to 15,000 dyn/cm2 for the 800 μm round orifice jet. The PReS 
field for the Channel 4 jet in Figure 6.2.3.3.2 is similar to that for Channel 2 and the 800 
μm round orifice jets. The peak value of 10,000 dyn/cm2 is lower due to the lower jet 
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velocity. The peak PReS values are also concentrated in the core of the jet as they are for 
the 800 μm round orifice indicating that the abrupt transition to the larger exit diameter of 
Channel 4 may concentrate these stresses in the jet core whereas the smoother transition 
in Channel 2 may spread out these stresses thus stabilizing the jet core. This result 
corresponds with the flatter jet profile downstream of Channel 4 compared to Channel 2. 
 
FIGURE 6.2.3.3.2. Principal Reynolds stress (PReS) field for the Channel 4 jet. PReS 
units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
The Channel 6 jet PReS field in Figure 6.2.3.3.3 is similar to that for the 800 μm round 
orifice jet. Like the 800 μm round orifice jet peak values are concentrated in the core of 
the jet; however, higher PReS values also extend to either side of the jet core. The peak 
PReS value for the Channel 6 jet is approximately 12,000 dyn/cm2 compared to 15,000 
dyn/cm2 for the 800 μm round orifice jet and 12,5000 for the Channel 2 jet. The PReS 
field for the Channel 8 jet in Figure 6.2.3.3.4 is similar to that for the Channel 4 and the 
800 μm round orifice jets. The peak value of 7,800 dyn/cm2 is lower due to the lower jet 
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velocity. The peak PReS values are also concentrated in the core of the jet as they are for 
the 800 μm round orifice. 
 
FIGURE 6.2.3.3.3. Principal Reynolds stress (PReS) field for the Channel 6 jet. PReS 
units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.3.3.4. Principal Reynolds stress (PReS) field for the Channel 8 jet. PReS 
units are dyn/cm2. PRes magnitudes are color coded according to the legend. 
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6.2.3.4. Shear stress fields 
The shear stress (SS) fields corresponding to the jet average velocity fields presented in 
the previous section will be shown in this section. These plots give an indication of the 
magnitude of the velocity gradients between the different shear layers in the flow that can 
cause blood element damage and/or platelet activation. The SS fields for the Channel 2, 
4, 6, and 8 jets are shown in Figures 6.2.3.4.1, 6.2.3.4.2, 6.2.3.4.3 and 6.2.3.4.4, 
respectively.  
 
FIGURE 6.2.3.4.1. Shear stress (SS) field for the Channel 2 jet. SS units are dyn/cm2. SS 
magnitudes are color coded according to the legend. 
 
Figure 6.2.3.4.1 shows that the highest SS values for the Channel 2 jet are found 
on either side of the jet core and have a peak value of approximately 90 dyn/cm2. The 
location of these higher SS values coincides with the mixing of the higher velocity jet and 
the lower velocity recirculation regions near the orifice. Thus, these areas may be 
vulnerable to inducing platelet activation, and the subsequent recirculation may enable 
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these activated platelets to aggregate. This SS field looks similar to that for the 800 μm 
round orifice jet except that this jet had concentrations of high SS values at the orifice, 
and these concentrations are absent for the Channel 2 jet. This may indicate that the 
smoother exit of Channel 2reduces the shear layers in this region. 
 
FIGURE 6.2.3.4.2. Shear stress (SS) field for the Channel 4 jet. SS units are dyn/cm2. SS 
magnitudes are color coded according to the legend. 
 
The SS field for the Channel 4 jet in Figure 6.2.3.4.2 is similar to that for the Channel 2 
jet. However, the peak SS value is somewhat lower than that for the Channel 2 jet at 75 
dyn/cm2. The SS field for the Channel 6 jet in Figure 6.2.3.4.3 is similar to that for the 
800 μm round orifice but with a lower peak SS values of 75 dyn/cm2. The SS field for the 
Channel 8 jet in Figure 6.2.3.4.4 is similar to that for the Channel 2 and 4 jets. However, 
the peak value is lower than those for the other channel jets at 45dyn/cm2. The skewing 
of the jet is evidenced by the asymmetry of the SS field. The side that the jet is skewed 
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towards has higher magnitude SS values as well as a more rapid decrease in these values 
showing the instability of this side of the jet compared to the other side. 
 
FIGURE 6.2.3.4.3. Shear stress (SS) field for the Channel 6 jet. SS units are dyn/cm2. SS 
magnitudes are color coded according to the legend. 
 
 
FIGURE 6.2.3.3.4. Shear stress (SS) field for the Channel 8 jet. SS units are dyn/cm2. SS 
magnitudes are color coded according to the legend. 
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6.3. Wall Shear Stress Calculations 
The wall shear stresses for the round and slit orifices were calculated using 
approximations for laminar pipe entrance flows. The wall shear stress for the round 
orifices was calculated as the dynamic viscosity, ν, times the magnitude of the partial 
derivative with respect to the radial direction, r, of the laminar pipe entrance velocity 
profile [54]  in Equation 5.1.5.1. For the slit orifices, the wall shear stress was calculated 
as the dynamic viscosity, ν, times the magnitude of the partial derivative with respect to 
the transverse direction, y, of the laminar parallel plate channel velocity profile [54] in 
Equation 5.1.5.3. For all of the wall shear stress (WSS) calculations, the derivative was 
calculated 50 μm downstream of the orifice inlet at x=50 μm. WSS was also calculated 
for the low and high flow rate experiments with the 800 μm round orifice. These wall 
shear stress WSS values are presented in Table 6.3.1 along with the jet Reynolds 
numbers, flow rates for the orifices, and estimated bulk velocities. 
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TABLE 6.3.1. Flow rate, bulk velocity, Reynolds number (Re=aU/ν for the round 
orifices, Re= hU/ν for the slit orifices), and estimated wall shear stress for the orifices 
used in this study. Bulk velocity was calculated based on the cross-sectional area and 
measured flow rate, and wall shear stress was estimated using a laminar pipe entrance 
flow profile for the round orifices and a parallel plate channel entrance flow profile for 
















200 μm round orifice 0.01 5.31 150 21,700 
400 μm round orifice 0.045 5.97 340 19,100 
800 μm round orifice-low 
flow 
0.09 3.0 340 5,300 
800 μm round orifice-
normal 
0.15 5.0 570 9,200 
800 μm round orifice-
high flow 
0.19 6.6 750 12,400 
1200 μm round orifice 0.32 4.72 810 6,000 
200 μm slit orifice 0.90 5.91 170 24,200 
400 μm slit orifice 1.7 5.58 320 21,100 
800 μm slit orifice 3.06 5.02 570 15,800 
 
 
6.4. Baboon ex vivo shunt studies 
The original purpose of these studies was to establish a relationship between slit size 
and platelet deposition. However, since only the 800 μm slit orifice was used in the ex 
vivo shunt, this relationship could not be established. However, by repeating the 
experiments with the 800 μm slit orifice, a reproducible protocol was established for 
these experiments so that future studies can investigate this connection. Figure 6.4.1 
shows the non-normalized results for all the ex vivo experiments. These results show that 
both the cumulative platelet deposition and the platelet deposition rate are dependent 



























FIGURE 6.4.1. Platelet count over time for the baboon ex vivo shunt experiments.  
 
Using the ‘new protocol,’ the administration of heparin was controlled so that the APTT 
clotting time was maintained between 95 and 125 seconds. However, even with the new 
protocol there was still an unacceptable level of variability. Thus, it was determined that 
initial platelet count was the controlling factor for these experiments. Figure 6.4.2 shows 
onlydata from experiments with initial platelet counts above 380. The APTT times, initial 
platelet count, and initial flow rate for each experiment are given in Table 6.4.1. These 
results show that by controlling the initial platelet count using more stringent animal 
selection, reproducibility of the platelet deposition rate is achieved. Thus, a protocol that 
dictates an initial platelet count above 380 and a starting APTT above 95 seconds is able 
to deliver more reproducible results.  
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TABLE 6.4.1. Important values for each of the ex vivo experiments. (*=same animal). 
Highlighted experiments had similar platelet deposition rate values. 
 
y = 0.0668x + 0.506
R2 = 0.9815
y = 0.0426x - 0.0388
R2 = 0.9932
























FIGURE 6.4.2. Platelet count over time for the baboon ex vivo shunt experiments with 
initial platelet counts within the newly established limits. Trendlines show the platelet 
deposition rate. These experiments with similar initial platelet counts had similar platelet 
deposition rates as shown in Table 7.2.1. 
 
Images of the orifice from 7/14/05 were taken after the experiment and are shown in 
Figure 6.4.3. The proximal image represents the upstream side of the orifice, and the 
distal image represents the downstream side. The corresponding platelet count on these 













6-17-03* 95 109 412 187 0.067 
6-24-03* 167 150 339 203 0.0074 
7-30-03 78 94 308 204 0.0048 
2-5-04 173 230 242 160 0.0009 
5-19-04 132 125 407 260 0.043 
7-14-05 105 132 380 200 0.050 
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sides of the orifice was 3.89x109 platelets and 0.54x109 platelets for the distal and 
proximal side, respectively. 
  
 
FIGURE 6.4.3. Photographs of the proximal and distal sides of the 800 μm slit orifice 
after the 7/14/05 baboon ex vivo shunt experiment. The distal side appears to have more 





In the past, the study of shear-activated platelet aggregation (SIPA) and activation 
(SIPAct) has been isolated mainly to cone and plate viscometer and parallel plate flow 
chamber studies in which the parameters are not strictly physiological in nature [39] [40] 
[42]. Furthermore, many of these studies have been conducted in the presence of 
collagen, vWF, or fibrin, which promote platelet aggregation thus biasing the results by 
artificially inducing thrombus formation [57]. The present system enables coagulation in 
a dynamic steady flow environment in which different orifices and channels as well as 
mechanical heart valves can be introduced to investigate the effect of different shapes and 
sizes that induce different flow fields and shear stresses on platelet activation and 
procoagulant potential. The discussion section is divided into four sections: 
recalcification system development, the round and slit orifice experiments, the channel 
experiments, and the MHV experiments. These sections address the specific aims of this 
study. The first of these aims was to develop an in vitro system in which coagulation can 
occur in response to an external agonist, shear stress in particular. This system was then 
used to investigate platelet activation and coagulation initiated by flow through different 
channels designed to approximate the hinge region of various bileaflet MHVs. These 
flow fields were also validated using DPIV to detail the differences in them that may 
make a specific geometry more susceptible to thromboemboli formation than another. 
Lastly, MHVs were used in the in vitro system to examine the effect of hinge gap width 
and hinge geometry on these parameters. 
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7.1. Recalcification system development 
One of the specific aims of this research was to develop a system in which thrombus 
formation could be reproducibly initiated by shear stress activation of platelets. Initial 
experiments were performed under low shear stress conditions with a glass tube as an 
agonist. A continuous infusion of calcium chloride served to partially reverse the 
anticoagulant effect of the sodium citrate. This system of recalcification proved to be 
successful in these experiments and in the later experiments with the orifices, channels, 
and MHVs that did impart high shear stresses on the blood elements. Indeed, experiments 
with the 400 μm round orifice without calcium chloride infusion showed that calcium 
infusion was necessary to produce significant TAT generation and clotting in the loop in 
a reproducible fashion. Although some TAT was formed in the non-calcium infused 
experiments (Figure 6.1.4.1.1), most likely due to the shear-induced calcium efflux from 
activated platelets enabling the propagation of the coagulation cascade, it was not 
significant or reproducible. Thus, a key finding of the study was that calcium may be 
infused into citrated blood in vitro to greatly enhance the haemostatic and procoagulant 
potential of citrated recirculating blood.  Thus, the method may be attractive for sensitive 
evaluation of the thrombus forming potential of other surfaces and devices, the effects of 
antithrombotic strategies, and the role of important variables. Indeed, this method clearly 
documents the role of platelet concentration for catalyzing coagulation reactions leading 
to the formation of TAT.  
Additional experiments were performed to investigate the role of platelets in the 
thrombus formation using platelet depleted blood. The purpose of these experiments was 
to show that thrombus formation in this system was dependent upon initiation of the 
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coagulation cascade by the activation of platelets. The significantly lower TAT increases 
seen with platelet depleted blood and the 400 μm orifice compared to the normal runs 
with this orifice (Figure 6.1.4.1.1), indicate that TAT generation in this system can be 
attributed predominantly to platelet activation which markedly enhances coagulation 
reactions. Platelet depleted blood still contains approximately 15% of the platelets found 
in normal whole blood (85% platelet removal efficiency); thus, the small amount of TAT 
formed in the platelet depleted experiments is consistent with the TAT increase 
demonstrated in the experiments with normal whole blood. Indeed, at 45 and 60 minutes 
the TAT concentrations for the platelet depleted experiments were 13% and 18%, 
respectively, of the TAT concentrations for the normal experiments at these sample 
times. This percentage correlates directly with the average percentage of remaining 
platelets in the depleted blood of 15%. Thus, TAT generation and therefore coagulation 
are directly dependent upon platelet count. 
Hemolysis occurred on a statistically insignificant scale (Figures 6.1.1.2.1 and 
6.1.2.2.1), but may have been sufficient to release ADP to further activate the platelets 
that were present. Platelet aggregates in whole blood have been shown to be more stable 
than those formed in platelet rich plasma, implying that RBCs play a role in clot 
formation [58]. Further, RBCs can adhere independently to activated platelets and fibrin 
under low shear rates instead of just being passively entrapped in clots [59]. Thus, the 
low shear rates present upstream and downstream of the orifices may have allowed the 
RBCs to aid in coagulation even when the platelet concentration was markedly reduced.  
However, because hemolysis was minimal, clotting was most likely due to shear-induced 
activation of the platelets and not to the release of ADP by damaged RBCs. Additionally, 
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the importance of circulating tissue factor in the plasma cannot be ruled out. Studies have 
suggested that this circulating tissue factor may be incorporated into thrombi in a shear-
dependent manner [60], although the importance of this pathway in the absence of tissue 
injury remains unclear. 
These experiments with platelet-depleted blood did show the importance of platelets 
in the thrombus formation in this system; however, the role of shear stress was still not 
documented. Thus, experiments with Aggrastat and the AN51 antibody were performed 
to block the GPIIb/IIIa and GPIb platelet receptors, respectively. In particular the GPIb 
has been implicated in shear activated platelet aggregation as shown in the diagram in 
Figure 7.1.1. The TAT results for the 400 μm round orifice experiments with Aggrastat 
and AN51 antibody addition (Figure 6.1.4.1.1) show that the independent inhibition of 
both the GPIIb/III and GPIb platelet receptors suppresses TAT formation in this shear-
activated system. However, the trendlines in Figure 6.1.4.1.2 and the rates of TAT 
increase in Table 6.1.4.1.1 show that Aggrastat is moderately more effective than AN51 
at suppressing TAT formation. This difference in effectiveness can be explained by a two 
step mechanism for SIPA [40] in which rapid binding of vWF to GPIb tethers platelets, 
and subsequent binding of fibrinogen to both GPIb and GPIIb/IIIa stabilizes the 
thrombus. Furthermore, the GPIIb/IIIa receptor on activated platelets can bind with at 
least four different ligands (fibrinogen, vWF, fibronectin, and vitronectin) and only with 
immobilized fibrinogen when not activated. However, the GPIb receptor can bind with 
only soluble vWF in the presence of shear stress and with immobilized vWF in the 
absence of shear stress [35]. Based on this knowledge, it is apparent that these two 
platelet receptors represent different pathways of platelet activation and aggregation 
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under shear stress conditions, and that the GPIIb/IIIa receptor is more versatile and has 
increased functionality compared to the GPIb receptor. Active GPIIb/IIIa receptors are 
critical to platelet recruitment in thrombus formation [61]. In the presence of Aggrastat, 
platelets can be immobilized in a transient manner, but further platelet recruitment is not 
possible without functional GPIIb/IIIa receptors. However, even in the absence of 
functional GPIb receptors, platelet aggregation and subsequent platelet recruitment may 
be possible in low flow regions where activated platelets mingle for sufficient residence 
times for fibrinogen to bind to activated GPIIb/IIIa receptors. In this system, activated 
platelets generally move too quickly for this to occur, but we did observe some TAT 
formation in the AN51 experiments that was above baseline levels showing that some 
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FIGURE 7.1.1. Diagram of the pathway from shear activation of platelets to activation of 
the coagulation cascade and platelet aggregation. 
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There is also evidence that vWF and fibrin have a cooperative effect on platelet 
adhesion and aggregation under high shear conditions. These studies indicate that resting 
platelets under flow conditions at high shear stresses adhere to immobilized vWF via the 
GPIb platelet receptor and are consequently slowed down and activated. This activation 
turns on the GPIIb/IIIa receptor and allows it to bind to vWF, since this adhesive reaction 
appears to take longer than the reaction between vWF and GPIb. This step is necessary 
for thrombus formation, since a fast dissociation rate and reversible bonds characterize 
the vWF-GPIb interaction, while the vWF-GPIIb/IIIa interaction is irreversible. After 
immobilization by the vWF-GPIIb/IIIa interaction, fibrinogen binding to the GPIIb/IIIa 
receptor may function to recruit more platelets and to stabilize the thrombus [39-42]. 
Thus, the vWF-GPIb interaction is crucial to initiating platelet arrest and activation, but 
the vWF-GPIIb/IIIa interaction is necessary for permanent thrombus formation and 
increasing the size of the thrombus. In addition to simple development of the thrombus 
by fibrinogen binding to GPIIb/IIIa, fibrinogen may also gradually replace the vWF that 
initially constructed the thrombi under high flow conditions [43].  
Histological observations also support a two-step mechanism for SIPA and 
subsequent thrombus formation. In the initial stages, the thrombus increases in height and 
volume with flow and under the adhesive power of vWF [43]. However, over time the 
vWF must be replaced by fibrinogen in order to stabilize the thrombus.  
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FIGURE 7.1.2. Carstairs and vWF immunofluorescence staining of two clots upstream 
and downstream of the orifice under normal conditions. (A) Carstairs stain of 
downstream clot. The dark blue areas indicate a concentration of platelets, and the 
orange-red cells are RBCs. Fibrin is shown by the red strands surrounding the clot. (B) 
anti-vWF stain of downstream clot. Bright green denotes vWF, and bright blue is RBCs. 
(C) Carstairs stain of upstream clot. This thrombus is composed mainly of RBCs with 
some platelets and fibrin enmeshed. (D) anti-vWF stain of upstream clot. In Carstairs 
stain navy blue is platelets, red is fibrin and orange-red is RBCs. In anti-vWF stain blue is 
RBCs and nuclei and bright green is vWF. 
 
This difference in morphology can be observed in the differences between the 
upstream and downstream thrombi in one of the experiments. The downstream thrombus 
(Figure 7.1.2A, B) has a more dense construction of mostly platelets and fibrin, whereas 
the upstream thrombus (Figure 7.1.2C, D) has a looser construction with an abundance of 
RBCs and vWF as well as some fibrin and platelets. Thus, the downstream thrombus 
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most likely occurred first and has already transitioned to mostly fibrinogen, while the 
upstream thrombus was probably still forming when the experiment was stopped. 
Platelet activation also seemed to be affected by the addition of Aggrastat and AN51. 
This study shows an increase in platelet activation in the AN51 experiments over the 
normal and Aggrastat experiments (Figure 6.1.4.2.2). Conversely, the Aggrastat 
experiments appeared to produce moderately less platelet activation. Thus, although 
neither Aggrastat nor AN51 appear to inhibit initial SIPAct, Aggrasat may attenuate 
further feedback activation by preventing fibrinogen binding to the GPIIb/IIIa receptor. 
AN51, however, does not inhibit this feedback activation and may even induce PF4 
release by its binding to the GPIb receptor. 
Previous cone and plate viscometer studies using the AN51 antibody to the GPIb 
platelet receptor showed a significant reduction in Annexin V expression, which is also a 
measure of platelet activation [37]. In the current study the measure of platelet activation 
was PF4, which has previously been shown to be a more sensitive measure of platelet 
activation than Annexin V expression, which indicates mechanical changes in the platelet 
membrane Travis [62]. Annexin V expression on the external cell membrane is a positive 
sign that phosphatidyl serine (PS) has moved from the inside to the outside of the platelet 
cell membrane. The mechanism behind this transmembrane redistribution is unknown. 
PF4 release occurs as a result of platelet activation by many different pathways via α-
granules released from activated platelets. It is not clear whether PS redistribution or PF4 
release occurs first. Thus, PF4 release may occur even in the absence of Annexin V 
expression. The suppression of Annexin V expression but not PF4 release by the AN51 
antibody indicates that PF4 release must occur via a different pathway than PS 
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translocation. However, since there was not a concomitant increase in TAT production, 
the release of PF4 observed in the AN51 experiments may not indicate a calcium influx. 
This calcium influx is necessary for complete shear activated platelet activation and the 
subsequent release of factors to initiate the coagulation cascade. Thus, this PF4 release 
may only indicate a conformational change in the GPIb receptor that induced PF4 release 
without the initiation of a calcium influx that customarily follows binding of GPIb to 
vWF. 
 
7.2. Round and slit orifice experiments 
The round and slit orifice models used in this study, particularly the 400 μm 
orifice, model the hinge region and the B-datum line of a closed bileaflet MHV, 
respectively. These are the two regions through which blood flows during the leakage 
phase of the cardiac cycle, and the resulting flow fields have been shown to impart 
considerable shear stresses on the blood. Studying these two geometries independently 
from the complexity of the bileaflet MHV has enabled us to better characterize the clot 
propensity of these sizes and shapes of orifices without the complications of moving 
leaflets and the presence of both leakage areas. 
 These experiments showed a considerable increase in TAT concentration over 
time for the 200 and 400 μm orifices, but not for the 800 μm or 1200 μm orifices 
(Figures 6.1.1.1.2 and 6.1.1.1.3). The absence of a significant increase in TAT formation 
with the 800 μm and 1200 μm orifice confirmed that coagulation was not induced by the 
flow loop alone. Thus, the TAT increase can be attributed to the platelet activation 
incurred as the blood flowed through the 200 μm and 400 μm orifices in combination 
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with the stagnation regions downstream of the smaller orifices. Additionally, since TAT 
concentration increased dramatically below an orifice size of 800 μm, there is most likely 
a critical orifice size threshold between 400 and 800 μm that induces thrombus formation.  
Surprisingly, TAT levels for the 200 μm orifices were not significantly larger than 
those for the 400 μm orifices. One explanation for this lack of an increase in the 
circulating TAT concentration may be that there is a limit for circulating TAT in the flow 
loop. An apparent leveling off of the TAT concentration at 60 minutes supports this 
explanation. Another interesting result is that the increase in TAT concentration at 15 
minutes is significantly higher for the 400 μm orifice than for the 200 μm orifice (Figure 
6.1.1.1.4). This could be due to the fact that the 400 μm orifice has a larger internal 
circumferential surface area on which a thrombus could form. This behavior also 
implicates a dependence of TAT formation in this system on the number of times that a 
blood volume passes through the orifice. At 15 minutes the estimated number of times 
that a blood volume passes through the 200 μm round orifice is 2, and the number of 
‘passes’ through the 400 μm round orifice at 15 minutes is 10. Thus, after only 2 passes 
through the system, the platelets may not be sufficiently primed for propagation of the 
coagulation cascade. This priming of the platelets may occur via exposure to the pump or 
to the foreign materials in the flow loop as well as via subsequent passes through the 
orifice. Although mechanical platelet activation via shear stress has been shown to occur 
in response to a single instance of shear stress, continuous exposure to the conditions in 
this steady flow loop may activate the GPIb platelet receptors without inducing complete 
platelet activation. Thus, after a certain amount of exposure, the platelets may be primed 
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to bind with vWF in an opportunistic fashion if they encounter a stagnation or circulation 
region. 
 Shankaran et al [37] showed, using Annexin V binding to GPIb on platelets as a 
marker, that shear stress induced platelet aggregation (SIPA) is dependent on the shear 
stress level but not on the shear rate. They found a threshold shear stress for whole blood 
to undergo SIPA of 83 dyn/cm2. Zhang et al [63] found that SIPA and subsequent platelet 
aggregation is increased when there is a small interval (2.5 sec) of high shear (100 
dyn/cm2) followed by a constant application of low shear (5 dyn/cm2) as opposed to a 
constant application of high shear. In the current study the average shear stresses 
experienced by the blood as it passed through the different orifices is estimated to be 
more than 100 dyn/cm2, and this high shear is transient followed by regions of stagnation 
and recirculation. However, there was an indication of significant coagulation in only the 
two smallest round orifices corresponding to the most pronounced recirculation zones. 
Thus, the high shear stresses may have activated the platelets, but the recirculation 
regions and subsequent longer residence times downstream of the orifice plate appear to 
have been key for inducing and accumulating thrombosis. 
Another interpretation for TAT formation in this loop could be the different 
residence times for the different orifices resulting in flow stagnation and subsequent 
thrombin formation. Since the smaller orifices have lower flow rates, the residence times 
in the orifice chamber and the rest of the loop is higher. To investigate these residence 
times, flow visualization with dye injection was performed for the round orifices since 
they had the longest residence times. The flow fields for the round orifices were all 
similar with regions of recirculation both upstream and downstream of the orifice plate. 
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Upstream of the orifice plate, the flow that did not go through the orifice impinged upon 
the orifice plate and was directed in two counter-rotational recirculation regions on either 
side of the chamber. Similarly, downstream of the orifice plate, as the jet expanded, flow 
at the edges of the jet impinged on the chamber walls at the throat and was directed in 
two counter-rotational recirculation regions on either side of the jet. In general the 
residence times upstream of all the round orifices were relatively long ranging from 3 to 
5 seconds for the 1200 μm round orifice to 16 to 18 seconds for the 200 μm orifice. If the 
particles became entrapped in a recirculation region, the residence time was even longer. 
The residence times downstream of the orifices were not nearly as long ranging from 1.3 
to 2.6 seconds for the 200 μm round orifice to less than 0.2 seconds for the 1200 μm 
orifice. However, if the particles became entrapped in a downstream region of 
recirculation this residence time could be much longer with observed entrapment times of 
up to 38 seconds for the 200 μm orifice and 9 seconds for the 400 μm. In general, 
however, the jet was mixed with the bulk flow efficiently.  
Detailing the kinetics of thrombus formation is critical in determining whether or 
not a thrombus will form under various flow conditions, especially in regions of high 
velocity such as mechanical heart valve leakage jets. Studies done using a 10-micron 
filter to retain platelet aggregates while applying a predetermined pressure leading to 
elevated shear stress have shown that activation and aggregation can occur within 8 ms 
[64]. Thus, activated platelets, if brought together, could aggregate in a very short time 
period. Another study that investigated the cytosolic calcium flux that occurs with 
platelet activation and subsequent thrombus formation found that interactions between a 
resting and a pre-formed thrombus, which contains activated platelets undergoing 
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sustained calcium flux oscillations, must occur within a temporal window of less than 0.6 
seconds in order for the signal to be propagated [46]. This activation was dependent upon 
the platelets coming into contact when the activated cell was expressing its peak calcium 
flux. Therefore, calcium flux propagation appears to be dependent upon timely and 
intimate platelet interactions between activated and resting platelets. At the location in 
the flow loop just downstream of the orifice, at least some of the platelets have been 
activated by the shear stress both inside and at the orifices. With a time of 0.6 seconds 
between initial platelet activation by shear and subsequent activation of adjacent platelets 
by communication of a calcium flux via contact with the activated platelet [46], the 
residence times downstream of the orifice, especially if the platelet is entrapped in a 
vortice, are crucial to propagation of platelet activation. Once the blood leaves the 
chamber it is mixed in the centrifugal pump with platelets that are most likely no longer 
activated or at least beyond the stage at which they can propagate activation. Thus, if 
platelet aggregation is to occur it is dependent upon activated platelets propagating a 
calcium flux to other platelets within 0.6 seconds of initial activation. 
Although these different residence times must play a part in the thrombus 
formation in this system, other evidence does not imply that TAT would be formed in the 
absence of the high shear stresses imparted during flow through the smaller orifices. To 
test whether the blood was in an artificially thrombogenic state after the addition of the 
calcium, the blood was sampled at the end of the experiments and placed in glass test 
tubes to measure the whole blood clotting times. However, in every case the clotting time 
was infinite. These results are contrary to what was seen in bench tests at higher citrate to 
Ca2+ ratios in which the blood did clot after an average of 200 seconds. Thus, it appears 
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that contact activation has a higher Ca2+ requirement than does shear stress-mediated 
platelet activation and subsequent thrombus formation.  
The role of residence time and varying shear stress with the same size orifice was 
investigated using the 800 μm round orifice at both higher and lower flow rates than the 
normal 800 μm round orifice experiments. At the higher flow rate, the pump speed had to 
be increased to increase the flow rate. The higher pump RPMs resulted in unacceptable 
temperature increases (up to 104 ° F) and consequent high levels of hemolysis (Figure 
6.1.3.2.1). Thus, these results were not considered valid to show the effect of elevated 
shear stress with the same orifice size. However, the low flow rate experiments were 
successful, and these results showed that decreasing the flow rate did not increase the 
TAT levels compared to the 800 μm round orifice normal shear stress experiments 
(Figure 6.1.3.1.1). This result shows that it was not only the lower flow rate and 
consequent lower Reynolds number for the 400 μm round orifice that caused significant 
TAT production compared to the 800 μm round orifice. The 400 μm round orifice had 
higher WSS (Table 6.3.1) than either the normal or low flow 800 μm round orifice 
experiments with estimated values of 19,100 dyn/cm2, 9,200 dyn/cm2, and 6,000 dyn/cm2 
for the 400 μm round, 800 μm round normal, and 800 μm round low flow experiments, 
respectively.  This WSS for the 400 μm round orifice is nearly twice that for the 800 μm 
round orifice under normal conditions with similar durations of exposure for the 
individual platelets. Thus, the TAT formation resulting from flow through the 400 μm 
round orifice is most likely a combination of the resulting high WSS and downstream 
stagnation regions. 
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Because of the short exposure time of the platelets to these high WSS of 
approximately 0.1 ms for each pass through the orifice, it may not be reasonable to 
assume that they are being activated by shear stress alone. In addition, the dependence 
upon passes discussed earlier for the 200 μm round orifice experiments implies that the 
flow loop itself may be responsible for placing the platelets in a state in which they are 
primed for activation due to the action of the centrifugal pump and the presence of 
foreign materials. In this primed state, the platelets can aggregate in response to 
stagnation regions thus propagating the coagulation cascade. In this system the addition 
of Ca2+ provides the final stimulus to enable coagulation and TAT formation. Although 
this contact activation of the platelets is not the effect that was initially desired, it may be 
similar to what is happening in vivo due to the implantation of foreign materials in the 
form of MHVs or other vascular devices.   
However, in discussing the possibility for the steady flow loop to place the 
platelets in a primed state, the cumulative effect of exposure to the wall shear stresses and 
Reynolds stresses encountered by the platelets as they pass through the orifices cannot be 
ignored. The cumulative exposure times for the different orifices are 0.8 ms, 3.5 ms, 11.7 
ms, and 24.9 ms for the 200 μm, 400 μm, 800 μm, and 1200 μm round orifices, 
respectively. These cumulative exposure times, especially for the larger orifices with 
higher flow rates, are sufficient to completely activate the platelets at the WSS and RSS 
levels present in these experiments. Control experiments without an orifice demonstrated 
a cumulative PF4 concentration of approximately 220 ng/ml. When compared to the 
cumulative PF4 levels found for the 400 μm and 1200 μm round orifices of 480 ng/ml 
and 990 ng/ml, respectively, it is evident that the although the pump and the rest of the 
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steady flow loop contribute to platelet activation in this system, they are not the dominant 
factor. Also, because of the larger volume of the pump head compared to the orifice plate, 
the exposure time in the pump is approximately 65% of the time that the blood spends in 
the steady flow loop. Thus, a larger contribution to platelet activation would be expected 
if the pump appreciably activates the platelets. For the control experiments at a flow rate 
of 3.4 l/min, the estimated amount of passes through the pump for each platelet at the end 
of the experiment was greater that 2500. Thus, when normalized by passes, the 
cumulative PF4 release for the control experiment and the 400 μm and 1200 μm round 
orifice experiments was 0.088 ng/ml*pass, 13.7 ng/ml*pass, and 4.0 ng/ml*pass, 
respectively. This implies that the flow through the orifice has a substantially greater 
contribution to platelet activation than flow through the pump head. 
 The result that the slit orifices did not produce a measurable increase in TAT 
concentration (Figure 6.1.2.1.1) contradicts a leakage jet study from Travis et al in which 
higher RSSs were measured in the jets through the B-datum line than through the hinge 
[17]. The analysis by Travis et al indicated that planar free jets may be more unstable 
than other leakage jets (round free jets and wall jets) based on its transitionally turbulent 
nature leading to faster spreading of the jet and thus more damaging to blood elements 
[17]. However the planar jets in the current study did not exhibit more instability than the 
round jets. The planar jets studied in Travis et al also differed in size and shape from the 
slit orifice jets and had different maximum velocities. The two planar jets were 4 mm x 1 
mm with a maximum velocity of 0.41 m/s and 2.8 mm x 0.8 mm with a maximum 
velocity of 0.78 m/s. Both of these jets had Reynolds numbers above 30. The maximum 
velocities of the jets in the current study were between 5 and 8 m/s with Reynolds 
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numbers above 160. These higher jet Reynolds numbers indicate that the slit jets in the 
current study are turbulent jets and are not directly comparable to the transitional jets 
from Travis et al. Furthermore, higher RSS values are not the only factor taken into 
consideration for propagation of the coagulation cascade. The presence of stagnation or 
circulation regions downstream of the high RSSs are also necessary.  
 DPIV was used to further investigate these flow fields and to illuminate the 
important differences between these different flow fields that could result in TAT 
formation for the smaller orifices but not for the larger orifices. These measurements 
showed that the 400 μm round orifice jet had a lower velocity than the 800 and 1200 μm 
jets and dissipated more rapidly (Figures 6.2.1.1.1, 6.2.1.1.4, and 6.2.1.1.8). Also, the 
flow field appeared to be more unstable, although this could have been due to problems 
with the DPIV measurements since the particles had a tendency to aggregate and occlude 
the 400 μm round orifice. To alleviate the orifice occlusion, the particle number and size 
were decreased, which resulted in a non-optimal seeding density for the cross-correlation 
scheme. The filter settings for the post-processing had to be relaxed to allow for the 
calculation of vectors from only one or a few particles in the flow. Thus, more noise was 
introduced into the measurements for the 400 μm round orifice DPIV experiments. 
Averaging the image pairs did help to remove some of the noise, but in doing so, low 
velocity vectors, which may or may not have been real or may not have been in the jet 
centerplane, were included in the averaged velocity field. 
 One important difference between the 400 μm round orifice jet and the 800 μm 
round orifice jets is the velocities in the recirculation regions on either side of the jet 
(Figures 6.2.1.1.2 and 6.2.1.1.5).  The reverse velocity magnitudes in this region for the 
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800 μm round orifice jet were twice that for the 400 μm round orifice (-0.09 m/s versus -
0.18 m/s) Thus, as was shown qualitatively in the flow visualization studies discussed 
earlier, platelets that become entrapped in these regions will remain in them longer for 
the 400 μm round orifice than for the large orifices. Stream traces placed in the flow for 
both of these orifice jets shown in Figure 7.2.1 demonstrate the potential entrapment 
pathways for these platelets. Vortices are also evident downstream of the jet where 
platelets can become entrapped and aggregate. These aggregates can travel through the 
flow loop and then become lodged in the orifice where they have the potential to grow 
into the larger thrombi that were seen at the end of the experiments.  
 
FIGURE 7.2.1. Stream traces for the 400 and 800 μm round orifice jet recirculation 
regions. These traces show where platelets travel from different origin points in the flow 
field. For both orifices, traces show a trend for the flow to impinge upon the chamber 
throat and return to the jet where Reynolds and shear stresses are high. There are also 
stagnation regions downstream of the orifice. 
 
These pathways, in addition to bringing activated platelets together to aggregate, also 
potentially expose platelets repeatedly to the high Reynolds stresses (Figures 6.2.1.3.1 
and 6.2.1.3.2) and high shear stresses (Figures 6.2.1.4.1 and 6.2.1.4.2) at edges of the jets. 
























FIGURE 7.2.2. Axial profiles of streamwise velocity 1 diameter downstream of the 400 
and 800 μm round orifices. The 800 μm round orifice jet appears to have a more 
Gaussian profile characteristic of a turbulent jet. 
 
To better understand the differences in the 400 μm and 800 μm round orifice jet 
flow fields, velocity cross-sections at 1 and 6 diameters downstream of the two orifices 
are shown in Figures 7.2.2 and 7.2.3. Besides the considerable difference in the peak 
centerline velocities between the two orifices, there is also a difference in the shape of the 
curves. The 800 μm round orifice jet exhibits a more Gaussian type curve that is more 
characteristic of a turbulent jet, whereas the 400 μm round orifice has a flatter profile that 




























FIGURE 7.2.3. Axial profiles of streamwise velocity 6 diameters downstream of the 400 
and 800 μm round orifices. The 800 μm round orifice jet appears to have a more 
Gaussian profile characteristic of a turbulent jet. 
 
This dissipation can be more clearly seen in Figure 7.2.4. This plot shows the 
centerline velocities for the 400 and 800 μm round orifice jets as a function of the axial 
direction. The trendline is the mean centerline velocity decay for a self preserving round 













 Equation 7.2.1 
where V is the average centerline velocity at Y, Yo is the jet origin (orifice plate 
location), Vc is the average centerline velocity at Yo, D is the orifice diameter, and a is a 
constant for the type of jet. This constant has values of 5.6 and 6.5 for nozzle and pipe 
jets, respectively. Values of the decay constant that deviate from these accepted values 
can give important insight into the decay behavior of the jet. A previous study of a 
turbulent jet issuing into a more viscous fluid than the jet fluid has shown a dependence 
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of the decay constant, a, on entrainment [66]. This study showed that increased 
entrainment of the relatively stagnant fluid by the jet results in a lower jet decay constant, 
and, consequently, the jet decays more quickly than expected. This faster decay is due to 
the higher laminar shear stresses that cause the jet decay to deviate from the normal 
behavior of a turbulent jet. Increased entrainment is an indication that more mixing is 
occurring. In the case of activated platelets issuing into a relatively stagnant pool of 
resting platelets, increased mixing can increase the probability for propagation of platelet 
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FIGURE 7.2.4. Axial centerline jet profiles for the 400 and 800 μm round orifice jets 
plotted with the jet decay model for self-similar round turbulent jets.  
 
Figure 7.2.4 shows that at approximately 5 diameters, the 800 μm round orifice jet has 
still not entered the self-similar region. Figure 7.2.5 shows the axial centerline velocity 
for the 800 μm round orifice jet even farther downstream, and when it reaches 10 
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diameters it clearly fits this model for a self-similar turbulent jet with a decay constant of 
6, which is between that for nozzle and pipe jets. The 400 μm round orifice has the 
correct slope for a turbulent jet between 5 and 11 diameters downstream of the orifice. 
However, the decay constant is lower than that for a turbulent jet. Thus, the 400 μm 
round orifice jet appears to entrain more of the chamber fluid than the larger jets resulting 
in a lower decay constant and faster decay rate. This behavior may explain its rapid 
dissipation since the entrainment disrupts the orderly jet structure relatively quickly. 
Entrainment of the relatively still chamber fluid would introduce platelets to the higher 
stresses in the jet potentially activating more of the platelets than if entrainment was not 
as prevalent. This increase in entrainment may also explain why the 400 μm round orifice 
jet induces TAT formation, while the 800 μm round orifice does not, even at lower 









Jet Decay Model (a=6)
 
FIGURE 7.2.5. Axial centerline jet profiles beyond 10 diameters downstream for the 800 
μm round orifice jets plotted with the jet decay model for self-similar turbulent jets. The 
800 μm round orifice jet does correlate with the model using a constant between that for 
nozzle and pipe jets (5.6 and 6.5, respectively). 
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Figure 7.2.6 shows the centerplane jet velocities plotted versus the axial direction 
for the 800 μm round orifice jets under normal and low flow rate conditions. These two 
jets have almost the same decay curves, and the decay constants are 4.0 and 4.1 for the 
low and normal shear stress cases, respectively. Despite the different Reynolds numbers 
(570 and 340 for the normal and low flow rate cases, respectively), and consequent 
different velocities and shear stresses, the universal jet properties are still the same. 
Therefore, it may be orifice size, and not the flow rate through the orifice that determines 
these jet properties at the Reynolds numbers tested in this study. This similarity in these 
jets may explain why there was no difference in TAT formation between the normal and 
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FIGURE 7.2.6. Axial centerline jet profiles for the 800 μm round low and normal shear 
stress orifice jets plotted with the jet decay model for round self-similar turbulent jets.  
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Despite the lower flow rate, the low flow rate jet did not demonstrate the rapid dissipation 
resulting from the increased entrainment that was seen in the 400 μm round orifice jet. It 
is this greater mixing of the jet flow with the relatively stagnant chamber fluid that 
appears to be key for inducing thrombus formation in this system. 
 
7.3. Channel experiments 
The channels used in this study model the geometrical features of the hinge region of 
various bileaflet MHVs (Figure 6.1.5.1). For the smaller channels with a minimum 
diameter of 400 μm, there was no significant difference in TAT formation. Thus, for this 
diameter, size was more important than the geometry in initiating coagulation resulting in 
subsequent thrombus formation. Since the minimum diameter of these smaller channels 
were the same as that of the 400 μm round orifice, the resulting TAT formation is most 
likely due to the same mechanism as that for the 400 μm round orifice. However, the 
elevated TAT levels for the larger channels indicates that there must be a difference 
either in the jets or in the internal channel fluid dynamics that results in an increased 
propensity for thromboemboli formation for some of the channels. The PF4 results 
(Figure 6.1.5.2.1) showed that there was no significant difference in platelet activation 
between the different channels, and PF4 release for all of the channels was above 400 
ng/ml, which shows that platelets were mechanically activated above the baseline level (7 
ng/ml) for all of the channels. Furthermore, PIV results for the larger channels showed 
similar flow fields (Figures 6.2.3.1.2, 6.2.3.1.4, 6.2.3.1.6, and 6.2.3.1.8) and similar 
Reynolds stress (Figures 6.2.3.3.1-6.2.3.3.4) and shear stress levels (Figures 6.2.3.4.1-
6.2.3.4.4). To further investigate the differences in the jet flow fields, the flow profiles 1 
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diameter and 5 diameters downstream of the channel exit were plotted for all of the 
channels (Figures 7.3.1 and 7.3.2). Although the centerline velocities were not the same 
for all of the channels due to the different flow rates through the channels (Table 7.3.1), 
the shape of the profile did fit with the expected Gaussian profile for turbulent jets. The 
velocities for Channels 4 and 8 were lower than expected from the estimated values, 
which indicates that the actual profile was flatter than the parabolic profile used to 
estimate the velocities. The Channel 8 profile 5 at diameters downstream of the channel 
was noticeably flatter than the other profiles at this point. 
 
TABLE 7.3.1. Flow rates and estimated centerline velocities for the large channels. 
Channel Flow Rate, l/min Estimated Velocity, m/s 
2 0.17 5.6 
4 0.14 4.6 
6 0.15 5.0 



























FIGURE 7.3.1. Axial profiles of streamwise velocity 1 diameter downstream of Channels 
2, 4, 6, and 8 Although the velocities differ, the shapes of the flow profiles are similar 


























FIGURE 7.3.2. Axial profiles of streamwise velocity 5 diameter downstream of Channels 
2, 4, 6, and 8 Although the velocities differ, the shapes of the flow profiles are similar 
and have a Gaussian profile. 
 
The jet decay for these channel jets was investigated further by fitting Equation 
7.2.1 to the log-log plots of the normalized centerline velocity versus the axial direction 
normalized by the minimum channel diameter. Figures 7.3.3, 7.3.4, 7.3.5, and 7.3.6 show 
these plots for Channels 2, 4, 6, and 8, respectively. At locations greater than 5 diameters 
downstream of the channel exit, the Channel 2 and Channel 6 jets correlated well with the 
jet decay model with decay constants, a, of 4.3 for both of them, which is close to the 
accepted literature values between 5 and 6. However, Channels 4 and 8 had decay 
constants of 2.6 and 2.75, respectively, indicating that these jets may have had more 
entrainment of the chamber fluid, which caused the jet to dissipate more rapidly. This 
entrainment may result in increased interaction between the activated platelets thus 
increasing the chance for propagation of platelet activation and the coagulation cascade. 
Since all other flow parameters were maintained the same except for the channel 
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geometry, the internal sharp edges in Channels 4 and 8 are responsible for this increase in 
entrainment indicated by the decrease in the decay constant. Thus, the sharper edges may 
increase the jet’s propensity for entrainment making it more vulnerable to mixing of the 
relatively stagnant chamber fluid with the jet flow and consequent rapid dissipation. 
Since PF4 release (Figure 6.1.5.2.1) was similar for all of the channel experiments 
showing comparable levels of platelet activation, this greater amount of mixing for the 
channels with sharper edges appears to be instrumental in enabling propagation of the 
coagulation cascade as demonstrated by greater TAT formation for these channels. Thus, 
an increase in TAT production for Channels 4 and 8 versus Channels 2 and 6 (Figure 
6.1.5.1.2) is dependent upon differences in the flow fields for these different jets. 
Significantly more entrainment for the Channel 4 and 8 jets relative to the Channel 2 and 
6 jets indicates a greater amount of mixing of the fluid in the chamber and thus more 
stagnation. A lower jet decay constant also implies that the jet has been hampered in its 
development compared to the jets with higher jet decay constants and has thus been 
unable to develop into a characteristic turbulent round free jet. This behavior suggests 
that the internal geometry of Channels 4 and 8 induces flow fields inside the channel that 
affect the jet character. These internal flow fields may also enable coagulation to be 
initiated within the channels that is propagated as the jet exits. In this case, mixing of the 













Jet Decay Model (a=4.3)
 
FIGURE 7.3.3. Axial centerline jet profiles for Channel 2 plotted with the jet decay 
model for round self-similar turbulent jets. The correlation with the turbulent decay 
model is good beyond 6 diameters downstream of the channel with a jet decay constant 










Jet Decay Model (a=2.6)
 
FIGURE 7.3.4. Axial centerline jet profiles for Channel 4 plotted with the jet decay 
model for round self-similar turbulent jets. The decay function has the same slope as that 
for a round turbulent jet, but the decay constant (a=2.6) is much lower than the accepted 










Jet Decay Model (a=4.3)
 
FIGURE 7.3.5. Axial centerline jet profiles for Channel 6 plotted with the jet decay 
model for round self-similar turbulent jets. The correlation with the turbulent decay 
model is good beyond 6 diameters downstream of the channel with a jet decay constant 










Jet Decay Model (a=2.75)
 
FIGURE 7.3.6. Axial centerline jet profiles for Channel 8 plotted with the jet decay 
model for round self-similar turbulent jets. The decay function has the same slope as that 
for a round turbulent jet, but the decay constant (a=2.75) is much lower than the accepted 
values for a round jet indicating that there may be a significant amount of entrainment. 
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Animations of instantaneous vorticity measurements (movies 7.3.1, 7.3.2, 7.3.3, 
and 7.3.4 for Channels 2, 4, 6, and 8, respectively) also show the susceptibility of the 
Channel 4 and 8 jets to entrainment compared to the Channel 2 and 6 jets. Although all of 
these jets demonstrate significant vorticity and transverse movement of the jet, the 
Channel 4 and 8 jets begin to expand at locations nearer to the jet origin than do the 
Channel 2 and 6 jets. The vortices on either side of the Channel 4 and 8 jets appear to 
infiltrate theses jets closer to the jet origin than is the case for the Channel 2 and 6 jets. 
 
7.4. Mechanical heart valve experiments 
Previous in vitro blood studies with bileaflet MHVs have been isolated to the 
assessment of platelet activation [49] or damage, and most of these used only platelets 
[50] or porcine blood [16], not whole human blood. However, no other in vitro human 
blood studies have been performed to investigate the procoagulant potential of different 
bileaflet MHVs. Thus, one of the aims of this study was to show in vitro that hinge gap 
width and the hinge geometry affect both platelet activation and the propensity for 
coagulation. Both of these factors did in fact affect platelet activation and coagulation. 
In the experiments to assess the affect of hinge gap width, both the high leaker and 
the low leaker prototype valves induced significantly more PF4 release than the SJM 
Standard valve (Figures 6.1.6.2.2 and 6.1.6.2.3). The hinge geometry of these valves does 
not differ significantly, thus the only difference was the hinge gap width, which was 
estimated to be 80 μm, 100 μm, and 230 μm for the low leaker, the SJM Standard, and 
the high leaker valves, respectively (Table 5.1.7.1.). Previous fluid dynamics studies with 
LDV [25] have shown than the flow fields through the low and high leaker valves and the 
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SJM Standard valve differ mainly in the leakage jet size as shown in Figure 7.4.1. The 
























SJM 27 mm Standard, flat level
m/s m/s
Low leaker SJM Standard High leaker
Leakage jet at lateral corner
 
FIGURE 7.4.1. Flow fields for the the low leaker prototypw, SJM Standard, and high 
leaker prototype valves acquired via LDV. These flow fields show the leakage jet at the 
lateral corner, which is the main difference between the valve leakage flow fields [25]. 
 
the high shear stresses in the hinge region. Additionally, the low leaker valve is subject to 
higher viscous stresses and more stagnation due to the smaller hinge gap and decreased 
flow through the hinge region. Gap width was also shown in this study to affect TAT 
formation, or the procoagulant potential of the valve. The low leaker prototype valve 
demonstrated significantly greater TAT formation (Figures 6.1.6.1.2 and 6.1.6.1.3) than 
the SJM Standard valve. This valve had lower flow rates through the hinge region, thus 
as was the case for the smaller round orifices, the recirculation regions after the valve 
may have had lower velocities giving the activated platelets more time to mingle and 
aggregate. Figure 7.4.1 does show lower flow in the area of the leakage jet at the lateral 
corner of the hinge compared to the SJM Standard and high leaker prototype valves, thus, 
this region may be vulnerable to thrombus formation. Additionally, estimation of the 
viscous shear stresses through these hinge areas assuming Newtonian flow through a long 
narrow channel show yield values for the viscous shear stresses in the high and low 
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leaker hinge gaps of 470 and 9450 dyn/cm2, respectively [49]. These high estimated 
viscous stresses for the low leaker valve may explain the significant amount of PF4 
release compared to the SJM Standard valve despite the smaller leakage jet. The 
estimated viscous shear stress value for the SJM Standard valve was 1080 dyn/cm2, 
which is considerable less than that for the low leaker valve. Thus, the SJM Standard 
hinge gap size provides a balance between the high and low leaker hinge gap width that 
minimizes leakage volume without inducing excessive viscous stresses and enabling the 
formation of stagnation regions. 
This study also showed that hinge geometry affects procoagulant potential but not 
platelet activation. The MP valve was used as an extreme example of an unfavorable 
hinge geometry, and this valve was compared to the SJM Standard valve, which has a 
very smooth hinge geometry with minimal change in hinge diameter (Figure 2.3.2). 
Figure 7.4.2 shows the exact geometry of the MP hinge channel as measured by the LDV 
probe volume [15]. In the current study the MP valve demonstrated significantly  
 
FIGURE 7.4.2. Diagram of the MP valve hinge. The peg and the relief are the 
mechanism by which the leaflet opens and closes in the hinge recess [15]. 
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higher TAT formation (Figures 6.1.6.1.2 and 6.1.6.1.3) than the SJM Standard valve 
without higher levels of PF4 release (Figures 6.1.6.2.2 and 6.1.6.2.3). However both the 
SJM Standard and the MP valves did exhibit PF4 levels greater than 300 ng/ml, which is 
an order of magnitude higher than the clinical baseline level (20 ng/ml) indicating 
mechanical platelet activation. Thus, the multiple steps in diameter with 90 degree angles 
present in the MP hinge region must engender flow conditions that are conducive to flow 
stasis and recirculation that enables platelet aggregation and subsequent thromboemboli 
formation. This valve was in fact removed from the market during clinical trials because 
of excessive thromboembolic complication rates, and hemodynamic studies of the hinge 
region [23] [15] detailing the MP valve leakage flow fields have shown vortical flow 
patterns and stagnation regions. These leakage flow fields measured with LDV are shown  
 
FIGURE 7.4.3. LDV measurements of leakage flow within the hinge of the MP valve. 
Vector colors indicate velocity (m/s). The central region is characterized by a stagnation 
region with low flow, and the vectors at the outflow region indicate vortice formation. 
High velocity vectors are present at the top and bottom flowing around the peg [15]. 
 
in Figure 7.4.3. In this figure the velocity vectors along the inflow channel suggest a 
vortical flow pattern, and the reverse velocities near the center were only 0.05 m/s, which 
is essentially stagnant flow where activated platelets can aggregate. Higher velocity flow 
 212 
is directed over the peg resulting in laminar shear stresses of about 200 dynes/cm2, which 
is sufficient for platelet activation. The converging flow at the outlet provides another 
region where activated platelets can interact. Flow visualization studies by Gross et al 
(Gross, 1996) with hydrogen bubbles have illuminated these flow pathways even more. 
The schematic in Figure 7.4.4 shows that there in the stagnation region downstream of 
the peg, there is significant recirculation and unstable flow patterns where activated 
platelets may be entrapped and propagate the coagulation cascade. Computational fluid 
dynamics (CFD) was also performed to investigate these flow patterns, and these studies 
gave similar results as shown in Figure 7.4.5 [23]. The flow patterns in the hinge of the 
SJM Standard valve do not exhibit this type of unstable behavior since the blood is able 
to flow over the hinge protrusion with minimal impedance. 
 
FIGURE 7.4.4. Schematic of leakage flow fields through the MP valve visualized using 




FIGURE 7.4.5. Leakage flow fields through the MP valve simulated using CFD. Vortice 
formation is evident downstream of the peg [23]. 
 
The platelet activation results for the high leaker prototype valve are corroborated 
by previous studies with the same valves that also used PF4 as an endpoint [49]. Figure 
7.4.6 shows the PF4 results from the previous study. In this study, there appears to be a 
plateau in the PF4 values after 60 minutes, which may indicate that the PF4 concentration 
has reached a limiting value in the flow loop. The values for the previous study at 60 
minutes, at which point significance was nearly reached with a p-value of 0.083, are 
similar to those from the present study as shown in Figure 7.4.7.  
In addition to illuminating the importance of the hinge geometry and gap width on 
platelet activation and propensity for thromboemboli formation, this study also describes 
a system that can be used to investigate these parameters for other vascular devices that 
expose the blood to high or varying shear stresses. This methodology has the sensitivity 
to detect changes in both platelet activation and thromboembolic potential based on 
changes in the hinge geometry. It also has a small volume requiring only relatively small 
amounts of human blood that can be drawn from one donor. Thus, this study provides a 
simple yet powerful methodology to investigate various vascular devices for both platelet 






























SJM Standard Valve *
*p=0.083
 
FIGURE 7.4.6. Data from a previous in vitro steady flow study using the SJM Standard 






























FIGURE 7.4.7. Combined PF4 data for the current study and Travis et al at 60 minutes. 
This time represented the endpoint for the current study, but only the midpoint for Travis 







8.1. Blood experiments 
The blood studies have certain limitations because of the in vitro nature of the 
experiments and because whole blood was used with as little manipulation as possible. 
The goal of the study was to characterize coagulation in response to flow through small 
orifices while maintaining the blood in as close to a normal state as possible. In doing 
this, the blood was not manipulated to keep RBC and platelet counts constant. However, 
these were measured and the deviations from the average values were less than 15% 
between different donors. Continuous recalcification was performed to slowly reverse the 
effect of the sodium citrate, but it was not possible to bring the blood back to normal 
clotting times without resulting in gross thrombosis of the entire flow loop. To further 
maintain this normal state of the blood, it was used within 3 hours of being drawn from 
the donor to ensure that haemostasis factors would not degrade. To make this possible the 
duration of the experiments was kept at 60 minutes. However, in comparing these results 
to others by Travis et al, this duration appears to be sufficient for reproducible results. 
Beyond 60 minutes there appears to be a leveling off of PF4 concentrations indicating the 
platelets may be refractory at this point. Also, in this study TAT concentration began to 
level off between 45 and 60 minutes indicating that the haemostasis factors may be 
beginning to break down. Another limitation was that experiments were performed at 
room temperature. However, although SIPA has been shown to increase significantly at 
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temperatures below 37 °C, there was not a concomitant increase platelet activation [67] 
or in the haemostasis factors that indicate thrombus formation [68]. Thus, since these 
experiments serve to compare outcomes between different geometries under the same 
conditions, temperature was not considered a factor that would alter these comparative 
results. Also absent are factors associated with blood vessels and blood vessel injury, as 
well as filtration, dilution, and inactivation mechanisms as occur in vivo. 
This study also has certain limitations due to the simplicity of the orifice model for 
the MHV geometry. Because the aim was to isolate the hinge region and b-datum line 
there are no moving parts. Consequently, the intentional washing of the hinge area that 
occurs each time the leaflets open and close is not present. This washing is meant to 
sweep any aggregating platelets from the hinge area before a clot can form. Another 
limitation is that flow through the model is steady instead of pulsatile. The absence of 
pulsatile flow means that there is no change in the flow field as there is in vivo. 
 
8.2. DPIV experiments 
The limitations of the DPIV studies were mainly due to the small size of the orifices 
relative to the particle size. The orifices and channels with diameters of 400 μm or less 
were prone to occlusion due to aggregation of the 1-20 μm fluorescent particles over time 
resulting in a decrease in the flow rate until it became zero. Smaller 1-2 μm glass 
microbeads were tried, but they did not emit enough light to be imaged using the zoom 
lens. Smaller 1 μm fluorescent particles were also used, but they were also not bright 
enough to be used with the zoom lens. The final solution, which was adequate for the 400 
μm round orifice was to filter the larger fluorescent particles with a 5 μm filter so that 
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they would be between 1 and 5 μm in diameter. This solution did, however, result in 
lower particle density. Thus, the measurements for the 400 μm round orifice may not 
have been as accurate as those for the larger orifices and channels. 
Another limitation of the DPIV study was that we were duplicating the flow loop 
used in the blood studies. Thus, the entrance length was not sufficient to assume a fully-
developed flow profile at the inlet. This assumption is necessary for the jet calculations 
used in the discussion. However, since the orifices were quite small compared to the 
chamber diameter (Dchamber/Dorifice<0.05), this probably did not greatly influence the 
calculations. 
Another limitation was introduced by the laser light arm that was used to transport the 
laser sheet to the experimental setup. As the laser beam traveled through this arm, small 
errors in the mirror positions at each bend were propagated resulting in an enlargement of 
the laser spot diameter at the outlet of the laser arm. Thus, the laser sheet was limited to a 
thickness of 0.8 to 1 mm. For the 400 μm round orifice, this resulted in low velocity out 
of plane particles being included in the jet flow field. These lower velocity particles may 
have biased the velocity measurements so that the average centerline velocity was lower 







 This study describes the development of a system to recalcify citrated human 
blood to assess the thrombogenic potential of different devices in an in vitro steady flow 
loop. The significant findings were that: 1) recalcification of recirculating citrated blood 
markedly increases the magnitude of thrombus forming reactions and the sensitivity for 
their detection; 2) a shear-dependent threshold for thrombin generation and coagulation 
exists, suggesting that thrombosis in a MHV is most likely due to leakage flow through 
the hinge area and not through the B-datum line; 3) platelet activation, and the presence 
of adequate platelet numbers, may be essential for the activation of coagulation under 
conditions of high shear; and 4) coagulation can be inhibited by blocking the platelet 
receptors that facilitate platelet aggregation. 
The shear-induced nature of the system was confirmed by the inhibition of 
thrombus formation by blocking two platelet receptors, GPIIb/IIIa and GPIb, that are 
crucial to shear-induced platelet activation and aggregation. Histological results further 
showed the evolving morphology of the formed thrombus under the high shear flow 
conditions. Based on these results this system can be used to assess differences in 
procoagulant potential of various geometries under steady flow conditions. Even though 
the specific application for this study is MHV hinge geometries, it can also be used to 
study the procoagulant potential of other medical devices that are exposed to blood under 
varying shear conditions such as stents, septal devices, and vascular grafts. 
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The results from the DPIV studies give some insight into why the different 
channels resulted in varying propensities for thrombosis as measured by TAT 
concentration. The channel geometries that induced significantly higher levels of 
thrombosis also formed jets that were subject to increased entrainment of the stagnant 
fluid in the chamber. Entrainment enables more mixing of the shear-activated platelets 
with the surrounding flow, which can propagate the coagulation cascade, thus increasing 
the chance for thrombus formation. The channel geometries that produced these less 
stable jets had abrupt changes in diameter with 90 degree angles. Thus, these abrupt 
changes in diameter engender flow fields that are more favorable for coagulation. 
The influence of abrupt changes in diameter was also evident in the human blood 
studies designed to investigate the effect of MHV hinge geometry. The MP valve, which 
has a tortuous pathway through the hinge channel induced significantly more TAT 
formation than the SJM Standard valve with a smoother hinge channel. This increased 
propensity for coagulation by the MP valve was not accompanied by an increase in 
platelet activation relative to the SJM Standard valve. Thus, although platelet activation 
was similar for both of the valves, coagulation was not. This result shows that it is not 
necessarily platelet activation that is important in determining whether or not a valve will 
induce thrombosis in vivo. It is the subsequent flow fields after platelet activation has 
occurred that determine procoagulant potential. Nevertheless this study does show that 
MHV hinge geometry should be as smooth and free of diameter changes as possible to 
eliminate circulation and stagnation regions that enable activated platelets to congregate 
and propagate the coagulation cascade.  
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Leakage gap width also had a significant effect not only on procoagulant potential 
but also on platelet activation. Both the low and high leaker prototype valves had 
significantly higher levels of platelet activation compared to the SJM Standard valve, but 
only the low leaker valve demonstrated a higher propensity for coagulation. Since it is 
important to minimize both platelet activation and thromboemboli formation, an optimal 
gap width should be maintained for BMHVs that is similar to that of the SJM Standard 
valve to minimize both of these parameters.  
Cumulatively, these results imply that the designers of BMHVs should endeavor 
to minimize areas of high shear stress followed by stagnation regions. This can be 
accomplished by expanding hinge channels using smooth transitions to the larger 
diameter. Right angles should be avoided as well as expansion regions that are enclosed 
on both sides by contraction regions. Additionally, hinge channel size should be 
optimized to expose the smallest blood volume possible to the high shear stresses in the 
channel without exposing the blood to high viscous stresses resulting from flow through 
smaller hinge gap widths, such as those in the low leaker valve, that may induce 
excessive platelet activation and blood element damage as well as enable stagnation 
regions to form. Based on the estimated viscous shear stresses in the SJM Standard valve, 
this objective can be achieved by designing the hinge channel with viscous shear stresses 







This study shows that this recalcification methodology can be used to investigate 
the procoagulant potential of BMHVs and geometries to mimic the BMHV hinge region. 
However, the slits used in this study may not have been small enough to accurately 
predict coagulation induced by jets through the B-datum line of BMHVs or around the 
periphery of the valve between the leaflet and the valve housing. Thus, in the future 
smaller slits could be used to investigate the effects of these jets.  Also, in the future this 
system could also be utilized to investigate the thrombus-forming potential of other 
vascular devices besides BMHVs. This methodology has the necessary sensitivity to 
investigate the effect of small nuances in geometry and relate these to procoagulant 
potential. Thus, it could be used to look at different stent or ventricular patch designs. 
In addition to investigating other types of vascular devices, this recalcification 
system can also be used to elucidate the mechanism behind the thrombus formation that 
occurs in response to high shear stress regions followed by recirculation and stagnation 
regions. Platelet activation induces a calcium influx that in turn propagates the 
coagulation cascade. Using fluorescently labeled Ca2+ as the infusion medium, this influx 
could be observed in real time with confocal microscopy. Aggregation of these 
fluorescently labeled platelets would yield a better understanding of the flow field 
properties necessary to enable platelet aggregation and subsequent thrombus formation. 
Coupled with inhibition strategies to block different pathways in the coagulation cascade 
 222 
and platelet activation and aggregation, this system could be a powerful tool to engender 
a better understanding of shear-activated thrombus formation. 
Despite its success at measuring thromboembolic potential, this system may not 
be optimal for detecting the influence of small changes in geometry on platelet activation. 
Significant differences were detected based on hinge gap width, but there was no 
difference in PF4 release between the orifices or channels. Also, PF4 release was not 
suppressed significantly by either Aggrastat or AN51, and it was significantly increased 
by AN51 addition. This increase occurred without a concomitant increase in TAT 
formation, which would be expected if the platelets were actually activated. Thus, PF4 
may not be the best indication platelet activation in this system. Future work could be 
focused on developing a better marker for platelet activation. 
These results could also be used to develop a CFD model to predict 
thromboembolic potentials for different flow fields. The flow fields in the current study 
are well-defined and simple to duplicate in CFD because of there symmetric nature. The 
experimental conditions were also well-controlled. Thus, these TAT and PF4 results can 
be used in conjunction with the flow fields to develop and validate this code. This CFD 
code could then be used to predict these endpoints for other more complex geometries 
such as the MHV hinge area and other vascular devices. 
The DPIV used in this study could also be improved by using smaller fluorescent 
particles with increased brightness compared to the 1 μm particles that were used for 
some of these experiments. If the particles emitted more light in response to the laser, the 
zoom lens would be better able to detect these particles and track them using the DPIV 
software. Another method to improve the DPIV results would be to use particle tracking 
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software instead of DPIV software. Although it would not enable the quantitative 
measurements that can be achieved with DPIV, it would allow for better tracking of lone 
particles that are lost in DPIV processing. Particle tracking would also provide a history 
of what is happening to a single platelet in the flow field. 
Another area of this research that has room for further study are the ex vivo 
baboon experiments. The preliminary research performed in this area shows that 
reproducible results can be obtained by controlling the initial platelet count of the animal 
used in the studies. Thus, the protocol developed in this research can be used to 
investigate the smaller slit orifices and perhaps a larger slit orifice. The platelet 
deposition rates found in these studies would provide insight into the influence of slit size 














Acid Citrate Dextrose solution is available from the pharmacy or can be prepared as 
follows: 
 2.45g Dextrose 
2.2g Sodium Citrate (dihydrate) 
0.75g Citric Acid (anhyrous) 
Make up to 100mL with distilled water. 
Filter sterilize and store at 4°C 
 
ASA 
Acetylsalicylic acid (Sigma) 
Weigh out 1.8g and dissolve in 10mL absolute ethanol 
Store at room temperature. 
 
PGE1 
Prostaglandin E1 (Sigma) 
Stock solution - 1mg/mL 
Add 1mL absolute ethanol to 1mg vial. 
Store at -20°C 
Working solution - 100µg/mL 
Dilute stock solution 1:10 in absolute ethanol 




Cocktail is prepared just before the blood collection and kept on ice. 





Keep the blood chilled on ice for at least 5min but less than 30min. 
Ideally the blood should be centrifuged at 48000g for 20min at 4°C. 
Remove 200µL of the top plasma and store at -20°C or colder until assay time. 
It is important not to remove plasma to close to the cell layer since even a single platelet 
can cause a substantial increase in the PF4 levels. 
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A.2. TAT ELISA Protocol 
 
Note: All determinations should be performed in duplicate. A reference curve must be 
established for each series of measurements using the standards found in the test kit. All 
samples and standards must be pipetted into the 96-well plate within 5 minutes. The 
incubation period begins when the plate is placed in the water bath. 
 
1. Into each well of the 96-well plate pipette 50 μl of Sample Buffer. To each well then 
add 50 μl standard, control, or sample. After filling the test plates, shake briefly to 
ensure thorough mixing. 
2. Cover with self-adhesive foil and incubate for 15 minutes at 37 °C. 
3. Remove the foil, use a pipette to empty the contents of the wells and fill them with 
0.3 ml diluted washing solution. Remove the washing solution with a pipette then 
refill with 0.3 ml diluted washing solution. Remove the washing solution then wash 
and remove with the pipette once more for a total of 3 washing steps. Expel any 
remaining washing solution by knocking the test plate on a paper towel. 
4. Pipette 100 μl of Working Conjugate Solution into each well, taking care not to wet 
the edges of the wells. 
5. Cover with fresh self-adhesive foil and incubate for 15 minutes at 37 °C. 
6. Prepare the Working Chromogen Solution shortly before the end of the incubation 
period by adding 10 ml Buffer/Substrate POD into a vial of Chromogen POD and 
shake to dissolve. 
7. Remove the foil, use a pipette to empty the contents of the wells and fill them with 
0.3 ml diluted washing solution. Remove the washing solution with a pipette then 
refill with 0.3 ml diluted washing solution. Remove the washing solution then wash 
and remove with the pipette once more for a total of 3 washing steps. Expel any 
remaining washing solution by knocking the test plate on a paper towel. 
8. To each well add 100 μl of the freshly prepared Working Chromogen Solution. 
9. Cover with fresh self-adhesive foil and incubate at 20 to 25 °C protected from light 
for 30 minutes. 
10. Remove the foil and add 100 μl of Stopping Solution POD, keeping to the same 
timing as for the dispensing of the Working Chromogen Solution. 
11. Within one hour read against distilled water at a measurement wavelength of 492 nm. 
12. After calculating the mean absorbance values of the standards plot the reference curve 
on log-log graph paper (abscissa: concentration, ordinate: absorbance). From this 
standard curve you can get the concentrations of the other samples. 
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A.3. PF4 ELISA Protocol 
 
1. Into each well of the 96-well plate pipette 50 μl of Sample Buffer. To each well then 
add 50 μl standard, control, or sample. After filling the test plates, shake briefly to 
ensure thorough mixing. 
2. Cover with self-adhesive foil and incubate for 15 minutes at 37 °C. 
3. Remove the foil, use a pipette to empty the contents of the wells and fill them with 
0.3 ml diluted washing solution. Remove the washing solution with a pipette then 
refill with 0.3 ml diluted washing solution. Remove the washing solution then wash 
and remove with the pipette once more for a total of 3 washing steps. Expel any 
remaining washing solution by knocking the test plate on a paper towel. 
4. Pipette 100 μl of Working Conjugate Solution into each well, taking care not to wet 
the edges of the wells. 
5. Cover with fresh self-adhesive foil and incubate for 15 minutes at 37 °C. 
6. Prepare the Working Chromogen Solution shortly before the end of the incubation 
period by adding 10 ml Buffer/Substrate POD into a vial of Chromogen POD and 
shake to dissolve. 
7. Remove the foil, use a pipette to empty the contents of the wells and fill them with 
0.3 ml diluted washing solution. Remove the washing solution with a pipette then 
refill with 0.3 ml diluted washing solution. Remove the washing solution then wash 
and remove with the pipette once more for a total of 3 washing steps. Expel any 
remaining washing solution by knocking the test plate on a paper towel. 
8. To each well add 100 μl of the freshly prepared Working Chromogen Solution. 
9. Cover with fresh self-adhesive foil and incubate at 20 to 25 °C protected from light 
for 30 minutes. 
10. Remove the foil and add 100 μl of Stopping Solution POD, keeping to the same 
timing as for the dispensing of the Working Chromogen Solution. 
11. Within one hour read against distilled water at a measurement wavelength of 492 nm. 
12. After calculating the mean absorbance values of the standards plot the reference curve 
on log-log graph paper (abscissa: concentration, ordinate: absorbance). From this 
standard curve you can get the concentrations of the other samples. 
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A.4. Deparaffinization Protocol    
 
Purpose: Removal of paraffin from tissue sections prior to staining. 
References:     Leica Autostainer Manual 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    




1. Xylene substitutes, 3 stations, 5 min each. 
2. 100% alcohol, twice, 2 min each. 
3. 95% alcohol, twice, 2 min each. 
4. 75%, 2 min. 
5. Wash in water for 2 minutes. 
 





A.5. Hematoxylin and Eosin Stain Protocol    
 
Purpose: Detection of cell nuclei and membranes. 
References:     Leica Autostainer Manual. 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    




1. Deparaffinized slides are stained in Hematoxylin for 30 seconds; 
2. Rinse in DI water. 
3. Dip in acid alcohol. 
4. Rinse in DI water. 
5. Place in Scott’s solution for 30 seconds. 
6. Rinse in DI water. 
7. Wash in 95% alcohol for 1 min. 
8. Stain in alcoholic Eosin for 30 seconds. 
9. Dehydrate through ascending grades of alcohol and clear to xylene. Mount in a 
permanent mounting media. 
 
Regents and Solutions: 
 
Hematoxylin:Dilute Gill’s hematoxylin no.2 (Polysciences #04570) one to one with 
dH2O before use. 
Acid alcohol:2ml HCl (Fisher #A144s) in 198 ml of 70% ethanol. 
Eosin: EM Science #588X 






Membranes  red 
Cell nuclei  blue 
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A.6. Carstair’s Stain Protocol    
 
Purpose: Detection of fibrin and platelets. 
References:     Sheehan's Theory and Practice of Histotechnology, 2nd edition. 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    
Hazards: Picric acid is highly explosive when dry.  Wipe lids after use and tighten 
to prevent drying of solutions.  Xylene and alcohol are highly flammable. 
    
Method: 
 
1. Deparaffinze and rehydrate to distilled water.  
2. Rinse well in distilled water. 
3. Mordant sections in 5% ferric alum for 10 minutes and then rinse in tap water. 
4. Stain with Harris’ hematoxylin for 5 minutes and rinse in tap water.  If necessary, 
differentiate in 0.25% acid alcohol. 
5. Stain in picric acid-orange G solution for 30 minutes (up to 1 hour).  
6. Rinse once in distilled water. 
7. Stain in ponceau fuchsin for 5 minutes. 
8. Rinse once in distilled water. 
9. Differentiate with 1% phosphotungstic acid for 2 minutes.  Rinse well in water if 
checking microscopically. 
10. Stain with aniline blue solution for 10 minutes (up to 1 hour). 
11. Rinse sections in several changes of distilled water. 




Fibrin  red 
Muscle  red 
Platelets gray-blue to navy 
Collagen bright blue  
Rbc’s  clear yellow 
 
Reagents and Solutions: 
 
Picric Acid-Orange G 
Saturated picric acid  20ml 
Saturate picric acid in isopropanol 80ml 
Orange-G (CI 16230)  0.2g 
 
Ponceau-fuchsin  
Acid fuchsin (CI 42685)  0.5g 
Ponceau 2R   0.5g 
Glacial acetic acid   1ml 
Distilled water   99ml 
 
1% Aniline Blue  
Aniline blue (CI 42755)  1g 
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1% acetic acid   100ml 
 
5% Ferric Alum   
1% Phosphotungstic acid  
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A.7. vWF Immunohistochemistry Protocol Using Avidin D Fluorochrome Conjugates 
 
Purpose: Detection of vWF. 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    
Hazards: None  
 
Please note: All antibodies and related reagents are temperature sensitive. Please 
keep at 4 deg C or on ice at all times. This will maintain the longevity of the reagents 
and limit antibody or reagent-related problems with experiments. 
 
1. Deparaffinize embedded tissue and rehydrate in descending grades of alcohol. Wash 
sections in 1X PBS for 4 minutes. 
2. Perform antigen retrieval by incubating in protease for 10 minutes at room 
temperature. 
3. Wash slides in 1X PBS twice for 4 minutes each. 
4. Block tissue using 1% gelatin/PBS mixture for 20 minutes at room temp. 
5. Prepare the working dilution of the vWF antibody (Sigma), 1/600, in 1% BSA in 1X 
PBS. Blot off gelatin/PBS and apply primary antibody. Incubate sections in a humid 
chamber for 1 hour at room temp. 
6. Blot off excess antibody and wash slides in 1X PBS twice for 4 minutes each. 
7. Prepare working dilution of the biotinylated secondary antibody in 1% BSA in 1X 
PBS and add 2% of normal serum from the source animal of the seconday antibody. 
Prepare secondary antibody at 1/400 dilution. Apply antibody and incubate 30 
minutes at room temp in a humid chamber. 
8. Blot off excess antibody and wash slides in 1X PBS twice for 4 minutes each. 
9. Incubate sections with fluorochrome conjugated avidin D for 30 minutes in the dark. 
Prep 1/100 in BSA/PBS Avidin-D-FITC. 
10. Blot off excess solution and wash slides in 1X PBS twice for 4 minutes each in the 
dark. 
11. Mount with vectashield mounting media with nuclear counterstain. Store slides in the 
dark at 4 deg C. 
 
Regents and Solutions: 
 
Avidin D Fluorochrome conjugated:  Texas red (Vector A-2006), Fluoroscein (Vector 
A-2001) 
1% BSA/PBS:  1 g fraction V BSA (Sigma A2153) in 100 ml 1X PBS 
10 mM Citrate buffer, pH 6.0 (500 ml):  Solution A: 9 ml, Solution B: 41 ml, dH2O: 
450 ml. Adjust pH to 6.0. Bring up to 500 ml. Final concentrations are 1.96 mM citric 
acid and 8.2 mM sodium citrate. 
Solution A, Citric acid (109 mM):  Citric acid: 4.2 g, dH2O: 200 ml 
Solution B, Sodium citrate (100 mM): Sodium citrate: 14.7 g, dH2O: 500 ml 
10X PBS:  Boehringer Mannheim 1666789 
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Protease:  Dissolve protease (Sigma P-8038) in PBS for a stock concentration of 100 
mg/ml. Store at -20 °C. 
Proteinase K:  Dissolve proteinase K (Sigma P-4914) in dH2O for a stock concentration 
of 20 mg/ml. Store at -20 °C. 
Secondary antibodies, avidn D conjugates, and normal animal serum:  Vector 
laboratories, Inc. 30 Ingold Road, Burlingame, CA 94010 
Vectashield Hardset Mountant with DAPI (nuclear counterstain): Vector H-1500 
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A.8. vWF Immunohistochemistry Protocol Using ABC-Peroxidase 
 
Purpose: Detection of vWF. 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    
Hazards: DAB is a carcinogen, use protective measures to prevent exposure.  
 
Please note: All antibodies and related reagents are temperature sensitive. Please 
keep at 4 deg C or on ice at all times. This will maintain the longevity of the reagents 
and limit antibody or reagent-related problems with experiments. 
 
1. Deparaffinize embedded tissue and rehydrate in descending grades of alcohol. Wash 
sections in 1X PBS for 4 minutes. 
2. Perform antigen retrieval by incubating in protease for 10 minutes at room 
temperature. 
3. Wash slides in 1X PBS twice for 4 minutes each. 
4. Block endogenous peroxidase using 3% H2O2 in methanol for 15 min. at room 
temperature (dilute 1.5 ml of 30% H2O2 in 150 ml methanol). 
5. Rehydrate sections in 1X PBS twice for 5 min. each at room temp. 
6. Block tissue using 1% gelatin/PBS mixture for 20 minutes at room temp. 
7. Prepare the working dilution of the vWF antibody (Sigma), 1/600, in 1% BSA in 1X 
PBS. Blot off gelatin/PBS and apply primary antibody. Incubate sections in a humid 
chamber for 1 hour at room temp. 
8. Blot off excess antibody and wash slides in 1X PBS twice for 4 minutes each. 
9. Prepare working dilution of the biotinylated secondary antibody in 1% BSA in 1X 
PBS and add 2% of normal serum from the source animal of the seconday antibody. 
Prepare secondary antibody at 1/400 dilution. Apply antibody and incubate 30 
minutes at room temp in a humid chamber. 
10. Prepare the working solution of ABC-peroxidase complex from the Vectastain Elite 
ABC kit (PK-6100). Mix 5 ml of 1X PBS, 2 drops reagent A, and 2 drops reagent B. 
Allow to sit for 30 minutes prior to use. 
11. Blot off excess antibody and wash slides in 1X PBS twice for 4 minutes each. 
12. Apply prepared ABC mixture to each slide. Incubate in humid chamber for 1 hour at 
room temp. 
13. Blot off excess solution and wash slides in 1X PBS twice for 4 minutes each, 
followed by one wash in sterile deionized/distilled water for 5 min. 
14. Make up substrate solution, diaminobenizidine (DAB), immediately before use. DAB 
is a carcinogen so wear gloves, goggles, work on a diaper, and save liquid waste 
to be disposed of with chemical waste. In order, add: 15 ml of TBS, pH 7.6, 1 tablet 
DAB (10 mg), and 12 μl of 30% H2O2. Mix to dissolve tablet. Filter using Whatman 
#1. Apply filtered solution to each section. Incubate slides in the dark up to 10 min., 
checking color periodically. Stop reaction by blotting off substrate and rinsing in 1X 
PBS 3 times for 4 minutes each. 
15. Lightly counterstain with hematoxylin. Rinse slides well in water until water is clear. 
Dehydrate through graded alcohols, then xylene and coverslip for viewing. 
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Regents and Solutions: 
 
1% BSA/PBS:  1 g fraction V BSA (Sigma A2153) in 100 ml 1X PBS 
10 mM Citrate buffer, pH 6.0 (500 ml):  Solution A: 9 ml, Solution B: 41 ml, dH2O: 
450 ml. Adjust pH to 6.0. Bring up to 500 ml. Final concentrations are 1.96 mM citric 
acid and 8.2 mM sodium citrate. 
Solution A, Citric acid (109 mM):  Citric acid: 4.2 g, dH2O: 200 ml 
Solution B, Sodium citrate (100 mM): Sodium citrate: 14.7 g, dH2O: 500 ml 
Diaminobenzidine Tetrahydrochloride (DAB):  Sigma D-5905, 10 mg tablets X 50 
tablets 
Elite ABC-Peroxidase Kit:  Vector PK-6100 
10X PBS:  Boehringer Mannheim 1666789 
Protease:  Dissolve protease (Sigma P-8038) in PBS for a stock concentration of 100 
mg/ml. Store at -20 °C. 
Proteinase K:  Dissolve proteinase K (Sigma P-4914) in dH2O for a stock concentration 
of 20 mg/ml. Store at -20 °C. 
Secondary antibodies, avidn D conjugates, and normal animal serum:  Vector 
laboratories, Inc. 30 Ingold Road, Burlingame, CA 94010 
TBS:  Tris base: 12.1 g, Sodium chloride: 8.77g, dH2O to l l. (pH to 7.6)
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A.9. Hematoxylin Counterstaining Protocol    
 
Purpose: Counterstain cell nuclei to identify cells after performing ABC-peroxidase 
immunohistochemcistry. 
Microtomy: 5 um sections. 
Fixation: Neutral buffered formalin (formalin saline recommended). 
QC: Clotted blood or thrombus.    




1. Hematoxylin for 10 seconds. 
2. Rinse in tap water until clear. 
3. Dip once in 1% acid alcohol. 
4. Rinse in water. 
5. Scott’s solution for 20 seconds. 
6. Rinse in water. 
7. Dehydrate through graded alcohols then xylene. 
8. Coverslip. 
 
Regents and solutions: 
 
Hematoxylin: Dilute Gill’s hematoxylin no.2 (Polysciences #04570) one to one with 
dH2O before use. 
1% Acid Alcohol: 2ml HCl (Fisher #A144s) in 198 ml of 70% ethanol. 




A.10. SEM Preparation Protocol 
 
Purpose: Prepare samples for viewing with SEM. 
Microtomy: 5 um sections. 
Fixation: Neutral 2.5% glutaraldehyde. 
QC: Clotted blood or thrombus.    




1. Harvest tissue and rinse briefly in 0.2M sodium cacodylate buffer, pH 7.2. 
2. Fix tissue in 2.5% glutaraldehyde in cacodylate buffer, pH 7.2 for 1-2 hours. Dilute 
the stock of 8% glutaraldehyde using 0.2M cacodylate buffer, pH 7.2 immediately 
before use. 
3. Rinse in 0.2M cacodylate buffer, pH 7.2, 3 x 10 minutes. 
4. Dehydrate tissue sample using the following schedule, each for 0.5-1 hour: 25% 
alcohol, 50%, 70%, 90% x 2, 100% x 2. 
5. In place of critical point drying, dry the sample using hexamethyldisilazane. Use one 
of the following schedules (if the sample is of animal origin, use schedule a or b): 
6. Ratio 100% ethanol:HMDS starting from 100% ethanol going to 100% HMDS, each 
step for 30 min. 
a. 100% Ethanol =>2:1, 1:1, 1:2 => 100% HMDS 
b. 100% Ethanol =>3:1, 1:1, 1:3 => 100% HMDS 
7. Rinse in 3 changes of 100% HMDS. 
8. Dry from the last 100% HMDS. The level of HMDS should just cover the tissue 
sample. Leave the tube containing the sample open in the fume hood and allow the 
HMDS to evaporate and thus dry the tissue. Depending on sample size, drying should 
occur overnight. 
9. Adhere the sample to an aluminum stub using conductive, double sided carbon 
adhesive tape. 
10. Sputter-coat the sample using gold to a thickness of approx. 100 Angstroms. 
Desiccate sample until ready to analyze (in MSE lab). 
11. Keep tissue in desiccators (vacuum oven) before viewing under microscope. 
 
Reagents and supplies: 
 
8% Glutaraldehyde:   Electron Microscopy Sciences #16019 
16% Paraformaldehyde:   Electron Microscopy Sciences #15710 
0.2M cacodylate buffer, pH 7.4:  Electron Microscopy Sciences # 11652 
Hexamethyldisilazane:   Electron Microscopy Sciences #16700 
Aluminum stubs for the Hitachi S-800: SPI #01506-BA (table dia.12.7mm, pin dia. 
3.2mm, pin length 8.0mm) 











B.1. TAT ELISA assays – Raw data 
 
Orifice TAT Data: 
 
200um round
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/19/2003 0.00 0.00 47.67 109.75 110.68 0.00 48.36 112.98 115.63
12/19/2003 0.00 4.53 11.10 62.74 103.74 4.53 11.26 64.58 108.39
1/5/2004 0.00 0.00 43.70 112.24 115.54 0.00 44.34 115.54 120.71
01/06/04 37.12 22.15 111.79 115.39 118.86 -14.97 76.28 81.66 87.06
01/14/04 10.00 8.12 na 32.35 19.49 -1.88 na 23.30 10.37
average 9.42 6.96 53.56 86.49 93.66 average -2.46 45.06 79.61 88.43
std dev 16.08 9.15 42.13 37.20 41.85 std deviation 7.38 26.64 38.09 45.49
std error 3.30 13.32 17.04 20.34




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/8/2004 25.99 50.33 41.65 36.29 34.51 24.33 16.49 11.77 10.66
7/8/2004 25.99 34.87 57.12 95.70 113.25 8.88 32.27 73.59 94.29
8/25/2004 0.19 47.32 80.74 85.55 82.38 47.13 82.15 88.82 87.30
8/30/2004 0.39 8.19 30.59 81.39 77.15 7.80 30.81 84.30 81.54
8/30/2004 0.39 9.74 25.40 79.19 87.15 9.34 25.51 82.01 92.17
9/2/2004 0.06 0.08 1.23 1.17 17.24 0.02 1.19 1.16 18.25
9/30/2004 1.40 1.88 123.89 139.24 134.23 0.48 124.95 143.49 141.16
9/30/2004 0.87 22.04 130.26 142.21 138.09 21.17 131.98 147.11 145.79
8/6/2003 0.00 3.24 33.02 81.58 164.32 3.24 33.49 83.98 171.68
8/20/2003 0.00 67.45 105.08 162.20 194.39 67.45 106.60 166.97 203.10
11/11/03 0.00 0.00 22.78 58.04 96.71 0.00 23.11 59.75 101.04
09/24/03 1.07 63.91 26.04 24.60 52.18 62.84 25.35 24.25 53.44
09/25/03 3.75 26.98 26.74 27.97 30.75 23.23 23.38 25.04 28.38
10/01/03 0.00 32.27 55.60 70.58 81.09 32.27 56.41 72.66 84.72
average 4.293129 26.30695 54.29491 77.55088 93.102421 average 22.013817 50.9771183 76.06389796 93.82292653
std dev 9.245708 23.80126 40.45622 47.07355 51.713205 std deviation 6.1102725 11.4120902 13.56769962 15.15778452
std error 1.633039 3.0500094 3.62612025 4.051088316




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/24/2003 1.07 2.83 3.12 30.31 27.64 1.76 2.09 30.13 27.81
10/1/2003 0.00 2.50 15.91 19.94 13.92 2.50 16.14 20.53 14.54
10/15/2003 0.09 0.00 0.00 1.96 8.08 -0.09 -0.09 1.93 8.36
10/16/2003 0.00 0.00 0.58 0.00 0.38 0.00 0.59 0.00 0.40
1/9/2004 0.00 11.87 33.79 46.00 52.82 11.87 34.28 47.35 55.19
1/14/2004 10.00 6.61 8.32 12.04 17.64 -3.39 -1.56 2.39 8.43
average 1.86 3.97 10.29 18.37 20.08 average 2.11 8.58 17.06 19.12
std dev 4.01 4.57 12.96 17.63 18.47 std deviation 5.20 14.15 19.16 19.89
std error 2.12 5.78 7.82 8.12




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/2/2004 48.08 40.40 137.13 138.87 132.98 -7.68 91.77 96.42 93.16
9/15/2004 20.44 8.65 41.70 91.51 81.60 -11.79 22.08 74.78 66.22
8/7/2003 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
8/20/2002 0.00 3.52 2.23 10.39 0.00 3.52 2.26 10.69 0.00
9/4/2003 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
9/25/2003 3.75 3.00 29.79 21.51 20.68 -0.75 26.47 18.39 17.86
10/2/2003 10.35 13.79 11.36 17.16 14.63 3.43 1.17 7.31 4.93
10/9/2003 0.00 4.11 6.76 8.30 10.18 4.11 6.85 8.55 10.64
average 10.33 9.18 28.62 35.97 32.51 average -1.14 18.83 27.02 24.10
std dev 16.89 13.42 46.38 51.05 48.75 std deviation 5.72 31.23 37.09 35.61
std error 2.02 11.04 13.11 12.59




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/22/2003 0.18 0.05 0.22 3.97 0.00 -0.12 0.05 3.91 4.83
10/23/2003 0.00 0.11 0.00 0.00 0.00 0.11 0.00 0.00 0.00
11/12/2003 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
average 0.06 0.05 0.07 1.32 0 average 0.00 0.02 1.30 1.61
std dev 0.10 0.06 0.13 2.29 0 std deviation 0.12 0.03 2.26 2.79
std error 0.07 0.02 1.30 1.61




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/22/2003 0.18 0.40 0.27 2.44 2.26 0.23 0.10 2.34 2.19
10/23/2003 0.00 0.27 0.00 0.51 0.11 0.27 0.00 0.52 0.11
10/30/2003 9.52 11.63 8.57 6.63 9.97 2.12 -0.82 -2.69 0.90
average 3.23 4.10 2.95 3.19 4.12 average 0.87 -0.24 0.06 1.07
std dev 5.44 6.52 4.87 3.13 5.19 std deviation 1.08 0.50 2.54 1.05
std error 0.62 0.29 1.47 0.60




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/3/2003 0.00 0.66 1.66 1.55 0.24 0.66 1.68 1.60 0.26
11/11/2003 0.00 0.00 0.00 1.95 0.07 0.00 0.00 2.01 0.07
11/12/2003 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
average 0.00 0.22 0.55 1.17 0.11 average 0.22 0.56 1.20 0.11
std dev 0.00 0.38 0.96 1.03 0.13 std deviation 0.38 0.97 1.06 0.13
std error 0.22 0.56 0.61 0.08




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
2/16/2004 0.28 0.06 12.05 19.97 20.03 -0.22 11.95 20.28 20.65
3/17/2004 0.00 0.00 0.63 6.03 10.48 0.00 0.64 6.21 10.95
3/25/2004 8.17 9.82 14.74 29.20 57.38 1.65 6.78 21.89 51.78
3/26/2004 0.72 0.92 0.77 2.04 1.02 0.20 0.07 1.38 0.35
4/9/2004 3.16 3.22 2.71 2.83 3.78 0.05 -0.42 -0.25 0.79
average 2.47 2.80 6.18 12.02 18.54 average 0.34 3.80 9.90 16.90
std dev 3.43 4.14 6.71 12.03 22.92 std deviation 0.75 5.41 10.50 21.21
std error 0.34 2.42 4.69 9.48
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
 
pf = experiments with platelet removal 
 
400um no ca2+
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/28/2004 0.64 0.00 0.00 8.38 2.68 -0.64 -0.64 7.98 2.16
1/28/2004 0.64 0.00 45.94 45.36 50.24 -0.64 45.97 46.06 51.85
2/4/2004 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2/4/2004 0.00 0.00 0.00 4.13 0.00 0.00 0.00 4.25 0.00
2/25/2004 0.00 0.00 0.00 1.31 4.50 0.00 0.00 1.35 4.70
2/25/2004 0.00 11.71 47.37 68.79 88.59 11.71 48.05 70.82 92.55
average 0.21 1.95 15.55 21.33 24.33 average 1.74 15.56 21.74 25.21
std dev 0.33 4.78 24.10 28.81 37.00 std deviation 4.90 24.37 29.61 38.65
std error 2.00 9.95 12.09 15.78
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
 
no ca2+ = experiments with no added Ca2+ 
 
400um 18g Agg
date nd flow (lpm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/30/2004 0.03 14.47 9.09 21.13 20.61 34.50 -5.38 7.08 6.98 22.17
6/30/2004 0.03 14.47 12.15 9.02 29.98 29.15 -2.32 -5.27 16.72 16.49
average 14.47 10.62 15.08 25.30 31.83 average -3.85 0.91 11.85 19.33
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
 
18g Agg = experiments with 18μg added Aggrastat 
 
400um 180g Agg
date nd flow (lpm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/24/2004 0.06 1.86 3.45 4.95 10.70 18.55 1.59 3.18 9.27 17.83
6/24/2004 0.01 1.86 2.28 2.06 2.27 3.23 0.42 0.24 0.50 1.57
7/20/2004 0 0.84 1.35 2.34 3.04 clotted 0.51 1.55 2.32 na
7-20-04b 0.02 0.84 2.29 2.63 3.63 1.65 1.45 1.84 2.94 0.91
7/23/2004 0.03 0.14 3.96 3.11 3.27 3.87 3.82 3.03 3.26 3.97
7/23/2004 0.02 0.14 0.27 0.62 0.63 0.54 0.13 0.49 0.51 0.43
Average 0.95 2.27 2.62 3.92 5.57 average 1.32 1.72 3.13 4.94
std dev 0.77 1.35 1.42 3.49 7.37 std deviation 1.36 1.23 3.23 7.33
std error 0.55 0.50 1.32 2.99
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
 
180g Agg = experiments with 180μg added Aggrastat 
date nd flow (lpm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/19/2005 0.01 2.84 1.01 0.92 0.85 0.99 -1.84 -1.90 -1.96 -1.79
1/19/2005 0.03 2.84 1.25 0.62 0.83 0.84 -1.59 -2.21 -1.98 -1.95
1/20/2005 0.06 0.59 2.98 48.01 79.23 92.90 2.39 48.37 81.85 98.08
1/20/2005 0.59 0.45 0.60 0.57 0.37 -0.14 0.02 0.00 -0.20
1/21/2005 1.26 1.82 4.41 3.59 3.32 0.55 3.23 2.47 2.26
1/21/2005 1.26 4.47 2.37 2.93 4.46 3.21 1.16 1.79 3.47
Average 1.57 2.00 9.49 14.67 17.15 average 0.43 8.11 13.69 16.65
std dev 1.03 1.49 18.93 31.65 37.15 std deviation 2.06 19.82 33.44 39.95
std error 0.42 0.61 7.73 12.92 15.17 std error 0.84 8.09 13.65 16.31
400um 125 ul AN51 Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
 
125 ul AN51 = experiments with 125 μl AN51 antibody 
 
 240 
800r low 0 25 50 75 100 25 50 75 100
7/29/2005 6.70 11.51 5.56 6.80 11.94 4.81 -1.07 0.30 5.77
8/3/2005 5.98 40.49 26.91 43.04 51.73 34.51 21.32 38.32 48.06
7/21/2005 0.34 0.41 0.81 2.76 1.85 0.07 0.49 2.50 1.60
7/15/2005 1.07 4.09 2.18 9.03 43.30 3.02 1.14 8.22 44.16
7/28/2005 2.53 2.72 9.42 8.63 11.41 0.19 7.03 6.36 9.39
7/27/2005 1.33 0.47 0.83 1.03 4.92 -0.86 -0.49 -0.27 3.81
average 2.99 9.95 7.62 11.88 20.86 average 6.96 4.74 9.24 18.80
std dev 2.70 15.51 10.02 15.60 21.17 std deviation 13.66 8.63 14.63 21.35
std error 5.58 3.52 5.97 8.71
800r high 0 25 50 75 100 25 50 75 100
7/29/2005 6.70 4.99 3.49 3.03 1.51 -1.72 -3.17 -3.59 -5.13
7/21/2005 0.34 0.46 4.94 36.85 62.88 0.12 4.67 37.54 65.22
7/28/2005 1.33 0.56 1.74 5.66 20.19 -0.77 0.44 4.48 19.72
8/3/2005 5.98 12.40 13.05 11.28 10.49 6.42 7.25 5.61 4.95
average 3.59 4.60 5.81 14.20 23.77 average 1.01 2.30 11.01 21.19
std dev 3.22 5.61 5.00 15.48 27.17 std deviation 3.68 4.60 18.16 31.08
std error 1.84 2.30 9.08 15.54
800r norm 0 25 50 75 100 25 50 75 100
7/13/2005 1.42 2.07 1.32 3.31 13.66 0.65 -0.07 2.03 13.09
9/24/2003 1.07 2.83 3.12 30.31 27.64 1.76 2.11 30.47 28.29
10/1/2003 0.00 2.50 15.91 19.94 13.92 2.50 16.22 20.75 14.78
10/15/2003 0.09 0.00 0.00 1.96 8.08 -0.09 -0.09 1.96 8.49
10/16/2003 0.00 0.00 0.58 0.00 0.38 0.00 0.59 0.00 0.41
1/9/2004 0.00 11.87 33.79 46.00 52.82 11.87 34.47 47.86 56.10
1/14/2004 10.00 6.61 8.32 12.04 17.64 -3.39 -1.51 2.53 8.74
average 1.80 3.70 9.01 16.22 19.16 average 1.90 7.39 15.08 18.56
std dev 3.66 4.23 12.30 17.08 17.03 std deviation 4.78 13.39 18.58 18.60
std error 1.81 5.06 7.02 7.03
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
Passes Passes
 
800r low = low flow rate experiments with the 800 μm round orifice 
800r high = high flow rate experiments with the 800 μm round orifice 
800r normal = standard flow rate experiments with the 800 μm round orifice 
 
control 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/13/2005 1.42 1.54 8.07 9.97 11.77 0.12 6.81 8.96 11.08
5/24/2005 2.59 3.03 3.14 1.51 2.48 0.43 0.61 -1.02 0.04
average 2.01 2.28 5.61 5.74 7.12 average 0.28 3.71 3.97 5.56
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
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Channel TAT data: 
 
Channel 1
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/14/03 2.21 9.56 69.77 114.13 120.89 7.35 68.57 115.28 124.10
11/21/03 2.01 0.00 20.99 32.40 44.59 -2.01 19.28 31.34 44.58
11/24/03 0.00 0.00 0.50 5.09 6.73 0.00 0.51 5.24 7.03
3/24/2003 0.07 3.63 65.84 109.43 114.35 3.56 66.72 112.58 119.40
5/14/2004 1.10 1.17 20.54 50.39 81.62 0.08 19.75 50.78 84.18
6/1/2005 5.83 23.14 43.26 41.50 59.30 17.31 38.29 37.36 57.15
average 1.87 6.25 36.82 58.83 71.25 average 4.38 35.52 58.76 72.74
std dev 2.15 9.02 27.58 43.77 43.47 std deviation 7.14 27.61 45.23 45.39
std error 2.92 11.27 18.47 18.53




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/14 2.21 2.47 20.46 32.38 5.81 0.26 18.55 31.12 3.87
11/24 0.00 10.21 10.75 9.57 10.68 10.21 10.90 9.85 11.16
11/25-B 0.40 7.75 5.40 4.49 6.13 7.35 5.08 4.22 6.01
3/24/2004 0.07 45.40 83.05 98.14 95.45 45.33 84.18 100.96 99.65
5/14/2004 1.10 9.89 13.47 13.40 13.86 8.79 12.57 12.70 13.38
6/1/2005 5.83 9.29 6.15 4.33 6.52 3.46 0.41 -1.37 0.99
average 1.60 14.17 23.21 27.05 23.08 average 12.57 21.95 26.25 22.51
std dev 2.23 15.56 29.82 36.33 35.59 std deviation 16.46 31.12 38.23 38.07
std error 6.72 12.71 15.61 15.54




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/27/2004 10.05 7.87 11.21 18.28 28.59 -2.18 1.38 8.97 20.32
5/26/2003 3.97 4.81 5.88 11.76 13.31 0.83 2.02 8.26 10.16
5/24/2003 2.47 3.26 4.36 7.69 9.81 0.79 1.98 5.53 7.95
6/16/2004 3.45 3.43 9.13 16.42 20.23 -0.01 5.87 13.64 18.04
5/19/2004 3.43 2.18 5.20 51.99 104.77 -1.25 1.88 50.67 107.85
9/15/2004 20.44 12.01 86.92 140.48 140.55 -8.44 68.20 125.73 128.83
9/20/2004 1.19 4.79 117.51 140.43 135.39 3.59 118.66 144.93 142.60
Average 6.43 5.48 34.32 55.29 64.66 average -0.95 28.57 51.11 62.25
std dev 6.79 3.40 47.28 59.94 59.57 std deviation 3.77 46.66 59.81 61.02
std error 1.43 17.64 22.61 23.06




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/27/2004 10.05 10.80 21.97 31.22 43.74 0.75 12.35 22.44 36.40
5/26/2003 3.97 6.48 35.22 116.48 108.20 2.51 31.95 117.23 110.95
5/24/2003 2.47 7.33 17.25 37.50 44.60 4.86 15.13 36.56 44.91
6/16/2004 3.45 26.17 31.16 36.23 38.72 22.72 28.34 34.25 37.67
5/20/2004 4.76 9.99 9.44 15.36 24.42 5.23 4.86 11.22 21.18
5/19/2004 3.43 0.93 1.36 17.81 14.51 -2.50 -2.04 15.10 11.98
9/9/2004 48.08 20.66 80.56 132.90 142.98 -27.42 34.08 90.21 103.77
9/20/2004 0.17 1.19 2.88 5.33 9.87 1.02 2.77 5.38 10.31
Average 9.55 10.44 24.98 49.10 53.38 average 0.90 15.93 41.55 47.15
std dev 15.82 8.89 25.60 48.13 47.30 std deviation 13.77 14.00 40.47 39.20
std error 4.87 4.95 14.31 13.86




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/6/2004 0.00 0.00 1.63 5.55 8.88 0.00 1.66 5.78 9.43
12/8/2004 24.68 67.30 82.80 83.10 115.03 42.62 59.76 61.79 97.49
12/13/2004 0.00 0.00 1.63 5.55 8.88 0.00 1.66 5.78 9.43
12/22/2004 0.00 0.00 28.90 103.05 109.97 0.00 29.47 107.23 116.80
1/12/2005 1.21 115.03 66.45 93.97 83.10 113.82 66.56 96.57 87.04
1/14/2005 0.00 88.83 90.29 90.56 89.33 88.83 92.09 94.23 94.88
12/6/2004 28.07 26.56 31.95 39.61 na -1.51 4.52 13.14 na
12/8/2004 20.25 17.34 27.03 44.70 36.05 -2.91 7.31 26.26 18.03
Average 9.28 39.38 41.33 58.26 64.46 average 30.10 32.88 51.35 61.87
std dev 12.65 45.12 34.53 39.69 45.79 std deviation 46.94 35.42 43.68 47.31
std error 16.59 12.52 15.44 16.73





date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 0.83 0.89 3.35 5.49 9.22 0.06 2.59 4.88 8.97
11/5/2004 1.74 10.46 9.11 14.44 19.82 8.72 7.54 13.28 19.30
10/26/2004 0.00 17.16 15.72 16.06 17.19 17.16 16.03 16.72 18.26
11/17/2004 2.62 6.09 46.29 73.31 82.61 3.47 44.59 73.66 85.12
11/19/2004 2.95 2.69 3.24 2.56 14.14 -0.25 0.35 -0.29 12.07
11/22/2004 0.94 109.97 2.32 0.44 0.51 109.03 1.43 -0.48 -0.40
11/17/2004 2.62 6.09 46.29 73.31 82.61 3.47 44.59 73.66 85.12
Average 1.67 21.91 18.05 26.52 32.30 average 20.24 16.73 25.92 32.63
std dev 1.12 39.20 19.85 32.48 34.93 std deviation 39.61 19.75 33.24 36.44
std error 14.97 7.46 12.56 13.77




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/8/2004 24.68 66.45 93.97 1.21 2.38 41.77 71.16 -23.42 -22.15
12/22/2004 0.00 2.32 0.44 0.51 0.94 2.32 0.45 0.53 1.00
1/12/2005 1.21 2.38 83.01 97.07 104.83 1.17 83.45 99.79 110.12
1/14/2005 0.00 102.03 103.58 105.22 117.82 102.03 105.64 109.48 125.14
1/24/2005 1.00 1.19 0.95 0.67 0.62 0.19 -0.03 -0.30 -0.34
Average 5.38 34.87 56.39 40.94 45.32 average 29.50 52.13 52.38 58.98
std dev 10.80 46.79 51.36 55.04 60.43 std deviation 44.19 48.98 62.39 69.17
std error 19.76 21.91 31.19 34.59




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 0.83 1.29 9.88 12.26 12.73 0.46 9.25 11.93 12.69
11/12/2004 0.00 13.56 17.13 19.24 21.55 13.56 17.47 20.02 22.89
11/5/2004 1.74 4.36 33.82 57.74 62.71 2.62 32.75 58.34 64.86
11/17/2004 2.62 22.59 60.97 69.73 72.08 19.97 59.56 69.93 73.93
11/22/2004 0.94 0.77 0.63 5.16 84.53 -0.17 -0.30 4.43 88.83
10/26/2004 0.00 56.74 41.55 36.08 54.83 56.74 42.37 37.54 58.23
Average 1.02 16.55 27.33 33.37 51.40 average 15.53 26.85 33.70 53.57
std dev 1.02 21.41 22.35 25.94 28.46 std deviation 21.74 22.27 26.28 29.73
std error 8.87 9.09 10.73 12.14
Raw data, TAT concentration (ng/ml) Initial value subtracted, adjusted for dilution (ng/ml)
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Valve TAT data: 
 
low leaker
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/29/2004 0.24 0.79 clotted na na 0.55 na na na
7/30/2004 2.09 0.07 3.36 2.85 3.14 -2.01 1.44 0.85 1.19
8/18/2004 39.70 76.10 84.49 82.93 90.76 36.39 44.79 43.23 51.06
9/10/2004 0.00 6.46 6.68 5.95 3.56 6.46 6.68 5.95 3.56
12/15/2004 18.96 0.08 na na na -18.88 na na na
1/10/2005 0.00 24.68 67.30 82.80 na 24.68 67.30 82.80 na
7/22/2005 1.32 2.61 7.20 21.58 52.79 1.29 5.88 20.26 51.47
7/12/2005 1.85 2.16 15.65 87.88 99.99 0.31 13.80 86.03 98.14
Average 8.02 14.12 30.78 47.33 50.05 average 6.10 23.31 39.85 41.08
std dev 14.30 26.35 35.60 41.29 46.15 std deviation 17.07 26.63 37.53 40.19
std error 6.04 10.87 15.32 17.98




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/28/2004 0.24 2.12 2.91 4.43 4.19 1.88 2.67 4.19 3.95
8/23/2004 1.24 2.02 2.04 2.43 2.34 0.78 0.80 1.19 1.10
8/2/2004 9.31 11.92 9.96 10.38 14.98 2.61 0.65 1.07 5.66
9/27/2004 15.76 30.96 32.50 37.61 33.98 15.20 16.74 21.85 18.21
12/20/2004 0.77 0.63 5.16 84.53 112.07 -0.15 4.38 83.75 111.29
1/27/2005 0.51 0.82 0.92 0.92 0.80 0.31 0.42 0.41 0.29
5/26/2005 25.26 19.71 21.06 23.41 22.88 -5.55 -4.20 -1.85 -2.38
Average 7.59 9.74 10.65 23.39 27.32 average 2.16 3.07 15.80 19.73
std dev 9.77 11.79 11.87 30.04 39.29 std deviation 6.33 6.58 31.00 40.92
std error 2.39 2.49 11.72 15.47




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
8/25/2004 0 2.24 1.45 1.95 3.19 2.24 1.45 1.95 3.19
9/8/2004 0 0.14 0.74 0.74 2.36 0.14 0.74 0.74 2.36
10/11/2004 0 1.59 1.19 1.23 2.22 1.59 1.19 1.23 2.22
11/10/2004 0 2.67 2.41 3.05 2.77 2.67 2.41 3.05 2.77
7/20/2005 0 2.34 3.98 3.32 2.63 2.34 3.98 3.32 2.63
Average 0 1.79 1.95 2.06 2.63 average 1.79 1.95 2.06 2.63
std dev 0 1.00 1.29 1.12 0.38 std deviation 1.00 1.29 1.12 0.38
std error 0.45 0.58 0.50 0.17




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/22/2004 0.70 2.31 4.53 6.06 6.40 1.61 3.83 5.37 5.70
9/29/2004 0.87 1.46 1.73 2.97 30.84 0.59 0.86 2.10 29.97
10/8/2004 0.00 6.74 3.96 5.73 6.95 6.74 3.96 5.73 6.95
10/14/2004 0.00 0.00 18.46 44.03 63.24 0.00 18.46 44.03 63.24
10/25/2004 0.00 2.91 5.36 5.88 9.83 2.91 5.36 5.88 9.83
11/23/2004 0.08 0.00 0.00 28.90 103.05 -0.08 -0.08 28.82 102.97
12/3/2004 0.00 0.00 0.00 0.00 18.96 0.00 0.00 0.00 18.96
Average 0.24 1.92 4.86 13.37 34.18 average 1.68 4.63 13.13 33.95
std dev 0.38 2.44 6.37 16.51 36.37 std deviation 2.48 6.46 16.64 36.45
std error 0.94 2.44 6.29 13.78





B.2. PF4 ELISA assays – Raw data 
 
Orifice PF4 Data: 
 
400r Norm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/8/2004 3.35 3.84 4.31 4.33 3.43 48.63 104.56 115.48 28.80
7/8/2004 3.35 7.00 11.30 12.36 10.72 365.40 817.83 950.70 803.75
8/25/2004 1.29 9.70 11.97 7.30 8.49 840.78 1091.18 630.00 772.14
8/30/2004 1.03 6.55 10.92 9.52 9.07 551.82 1010.29 887.36 859.40
8/30/2004 1.03 6.07 8.55 9.35 na 503.83 768.31 869.38 na
9/2/2004 0.99 1.82 2.15 2.36 1.96 83.08 121.06 147.21 109.51
9/30/2004 0.70 1.81 2.38 2.67 3.78 110.22 171.87 207.09 331.39
9/30/2004 0.70 3.05 5.11 4.38 5.06 234.72 450.83 385.49 466.95
average 342.31 566.99 524.09 481.71
std deviation 277.20 406.56 353.17 369.26
std error 98.00 143.74 124.86 139.57
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
400r Norm = Standard experiments with the 400 μm round orifice 
 
400r Agg (18) 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/30 4.10 10.54 15.51 19.03 14.44 429.82 781.70 1047.30 749.24
6/30 4.10 12.14 15.08 14.95 12.27 536.56 752.21 763.91 596.02
average 483.19 766.96 905.60 672.63
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
Agg (18) = experiments with 18μg added Aggrastat 
 
400r Agg (180) 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/24 0.90 4.65 1.60 2.00 2.28 249.87 49.17 78.61 101.41
6/24 0.90 9.78 8.46 6.89 7.98 592.00 515.14 418.45 505.33
7/20 1.21 5.09 5.65 6.88 388.38 456.03 594.93 na
7/20 1.21 4.83 4.74 6.31 5.58 362.21 362.49 536.04 471.86
7/23 0.52 2.46 2.89 3.34 2.97 194.50 242.82 295.73 263.68
7/23 0.52 1.41 1.52 1.81 1.72 89.07 103.00 136.72 130.90
average 312.67 288.11 343.41 294.63
std deviation 175.57 189.04 210.29 187.68
std error 71.67 77.17 85.85 83.93
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
Agg (180) = experiments with 180μg added Aggrastat 
 
400r AN51 (125 ul) 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/19/2005 1.54 3.11 3.89 5.19 6.67 156.53 242.47 386.52 554.28
1/19/2005 1.54 3.44 4.98 7.24 9.80 189.73 354.33 599.09 886.39
1/20/2005 0.96 4.30 8.49 14.45 12.50 334.31 769.38 1407.23 1231.95
1/20/2005 0.96 5.23 8.11 9.98 11.24 427.32 731.27 942.23 1098.10
1/21/2005 1.53 7.52 14.92 15.19 12.32 598.97 1368.32 1427.57 1155.08
1/21/2005 1.53 9.37 7.67 11.95 11.16 784.09 629.34 1090.78 1032.30
average 415.16 682.52 975.57 993.02
std deviation 242.61 396.09 422.79 244.87
std error 99.04 161.70 172.60 99.97
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
AN51 (125 ul) = experiments with 125 μl added AN51 antibody 
1200r Norm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/2/2004 0.99 5.00 8.22 11.64 10.41 401.32 739.94 1113.00 1006.78
9/9/2004 2.18 5.80 8.59 6.34 5.28 361.87 658.05 440.95 342.58
9/15/2004 0.87 5.33 11.70 13.14 16.17 445.69 1106.44 1279.97 1629.90
average 402.96 834.81 944.64 993.09
std deviation 41.93 238.78 444.13 643.77
std error 24.21 137.86 256.42 371.68
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
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1200r Norm = Standard experiments with the 1200 μm round orifice 
 
800r norm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/13/2005 1.05 2.52 4.18 3.97 5.50 147.40 321.30 307.65 479.05
800r high 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/29/2005 2.50 5.81 5.45 5.54 4.81 330.26 305.60 326.37 260.58
7/21/2005 0.61 6.15 4.51 6.66 7.89 553.90 398.54 631.22 776.19
7/22/2004 10.36 5.11 4.38 5.97 9.18 -525.07 -589.49 -414.93 -60.56
7/28/2005 1.11 10.64 9.78 5.59 8.85 953.81 886.79 471.07 829.68
8/3/2005 2.88 9.01 8.60 10.04 11.82 613.57 589.67 756.60 967.43
average 385.29 318.22 354.07 554.66
std deviation 555.78 553.97 459.52 435.91
std error 277.89 276.98 229.76 217.96
800r low 0 min 17.5 min 35 min 52.5 min 70 min 15 min 30 min 45 min 60 min
7/29/2005 2.50 2.41 3.01 3.52 5.15 -9.29 57.01 116.04 296.71
8/3/2005 2.88 4.68 4.98 6.27 5.78 180.51 220.47 364.14 326.39
7/21/2005 0.61 3.92 7.08 5.27 10.17 330.64 660.61 487.23 1018.51
7/28/2005 1.11 4.78 5.94 7.96 6.63 366.99 495.13 718.12 593.14
7/27/2005 2.26 2.69 4.12 6.29 4.20 43.76 194.30 428.35 220.60
7/15/2005 2.67 4.60 5.72 8.03 8.61 193.37 316.64 569.32 648.36
average 184.33 324.03 447.20 517.28
std deviation 149.74 219.76 203.39 299.09
std error 61.13 89.72 83.03 122.10
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop Raw data, PF4 concentration (ng/ml)
 
800r low = low flow rate experiments with the 800 μm round orifice 
800r high = high flow rate experiments with the 800 μm round orifice 




Channel PF4 data: 
 
Channel 1 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/1/2005 3.69 4.80 4.07 13.25 11.85 110.94 46.40 1010.03 889.61
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
Channel 2 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/1/2005 3.69 4.09 15.50 8.90 10.63 40.60 1212.23 557.09 760.59
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
Channel 3 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/19 0.21 5.33 11.98 7.78 9.21 340.99 800.48 525.36 638.06
5/20 1.37 5.97 3.08 4.37 4.62 306.63 117.82 211.94 235.46
5/24 0.67 3.55 8.05 4.73 5.85 191.95 502.89 283.25 369.64
5/26 1.02 3.34 8.99 10.49 10.41 154.28 542.79 659.26 668.79
6/16 0.96 10.85 9.87 15.70 11.27 659.64 607.23 1025.10 734.35
9/15/2004 0.87 6.26 8.90 7.95 10.56 538.90 820.92 739.68 1033.97
9/20/2004 1.57 6.11 7.97 7.71 12.83 453.41 656.13 645.40 1205.34
average 377.97 578.32 584.28 697.95
std deviation 183.50 235.98 277.06 341.03
std error 69.35 89.19 104.72 128.90
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
Channel 4 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/19 0.21 0.66 5.74 9.97 1.82 29.63 376.42 677.77 114.49
5/20 1.37 3.52 4.62 10.32 17.41 143.30 222.58 624.53 1141.40
5/24 0.67 2.64 6.18 4.84 5.22 131.21 375.93 291.24 325.34
5/26 1.02 4.75 10.98 9.31 8.77 248.75 678.12 577.52 552.50
6/16 0.96 4.85 10.26 16.07 10.13 259.52 634.10 1050.84 653.73
9/9/2004 2.18 16.95 12.15 17.12 18.04 1476.30 1021.29 1563.43 1697.59
9/20/2004 1.57 8.75 19.60 18.74 19.54 718.18 1842.26 1792.43 1918.10
average 429.56 735.81 939.68 914.73
std deviation 511.77 554.00 555.00 690.18
std error 193.43 209.39 209.77 260.86
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
Channel 5 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/14/2005 1.00 9.44 10.37 11.30 10.99 844.20 957.11 1076.17 1066.91
1/12/2005 0.92 10.82 11.63 11.92 13.91 990.07 1094.34 1148.37 1385.23
12/13/2005 2.82 9.77 12.28 13.27 12.89 694.94 970.62 1098.53 1086.48
12/22/2004 0.09 1.54 3.94 5.95 6.49 145.07 392.99 610.70 680.69
average 668.57 853.76 983.45 1054.83
std deviation 369.21 313.33 250.32 288.84
std error 184.61 156.66 125.16 144.42
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop Raw data, PF4 concentration (ng/ml)
 
 
Channel 6 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 2.01 8.94 8.01 7.98 6.92 693.57 616.56 629.41 534.42
10/26/2004 1.83 3.41 5.98 5.50 5.84 158.25 426.99 388.78 436.89
11/5/2004 1.72 13.07 12.54 14.66 14.60 1134.94 1107.06 1353.26 1379.04
average 662.25 716.87 790.49 783.45
std deviation 489.10 350.95 502.01 518.10
std error 282.38 202.62 289.83 299.12
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 




Channel 7 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/14/2005 1.00 11.82 10.24 10.42 11.58 1081.50 944.82 984.76 1130.00
1/12/2005 0.92 1.67 2.73 2.45 4.06 75.06 186.44 163.16 339.19
12/13/2004 2.82 2.67 3.87 7.15 11.30 -15.28 112.93 461.73 918.15
12/22/2004 0.09 2.87 2.28 2.86 6.24 278.08 223.46 288.96 653.60
1/24/2005 0.14 0.59 0.92 0.85 0.64 44.94 79.80 74.05 53.22
average 292.86 309.49 394.53 618.83
std deviation 454.43 359.71 360.65 433.08
std error 203.23 160.87 161.29 193.68
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop Raw data, PF4 concentration (ng/ml)
 
 
Channel 8 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 2.01 6.22 7.14 7.21 6.80 421.22 527.52 550.08 521.90
10/26/2004 1.83 8.70 9.54 11.06 10.62 687.20 789.92 967.82 944.48
11/5/2004 1.72 7.53 5.85 6.18 6.55 581.09 425.19 471.88 523.92
11/12/2004 2.95 4.86 5.95 4.55 4.76 190.53 312.09 178.05 210.34
6-10-05 b 2.56 6.27 9.93 9.57 10.06 371.11 757.55 740.46 812.91
average 450.23 562.45 581.66 602.71
std deviation 192.24 207.69 295.92 286.22
std error 85.97 92.88 132.34 128.00
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
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Valve PF4 data: 
 
low leaker 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/29/2004 2.03 5.96 na na na 415.08 na na na
7/30/2004 1.07 1.74 2.22 2.16 2.50 73.72 125.50 121.81 159.90
8/18/2004 1.00 0.02 9.88 13.82 14.63 -98.08 934.92 1361.29 1461.68
9/10/2004 1.28 1.72 2.30 2.31 2.45 50.48 112.90 116.04 133.28
10/1/2004 1.03 5.08 9.12 11.08 10.05 424.13 852.56 1068.35 970.34
1/10/2005 0.94 5.58 9.95 13.03 na 484.54 948.27 1283.87 na
12/15/2005 0.80 6.04 na na na 546.58 na na na
7/22/2005 0.89 2.69 4.48 6.26 6.78 190.11 380.61 572.86 634.51
7/12/2005 2.96 5.64 4.29 10.44 9.78 289.32 153.83 808.22 748.48
average 263.99 501.23 761.78 684.70
std deviation 222.47 395.51 514.84 504.25
std error 74.16 149.49 194.59 205.86
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
SJM Std 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
8/25/2004 0.58 2.21 6.62 4.23 4.96 172.04 635.93 389.21 471.89
9/8/2004 0.51 8.11 1.90 2.12 2.84 790.35 148.46 173.25 252.54
11/15/2004 0.95 2.14 2.92 3.35 3.06 126.38 210.65 258.56 231.58
10/11/2004 0.57 1.60 1.90 2.16 2.32 108.49 141.82 170.88 190.55
11/10/2004 0.44 2.36 2.92 4.31 3.60 201.40 261.74 412.07 340.62
7/22/2005 1.35 2.42 3.07 3.57 3.89 115.77 185.97 242.80 280.23
average 252.40 264.10 274.46 294.57
std deviation 265.97 187.38 104.24 100.32
std error 108.58 76.50 42.56 40.96
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop Raw data, PF4 concentration (ng/ml)
 
 
high leaker 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/28/2004 0.81 1.79 2.09 2.98 3.29 104.69 138.08 234.28 270.19
8/2/2004 1.81 3.36 5.53 4.63 7.21 166.87 397.92 308.45 588.47
8/23/2004 1.00 2.11 7.01 10.09 7.16 119.03 633.84 966.60 664.35
1/27/2005 0.94 2.86 7.09 8.36 8.37 202.96 648.72 790.60 799.64
9/27/2004 2.30 2.32 3.26 4.83 5.81 11.18 111.82 281.33 390.98
12/20/2005 2.09 6.77 10.29 11.48 12.35 492.77 868.19 1005.12 1109.72
5/26/2005 1.05 4.01 6.08 9.35 9.80 311.29 532.05 883.67 941.05
average 201.25 475.80 638.58 680.63
std deviation 158.37 278.27 347.66 296.43
std error 59.86 105.18 131.40 112.04
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
 
 
MP 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/22/2004 0.90 3.08 5.16 5.09 5.67 229.50 450.28 448.17 515.10
12/3/2004 3.04 2.09 3.65 4.09 5.51 -87.28 78.29 128.19 284.09
9/29/2004 1.49 2.14 3.78 3.32 4.62 72.70 247.16 202.10 343.48
10/8/2004 1.25 2.54 3.31 3.93 4.83 138.09 221.10 289.90 390.00
10/14/2004 1.55 3.01 3.97 6.23 5.39 156.95 260.94 503.05 420.35
10/25/2004 0.51 1.60 2.21 3.33 3.86 115.31 180.43 300.65 360.62
10/27/2004 2.21 4.93 5.85 7.23 7.00 290.49 392.06 543.41 526.19
average 130.82 261.47 345.07 405.69
std deviation 120.52 125.61 156.75 89.11
std error 45.55 47.47 59.25 33.68
Raw data, PF4 concentration (ng/ml)
Initial value subtracted, adjusted for dilution and 
multiplied by 100 to obtain concentration in flow loop 
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B.3. Plasma hemoglobin assays – Raw data 
 
Orifice Hemolysis Data: 
 
200um round
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/19/2003 1.64 4.28 6.25 5.37 7.51 2.64 4.70 3.89 6.21
12/19/2003 1.64 7.46 6.05 6.80 8.34 5.83 4.50 5.37 7.08
1/5/2004 1.32 2.89 4.05 4.40 4.48 1.57 2.79 3.21 3.36
01/06/04 2.55 4.02 4.69 6.98 5.04 1.46 2.21 4.64 2.71
01/06/04 2.55 4.76 6.51 na na 2.21 4.05 na na
average 1.94 4.68 5.26 5.89 6.34 average 2.74 3.65 4.28 4.84
std dev 0.57 1.70 1.06 1.23 1.88 std deviation 1.79 1.10 0.93 2.13
std error 0.80 0.49 0.42 0.95
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/8/2004 2.08 3.11 3.18 3.61 2.39 1.03 1.14 1.64 0.42
7/8/2004 2.08 4.30 4.71 6.51 7.52 2.21 2.72 4.69 5.91
7/22/2004 2.14 5.87 4.27 6.79 9.55 3.73 2.19 4.85 7.84
7/23/2004 1.67 5.23 4.44 4.59 5.15 3.56 2.85 3.10 3.80
7/23/2004 1.67 1.79 2.12 2.13 2.04 0.12 0.49 0.54 0.50
8/25/2004 1.90 2.82 3.89 3.41 4.30 0.91 2.06 1.65 2.67
8/30/2004 1.21 3.10 3.82 3.91 4.07 1.89 2.68 2.85 3.11
8/30/2004 1.21 2.49 3.05 3.44 2.03 1.28 1.89 2.37 0.95
9/2/2004 1.52 5.81 7.76 13.68 14.30 4.29 6.40 12.72 13.67
9/2/2004 1.52 1.97 1.99 2.00 1.61 0.45 0.51 0.56 0.19
08/06/03 2.91 2.67 3.15 5.39 3.31 -0.24 0.29 2.64 0.56
8/20/2003 2.76 4.36 6.14 6.86 7.06 1.60 3.46 4.30 4.61
9/4/2003 1.94 3.46 4.08 na 2.97 1.51 2.19 na 1.16
9/24/2003 1.80 2.87 3.45 3.48 3.54 1.08 1.70 1.79 1.91
9/25/2003 2.81 2.61 3.02 2.91 3.76 -0.20 0.25 0.18 1.12
10/1/2003 1.81 2.98 3.55 3.41 3.49 1.17 1.79 1.70 1.84
10/16/2003 1.88 2.70 2.95 8.55 3.53 0.83 1.12 6.92 1.81
average 1.94 3.42 3.86 5.04 4.43 average 1.48 1.98 3.28 3.06
std dev 0.50 1.25 1.41 2.96 3.29 std deviation 1.32 1.49 3.10 3.45
std error 0.32 0.36 0.77 0.84
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/22/2003 1.88 3.77 4.14 4.20 4.20 1.90 2.32 2.44 2.51
9/24/2003 1.80 4.46 4.56 6.85 5.78 2.67 2.83 5.25 4.24
10/1/2003 1.81 3.79 4.36 4.32 4.33 1.98 2.61 2.63 2.71
10/15/2003 2.18 5.40 5.03 5.24 4.89 3.22 2.92 3.21 2.92
10/16/2003 1.88 2.64 3.04 2.77 2.61 0.76 1.21 0.97 0.85
1/9/2004 0.00 4.43 5.66 7.39 7.41 4.43 5.74 7.60 7.74
average 2.49 2.94 3.69 3.49
std deviation 1.26 1.51 2.37 2.34
std error 0.51 0.61 0.97 0.96
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
 
 
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
8/7/2003 1.77 2.38 3.45 3.44 3.30 0.61 1.75 1.81 1.73
8/20/2003 2.82 3.68 4.21 4.15 5.06 0.86 1.48 1.50 2.55
9/4/2003 1.94 2.33 2.56 2.77 2.82 0.38 0.66 0.91 1.00
9/25/2003 2.81 2.67 2.63 3.42 2.79 -0.15 -0.14 0.70 0.10
10/2/2003 1.74 3.48 3.30 3.39 3.56 1.74 1.60 1.74 1.98
10/9/2003 1.91 2.86 2.77 2.93 2.77 0.95 0.91 1.11 0.98
9/2/2004 1.58 1.97 1.99 2.00 1.61 0.38 0.43 0.48 0.10
9/9/2004 1.48 5.51 6.79 8.87 12.06 4.03 5.41 7.65 11.12
9/15/2004 1.21 2.12 2.55 3.14 3.78 0.92 1.38 2.03 2.74
average 1.92 3.00 3.36 3.79 4.19 average 1.08 1.50 1.99 2.48
std dev 0.56 1.11 1.44 1.99 3.09 std deviation 1.22 1.59 2.19 3.38
std error 0.41 0.53 0.73 1.13
1200um new setup
Initial value subtracted, adjusted for dilution and multiplied 





date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/22/2003 1.98 3.67 4.03 4.66 4.47 1.68 2.11 2.81 2.69
11/12/2003 1.36 2.54 2.80 2.88 2.85 1.18 1.48 1.60 1.62
average 1.67 3.10 3.42 3.77 3.66 average 1.43 1.79 2.21 2.15
std deviation 0.35 0.44 0.85 0.75
std error 0.25 0.31 0.60 0.53
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/22/2003 1.98 3.70 3.98 4.27 4.50 1.72 2.06 2.42 2.72
10/30/2003 1.39 2.02 3.11 3.23 3.15 0.62 1.76 1.93 1.90
average 1.17 1.91 2.17 2.31
std deviation 0.77 0.21 0.34 0.58
std error 0.55 0.15 0.24 0.41
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/3/2003 1.10 1.78 2.00 1.89 2.07 0.69 0.93 0.85 1.06
11/11/2003 0.00 2.49 2.88 3.28 4.07 2.49 2.93 3.38 4.25
11/12/2003 1.36 2.70 3.08 2.91 2.94 1.34 1.76 1.64 1.71
average 0.82 2.32 2.65 2.70 3.03 average 1.51 1.87 1.96 2.34
std dev 0.72 0.48 0.57 0.72 1.01 std deviation 0.91 1.00 1.29 1.69
std error 0.53 0.58 0.75 0.97
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
2/16/2004 0.94 2.62 3.55 3.69 3.63 1.68 2.66 2.86 2.86
3/17/2004 1.97 1.89 2.04 2.27 2.45 -0.08 0.10 0.37 0.59
3/18/2004 3.82 4.53 5.37 6.43 6.66 0.71 1.63 2.81 3.15
3/25/2004 1.45 4.57 6.21 6.93 6.78 3.12 4.86 5.69 5.63
3/26/2004 3.28 2.11 2.48 3.30 3.14 -1.18 -0.77 0.12 -0.01
4/9/2004 1.23 1.65 1.88 1.83 1.60 0.42 0.68 0.66 0.45
average 2.29 3.14 3.93 4.53 4.53 average 0.78 1.53 2.08 2.11
std dev 1.22 1.31 1.81 2.04 2.04 std deviation 1.48 2.02 2.14 2.17
std error 0.61 0.83 0.88 0.89
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
 
pf = experiments with platelet removal 
 
400um no ca2+
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/28/2004 1.33 3.05 3.76 2.92 3.69 1.72 2.48 1.67 2.53
1/28/2004 1.33 2.00 3.07 2.93 3.08 0.67 1.78 1.68 1.89
2/4/2004 1.34 3.71 4.80 4.76 5.21 2.37 3.53 3.56 4.10
2/4/2004 1.34 3.31 3.96 3.95 4.66 1.96 2.68 2.73 3.52
2/25/2004 2.59 5.28 6.62 7.07 7.35 2.69 4.12 4.68 5.09
2/25/2004 2.59 4.26 5.40 7.06 7.50 1.67 2.88 4.67 5.24
average 1.76 3.60 4.60 4.78 5.25 average 1.85 2.91 3.17 3.73
std dev 0.65 1.12 1.28 1.90 1.84 std deviation 0.70 0.82 1.37 1.35
std error 0.28 0.33 0.56 0.55
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
 
no ca2+ = experiments with no added Ca2+ 
 
400um 18g Agg
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
6/30/2004 4.93 2.90 2.86 2.44 3.19 -2.02 -2.01 -2.39 -1.54
6/30/2004 4.93 2.84 2.16 3.14 2.54 -2.08 -2.72 -1.65 -2.22
average 4.93 2.87 2.51 2.79 2.87 -2.05 -2.37 -2.02 -1.88
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
 
18g Agg = experiments with 18μg added Aggrastat 
 
400um 180g Agg
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/20/2004 2.32 2.80 3.72 4.38 na 0.47 1.47 2.23 na
7-20-04b 2.32 3.68 3.99 4.93 3.08 1.35 1.75 2.80 0.95
Average 2.32 3.24 3.86 4.65 3.08 0.91 1.61 2.52 0.95
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
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180g Agg = experiments with 180μg added Aggrastat 
 
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
1/19/2005 1.84 2.28 2.02 2.39 2.33 0.43 0.22 0.65 0.63
1/19/2005 1.84 1.98 2.18 2.95 3.54 0.14 0.38 1.23 1.92
1/20/2005 1.67 2.79 3.59 4.57 5.02 1.11 1.99 3.08 3.65
1/20/2005 1.67 2.56 2.73 2.50 2.51 0.89 1.11 0.93 0.99
1/21/2005 1.62 2.06 2.26 2.41 2.92 0.44 0.69 0.89 1.48
1/21/2005 1.62 2.99 2.31 2.69 2.33 1.37 0.74 1.18 0.86
Average 1.71 2.44 2.52 2.92 3.11 average 0.73 0.85 1.33 1.59
std dev 0.10 0.41 0.58 0.84 1.04 std deviation 0.47 0.64 0.89 1.11
std error 0.04 0.17 0.24 0.34 0.43 std error 0.19 0.26 0.36 0.45
400um 125 ul AN51 Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
 
125 ul AN51 = experiments with 125 μl AN51 antibody 
 
800r low 0 25 50 75 100 25 50 75 100
7/29/2005 2.12 2.89 3.26 3.64 2.89 0.77 1.19 1.64 0.90
8/3/2005 1.55 2.38 2.54 3.18 2.90 0.84 1.02 1.73 1.48
7/21/2005 2.06 4.34 4.20 4.77 4.83 2.28 2.20 2.85 2.99
7/15/2005 1.81 2.34 2.91 2.44 5.92 0.53 1.15 0.70 4.37
7/28/2005 2.07 3.76 1.88 2.45 3.13 1.68 -0.16 0.45 1.19
7/27/2005 3.57 4.40 4.42 5.15 3.24 0.83 0.91 1.74 -0.18
average 2.20 3.35 3.20 3.61 3.82 average 1.16 1.05 1.52 1.79
std dev 0.70 0.94 0.97 1.15 1.26 std deviation 0.68 0.75 0.86 1.63
std error 0.28 0.31 0.35 0.66
800r high 0 25 50 75 100 25 50 75 100
7/29/2005 2.12 3.88 3.73 10.75 21.00 1.77 1.67 8.94 19.78
7/21/2005 2.06 6.29 49.53 93.28 112.07 4.23 48.15 93.83 114.78
7/28/2005 2.07 1.43 1.56 23.60 36.73 -0.64 -0.49 22.19 36.23
8/3/2005 0.00 2.54 2.71 3.27 3.62 2.54 2.75 3.37 3.78
average 1.56 3.54 14.38 32.73 43.35 average 1.97 13.02 32.08 43.64
std dev 1.04 2.09 23.45 41.23 47.76 std deviation 2.02 23.46 41.92 49.24
std error 1.01 11.73 20.96 24.62
800r norm 0 25 50 75 100 25 50 75 100
7/13/2005 1.88 3.77 4.14 4.20 4.20 1.90 2.34 2.49 2.58
9/24/2003 1.80 4.46 4.56 6.85 5.78 2.67 2.85 5.33 4.34
10/1/2003 1.81 3.79 4.36 4.32 4.33 1.98 2.63 2.68 2.78
10/15/2003 2.18 5.40 5.03 5.24 4.89 3.22 2.95 3.27 3.01
10/16/2003 1.88 2.64 3.04 2.77 2.61 0.76 1.22 1.00 0.90
1/9/2004 1.32 4.43 5.66 7.39 7.41 3.11 4.45 6.37 6.55
1/14/2004 7.65 6.08 5.55 6.05 6.60 -1.57 -2.00 -1.36 -0.65
average 2.65 4.37 4.62 5.26 5.12 average 1.72 2.06 2.83 2.79
std dev 2.22 1.13 0.90 1.63 1.62 std deviation 1.68 2.03 2.58 2.31
std error 0.63 0.77 0.98 0.87
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
Passes Passes
 
800r low = low flow rate experiments with the 800 μm round orifice 
800r high = high flow rate experiments with the 800 μm round orifice 






Channel Hemolysis data: 
 
Channel 1
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/14/2003 0.75 1.19 1.12 2.31 2.07 0.44 0.39 1.62 1.41
11/17/2003 0.36 0.67 0.78 0.85 0.91 0.32 0.44 0.52 0.60
11/21/2003 0.52 1.86 3.27 2.59 3.01 1.33 2.80 2.14 2.62
11/24/2003 0.61 2.46 3.34 3.34 3.34 1.85 2.78 2.83 2.88
3/24/2003 1.47 4.00 6.34 6.46 5.36 2.53 4.96 5.18 4.13
3/31/2003 0.00 6.97 8.92 na na 6.97 9.05 na na
5/14/2004 1.10 2.04 2.55 2.58 2.92 0.94 1.51 1.58 2.01
average 0.69 2.74 3.76 3.02 2.94 average 2.06 3.13 2.31 2.27
std dev 0.48 2.14 2.91 1.87 1.48 std deviation 2.30 3.06 1.60 1.23
std error 0.87 1.15 0.65 0.50
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date nd flow (lpm 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/14/2003 0.75 0.86 1.80 1.46 0.85 0.11 1.08 0.75 0.14
11/24/2003 0.61 1.60 2.03 2.60 1.54 1.00 1.45 2.06 1.00
11/25/2003 0.51 0.77 1.23 2.19 2.27 0.27 0.74 1.74 1.86
11/25/2003 0.51 1.09 1.59 1.75 2.06 0.58 1.11 1.30 1.65
3/24/2004 1.47 3.58 4.62 5.41 5.13 2.10 3.22 4.09 3.89
5/14/2004 1.10 2.14 3.31 3.91 4.71 1.04 2.25 2.92 3.82
average 0.82 1.67 2.43 2.89 2.76 average 0.85 1.64 2.15 2.06
std dev 0.39 1.06 1.29 1.50 1.75 std deviation 0.72 0.93 1.20 1.51
std error 0.29 0.38 0.49 0.62
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/19/2004 1.25 4.42 5.11 5.45 6.15 3.18 3.97 4.43 5.29
5/20/2004 1.25 1.78 1.72 1.99 2.15 0.53 0.51 0.83 1.03
9/15/2004 1.21 2.63 3.91 4.82 5.34 1.42 2.78 3.81 4.47
Average 1.23 2.94 3.58 4.09 4.55 average 1.71 2.42 3.02 3.60
std dev 0.02 1.35 1.72 1.84 2.12 std deviation 1.35 1.76 1.92 2.26
std error 0.78 1.02 1.11 1.30
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
5/20/2004 1.54 3.14 1.57 2.92 4.14 1.60 0.06 1.50 2.86
5/19/2004 1.25 2.61 2.84 3.03 3.24 1.36 1.65 1.91 2.20
9/9/2004 1.48 2.18 2.46 3.21 3.50 0.70 1.03 1.86 2.24
Average 1.42 2.64 2.29 3.05 3.63 average 1.22 0.91 1.76 2.43
std dev 0.15 0.48 0.65 0.14 0.46 std deviation 0.47 0.80 0.22 0.37
std error 0.27 0.46 0.13 0.21
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/6/2004 1.25 2.73 4.38 3.26 2.10 1.48 3.21 2.14 0.98
12/8/2004 1.08 2.34 3.44 4.49 6.24 1.26 2.43 3.60 5.54
12/13/2004 1.22 3.16 4.98 5.29 7.17 1.94 3.86 4.28 6.40
12/22/2004 1.43 2.05 2.71 3.96 4.32 0.62 1.34 2.69 3.16
1/12/2005 1.00 2.82 3.51 3.81 3.91 1.81 2.58 2.96 3.15
1/14/2005 1.42 2.08 2.07 1.90 2.45 0.67 0.69 0.56 1.18
Average 1.23 2.53 3.52 3.78 4.36 average 1.30 2.35 2.70 3.40
std dev 0.17 0.45 1.06 1.15 2.02 std deviation 0.56 1.17 1.29 2.21
std error 0.20 0.41 0.46 0.78
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 





date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 2.70 4.61 4.93 7.20 2.60 1.91 2.33 4.79 0.06
10/26/2004 1.59 2.56 2.40 3.56 2.86 0.97 0.86 2.11 1.45
11/17/2004 1.63 3.92 5.51 7.57 9.30 2.29 3.99 6.24 8.25
11/19/2004 1.65 2.86 4.18 4.70 3.45 1.21 2.62 3.24 2.02
11/22/2004 1.14 3.55 4.39 5.86 6.97 2.40 3.33 4.96 6.26
Average 1.74 3.50 4.28 5.78 5.04 average 1.76 2.63 4.27 3.61
std dev 0.57 0.82 1.17 1.68 2.96 std deviation 0.64 1.18 1.61 3.48
std error 0.26 0.48 0.66 1.42
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
12/8/2004 1.08 1.39 1.53 1.94 1.50 0.31 0.48 0.94 0.52
12/13/2004 1.22 1.03 1.86 1.54 1.54 -0.19 0.68 0.38 0.41
12/22/2004 1.43 2.71 2.01 2.01 4.81 1.28 0.62 0.66 3.68
1/12/2005 1.00 1.11 1.17 1.39 1.82 0.11 0.19 0.44 0.93
1/14/2005 1.42 1.85 1.62 1.50 1.59 0.43 0.23 0.14 0.27
1/24/2005 1.62 1.86 1.98 1.85 2.17 0.24 0.39 0.30 0.68
Average 1.30 1.66 1.69 1.71 2.24 average 0.36 0.43 0.48 1.08
std dev 0.24 0.62 0.32 0.26 1.28 std deviation 0.50 0.20 0.29 1.29
std error 0.20 0.08 0.12 0.53
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
10/15/2004 2.70 3.64 4.73 5.58 4.95 0.94 2.12 3.11 2.56
11/12/2004 1.84 6.24 4.30 8.36 7.58 4.39 2.55 6.86 6.21
11/5/2004 2.66 2.98 4.00 3.63 4.19 0.32 1.42 1.12 1.79
11/17/2004 1.63 3.51 4.90 5.07 7.14 1.88 3.37 3.65 5.95
11/22/2004 1.14 2.00 2.74 3.46 5.10 0.85 1.65 2.46 4.28
10/26/2004 1.59 2.42 2.68 2.22 2.48 0.83 1.15 0.72 1.05
Average 1.93 3.46 3.89 4.72 5.24 average 1.54 2.04 2.98 3.64
std dev 0.62 1.50 0.97 2.15 1.89 std deviation 1.49 0.82 2.21 2.17
std error 0.61 0.33 0.90 0.89
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
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Valve Hemolysis data: 
 
low leaker
date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/29/2004 1.77 2.28 na na na 0.60 na na na
7/30/2004 3.49 1.61 4.68 4.20 4.46 -1.82 1.41 0.96 1.28
8/18/2004 1.45 3.07 4.07 4.45 4.82 1.62 2.62 3.00 3.37
9/10/2004 2.29 1.83 2.23 2.61 2.86 -0.46 -0.06 0.32 0.57
12/15/2004 1.28 2.16 na na na 0.88 na na na
1/10/2005 1.19 2.01 3.10 4.50 na 0.82 1.91 3.31 na
7/22/2005 1.87 2.26 2.41 3.38 3.14 0.39 0.55 1.51 1.28
7/12/2005 1.54 2.37 3.21 3.01 2.95 0.83 1.67 1.47 1.41
Average 1.86 2.20 3.29 3.69 3.65 average 0.36 1.35 1.76 1.58
std dev 0.75 0.43 0.95 0.80 0.92 std deviation 1.05 0.97 1.17 1.05
std error 0.35 0.37 0.44 0.43
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
7/28/2004 1.76 3.52 4.26 5.68 5.44 1.75 2.49 3.91 3.68
8/23/2004 0.14 1.62 2.29 2.33 2.74 1.47 2.14 2.19 2.60
8/2/2004 1.70 1.52 3.13 2.07 2.44 -0.18 1.43 0.37 0.74
12/20/2004 1.10 1.97 2.68 3.32 4.20 0.87 1.58 2.22 3.10
1/27/2005 1.52 1.78 2.11 2.44 2.97 0.26 0.59 0.92 1.44
Average 1.25 2.08 2.89 3.17 3.56 average 0.83 1.65 1.92 2.31
std dev 0.67 0.82 0.86 1.48 1.25 std deviation 0.81 0.73 1.37 1.21
std error 0.36 0.33 0.61 0.54
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
11/10/2004 1.72 2.66 2.83 3.00 3.45 0.94 1.11 1.28 1.73
11/15/2004 1.50 1.93 2.31 2.53 3.10 0.43 0.81 1.03 1.60
7/20/2005 1.55 2.06 2.59 2.32 2.50 0.51 1.04 0.77 0.95
Average 1.59 2.22 2.57 2.62 3.02 average 0.63 0.99 1.03 1.43
std dev 0.11 0.39 0.26 0.35 0.48 std deviation 0.27 0.16 0.26 0.42
std error 0.16 0.09 0.15 0.24
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 




date 0 min 15 min 30 min 45 min 60 min 15 min 30 min 45 min 60 min
9/22/2004 1.26 2.17 2.38 2.80 2.91 0.91 1.12 1.54 1.65
10/14/2004 2.40 3.61 4.51 4.83 4.81 1.21 2.11 2.43 2.41
10/25/2004 1.58 1.55 1.61 1.72 2.53 -0.03 0.03 0.14 0.94
10/27/2004 1.57 1.62 1.66 2.10 1.94 0.04 0.09 0.52 0.37
11/23/2004 1.17 1.53 2.57 2.62 3.98 0.37 1.40 1.45 2.81
12/3/2004 1.47 1.93 2.08 2.20 2.96 0.46 0.61 0.72 1.49
Average 1.58 2.07 2.47 2.71 3.19 average 0.49 0.89 1.13 1.61
std dev 0.44 0.80 1.07 1.11 1.04 std deviation 0.49 0.81 0.83 0.90
std error 0.20 0.33 0.34 0.37
Raw data, Hemoglobin concentration (mg/ml)
Initial value subtracted, adjusted for dilution and multiplied 
by 100 to obtain concentration in flow loop (mg/ml)
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35 then 92 187
time platelets time platelets time platelets APTT* flow (ml/min)
5 1.03 5 1.2 5 1.77
10 1.12 10 1.3 10 1.93 170
15 1.29 15 1.57 15 2.24 94.4 160
20 1.41 20 1.84 20 2.57 130
25 1.63 25 2.19 25 3
30 1.83 30 2.51 30 3.4 108.9 100
after flush 1.11 after flush 2.24 after flush 2.59
0.72 0.27 0.81
time platelets time platelets time platelets
norm (by initial 
Platelet #) norm, e11
5 0.31 5 0.93 5 0.96 0.002330097 0.23301
10 0.4 10 1.03 10 1.12 0.002718447 0.271845
15 0.57 15 1.3 15 1.43 0.003470874 0.347087
20 0.69 20 1.57 20 1.76 0.004271845 0.427184
25 0.91 25 1.92 25 2.19 0.005315534 0.531553
30 1.11 30 2.24 30 2.59 0.006286408 0.628641
*APTT was measured prior to heparin addition and then at 15 minute intervals during the experiment
initial
background
Rt 30x30 (proximal) Lft 30x30 (distal)
with background removed
Ctr 30x30








27 then 166.9 175
time platelets time platelets time platelets
norm (by initial 
Platelet #) norm, e11 APTT* flow, ml/min
3 0.93 3 1.51 3 2.01 0.005929204 0.59292 203
6 0.95 6 1.52 6 2.01 0.005929204 0.59292 192
9 0.99 9 1.55 9 2.1 0.00619469 0.619469 186
12 1 12 1.55 12 2.08 0.006135693 0.613569
15 0.97 15 1.55 15 2.06 0.006076696 0.60767 138.9
18 0.99 18 1.58 18 2.08 0.006135693 0.613569
21 1 21 1.63 21 2.14 0.006312684 0.631268 196
24 1 24 1.61 24 2.12 0.006253687 0.625369
27 1.06 27 1.68 27 2.19 0.006460177 0.646018
30 1 30 1.7 30 2.19 0.006460177 0.646018 144
33 0.98 33 1.68 33 2.1 0.00619469 0.619469
36 0.99 36 1.68 36 2.1 0.00619469 0.619469
39 1 39 1.76 39 2.19 0.006460177 0.646018
42 0.95 42 1.85 42 2.17 0.00640118 0.640118
45 1.02 45 1.9 45 2.26 0.006666667 0.666667 146.4 200
48 1.05 48 1.96 48 2.34 0.006902655 0.690265
51 1.01 51 2.01 51 2.32 0.006843658 0.684366
54 1.08 54 2.05 54 2.46 0.007256637 0.725664
57 1.04 57 2.08 57 2.41 0.007109145 0.710914
60 1.06 60 2.16 60 2.5 0.007374631 0.737463 150.4
after flush 0.28 after flush 0.9 after flush 0.9
0.78 1.26 1.6
time platelets time platelets time platelets
norm (by initial 
Platelet #) norm, e11
divide by flow rate 
(platelets/l/min)
3 0.15 3 0.25 3 0.41 0.00120944 0.120944 2.05
6 0.17 6 0.26 6 0.41 0.00120944 0.120944 2.05
9 0.21 9 0.29 9 0.5 0.001474926 0.147493 2.5
12 0.22 12 0.29 12 0.48 0.001415929 0.141593 2.4
15 0.19 15 0.29 15 0.46 0.001356932 0.135693 2.3
18 0.21 18 0.32 18 0.48 0.001415929 0.141593 2.4
21 0.22 21 0.37 21 0.54 0.00159292 0.159292 2.7
24 0.22 24 0.35 24 0.52 0.001533923 0.153392 2.6
27 0.28 27 0.42 27 0.59 0.001740413 0.174041 2.95
30 0.22 30 0.44 30 0.59 0.001740413 0.174041 2.95
33 0.2 33 0.42 33 0.5 0.001474926 0.147493 2.5
36 0.21 36 0.42 36 0.5 0.001474926 0.147493 2.5
39 0.22 39 0.5 39 0.59 0.001740413 0.174041 2.95
42 0.17 42 0.59 42 0.57 0.001681416 0.168142 2.85
45 0.24 45 0.64 45 0.66 0.001946903 0.19469 3.3
48 0.27 48 0.7 48 0.74 0.002182891 0.218289 3.7
51 0.23 51 0.75 51 0.72 0.002123894 0.212389 3.6
54 0.3 54 0.79 54 0.86 0.002536873 0.253687 4.3
57 0.26 57 0.82 57 0.81 0.002389381 0.238938 4.05
60 0.28 60 0.9 60 0.9 0.002654867 0.265487 4.5
*APTT was measured prior to heparin addition and then at 15 minute intervals during the experiment
background











time platelets time platelets time platelets
3 0.50 3 0.69 3 0.96
6 0.52 6 0.71 6 1.00
9 0.54 9 0.70 9 1.00
12 0.50 12 0.72 12 1.00
15 0.53 15 0.69 15 1.03
18 0.52 18 0.70 18 0.99
21 0.57 21 0.68 21 1.02
24 0.52 24 0.70 24 1.01
27 0.54 27 0.72 27 1.03
30 0.53 30 0.70 30 0.99
33 0.53 33 0.75 33 1.03
36 0.57 36 0.73 36 1.07
39 0.57 39 0.73 39 1.05
42 0.60 42 0.77 42 1.10
45 0.63 45 0.72 45 1.10
48 0.67 48 0.77 48 1.18
51 0.63 51 0.77 51 1.15
54 0.69 54 0.83 54 1.22
57 0.73 57 0.84 57 1.24
60 0.74 60 0.88 60 1.30
after flush 0.51 after flush 0.61 after flush 0.91
0.23088 0.268423 0.38654
35.4 then 78 204
time platelets time platelets time platelets
norm (by initial 
Platelet #) norm, e11 APTT* flow, ml/min
3 0.27333 3 0.41792 3 0.57386 0.001863182 0.186318
6 0.28705 6 0.4385 6 0.61159 0.001985682 0.198568
9 0.3042 9 0.43164 9 0.61502 0.001996818 0.199682
12 0.27333 12 0.45565 12 0.61502 0.001996818 0.199682
15 0.30077 15 0.42135 15 0.63903 0.002074773 0.207477 88.4
18 0.29391 18 0.42821 18 0.6013 0.001952273 0.195227
21 0.33507 21 0.41449 21 0.62874 0.002041364 0.204136
24 0.29391 24 0.43164 24 0.62188 0.002019091 0.201909
27 0.3042 27 0.44879 27 0.64246 0.002085909 0.208591
30 0.30077 30 0.43164 30 0.6013 0.001952273 0.195227 84.9
33 0.29734 33 0.47966 33 0.64589 0.002097045 0.209705
36 0.3385 36 0.46251 36 0.68019 0.002208409 0.220841
39 0.33507 39 0.46594 39 0.65961 0.002141591 0.214159
42 0.36937 42 0.49681 42 0.71106 0.002308636 0.230864
45 0.39681 45 0.45222 45 0.71792 0.002330909 0.233091 89.4
48 0.43797 48 0.50367 48 0.78995 0.002564773 0.256477
51 0.40024 51 0.50024 51 0.75908 0.002464545 0.246455
54 0.46198 54 0.55855 54 0.83454 0.002709545 0.270955
57 0.49628 57 0.56884 57 0.85169 0.002765227 0.276523
60 0.51 60 0.61 60 0.91 0.002954545 0.295455 93.9
*APTT was measured prior to heparin addition and then at 15 minute intervals during the experiment











Baboon 23871 Computer NQ Plt Cnt Pre 243 Whole Blood 244296
Date 2/5/2004 Data Partition Plt Cnt Post 242 Plasma 40120
Camera G E WBC 3.9 Fraction 88.5%
Study Description ROI (device) Hct Pre 29.80% Free 11.5%
Anna's 800µ slit Window 10% Hct Post 29.50% Volume (cc) 3
60u/kg bolus heparin + 50u/kg/hr infusion Energy > 172 Flow  (ml/min) 160 open
> 247 Blood Std CPM 3126
Collimator > low Bkg CPM 982
med Bkgd CPM 1 2144
Iodine Matrix word CPM In-plts 1896.8239
Remarks 256 > byte CPM/ml In-plts 632.27464
 FINAL 0.0003843
ROI ROI ROI ROI
Time 6.6 x 78.6 CPM  Time CPM  
Min CPM CPM bkg Thrombus Standard Plts x109
norm (by initial 
Platelet #) norm, e11 Min CPM CPM bkg Thrombus Standard Plts x109
3 952 952 0.00 0.000384 0.00 0 0 APTT sec T results (ng/mL)
6 1018 952 66.00 0.000384 0.03 0.000104727 0.010473 Pre 30 3.80
9 1056 952 104.00 0.000384 0.04 0.000165025 0.016502 8min 179.8
12 1076 952 124.00 0.000384 0.05 0.00019676 0.019676 15min 172.9
15 1001 952 49.00 0.000384 0.02 7.77521E-05 0.007775 0time start of shunt
18 1053 952 101.00 0.000384 0.04 0.000160264 0.016026 15 198 3.9
21 1109 952 157.00 0.000384 0.06 0.000249124 0.024912 30 222 3.80
24 987 952 35.00 0.000384 0.01 5.55372E-05 0.005554 45 238 4.40
27 1002 952 50.00 0.000384 0.02 7.93388E-05 0.007934 60 230 5.00
30 993 952 41.00 0.000384 0.02 6.50579E-05 0.006506
33 1095 952 143.00 0.000384 0.05 0.000226909 0.022691
36 1021 952 69.00 0.000384 0.03 0.000109488 0.010949
39 1092 952 140.00 0.000384 0.05 0.000222149 0.022215
42 1070 952 118.00 0.000384 0.05 0.00018724 0.018724
45 1137 952 185.00 0.000384 0.07 0.000293554 0.029355
48 1130 952 178.00 0.000384 0.07 0.000282446 0.028245
0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00
95 0.00 0.00 0.00 0.00
100 0.00 0.00 0.00 0.00
105 0.00 0.00 0.00 0.00
110 0.00 0.00 0.00 0.00
115 0.00 0.00 0.00 0.00
120 0.00 0.00 0.00 0.00
125 0.00 0.00 0.00 0.00
130 0.00 0.00 0.00 0.00
135 0.00 0.00 0.00 0.00
140 0.00 0.00 0.00 0.00
145 0.00 0.00 0.00 0.00




Baboon 24080 Computer NQ Plt Cnt Pre 426 Whole Blood 818798
Date 5/19/2004 Data Partition Plt Cnt Post 407 Plasma 48003
Camera G E WBC 10.6 Fraction 96.1%
Study Description ROI (device) Hct Pre 33.00% Free 3.9%
Anna's 800µ slit Window 10% Hct Post 32.90% Volume (cc) 3
Energy > 172 Flow  (ml/min) 260open
50u/kg bolus heparin + 40u/kg/hr infusion > 247 Blood Std CPM 3625
Collimator > low Bkg CPM 292
med Bkgd CPM 1 3333
Iodine-no Matrix word CPM In-plts 3202.0813
Remarks 256 > byte CPM/ml In-plts 1067.3604
 FINAL 0.0003991
ROI ROI ROI ROI
Time 6.6 x 78.6 CPM  Time CPM  
Min CPM CPM bkg Thrombus Standard Plts x109 Min CPM CPM bkg Thrombus Standard Plts x109
3 952 -952.00 0.000384 -0.37 5 1696 893 803.00 0.000399 0.32
6 952 -952.00 0.000384 -0.37 10 1891 893 998.00 0.000399 0.40
9 952 -952.00 0.000384 -0.37 15 2311 893 1418.00 0.000399 0.57
12 952 -952.00 0.000384 -0.37 20 2783 893 1890.00 0.000399 0.75
15 952 -952.00 0.000384 -0.37 25 3411 893 2518.00 0.000399 1.00
18 952 -952.00 0.000384 -0.37 30 3786 893 2893.00 0.000399 1.15
21 952 -952.00 0.000384 -0.37 35 4441 893 3548.00 0.000399 1.42
24 952 -952.00 0.000384 -0.37 40 4978 893 4085.00 0.000399 1.63
27 952 -952.00 0.000384 -0.37 45 5602 893 4709.00 0.000399 1.88
30 952 -952.00 0.000384 -0.37 50 6116 893 5223.00 0.000399 2.08
33 952 -952.00 0.000384 -0.37 55 6748 893 5855.00 0.000399 2.34
36 952 -952.00 0.000384 -0.37 60 7405 893 6512.00 0.000399 2.60
39 952 -952.00 0.000384 -0.37
42 952 -952.00 0.000384 -0.37 Rinsed Static Image
45 952 -952.00 0.000384 -0.37 6512 58 6454.00 0.000399 2.58
48 952 -952.00 0.000384 -0.37
0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00
95 0.00 0.00 0.00 0.00
100 0.00 0.00 0.00 0.00
105 0.00 0.00 0.00 0.00
110 0.00 0.00 0.00 0.00
115 0.00 0.00 0.00 0.00
120 0.00 0.00 0.00 0.00
125 0.00 0.00 0.00 0.00
130 0.00 0.00 0.00 0.00
135 0.00 0.00 0.00 0.00
140 0.00 0.00 0.00 0.00
145 0.00 0.00 0.00 0.00




Baboon 24568 Computer NQ Plt Cnt Pre 364 Whole Blood 342949
Date 7/14/2005 Data Partition 620 Plt Cnt Post 380 Plasma 49231
Camera G E WBC 7.1 Fraction 90.2%
Study Description ROI (device) Hct Pre 31.50% Free 9.8%
Anna's 800µ slit Window 10% Hct Post 33.90% Volume (cc) 3
50u/kg heparin + 40u/kg/hr infusion Energy > 172 Flow  (ml/min) 200 open
Heparin started 20min pre shunt > 247 Blood Std CPM 1109
Collimator > low Bkg CPM 179
med Bkgd CPM 1 930
Iodine No Matrix word CPM In-plts 838.55023
Remarks 256 > byte CPM/ml In-plts 279.51674
 FINAL 0.0013022
3.5cm region 6cm high ROI ROI
Time CPM  Time CPM  
Min CPM CPM bkg Thrombus Standard Plts x109 Plt norm Min CPM CPM bkg Thrombus Standard Plts x109
3 1432 1432 0.00 0.001302 0.00 0 post study device 2693 1432 1261.00 0.001302 1.64
6 1446 1433 13.00 0.001302 0.02 0.0044542 intact but rinsed
9 1455 1434 21.00 0.001302 0.03 0.0071953 Disc flat on camera 3478 76 3402.00 0.001302 4.43
12 1493 1435 58.00 0.001302 0.08 0.0198726 Disc flat prox side 0.00
15 1571 1436 135.00 0.001302 0.18 0.0462553 scraped clean 3064 76 2988.00 0.001302 3.89
18 1695 1437 258.00 0.001302 0.34 0.0883989 0.00 0.0001 0.00
21 1709 1438 271.00 0.001302 0.35 0.0928532 0.00 0.0001 0.00
24 1749 1439 310.00 0.001302 0.40 0.1062158 0.00 0.0001 0.00
27 1897 1440 457.00 0.001302 0.60 0.1565826 0.00 0.0001 0.00
30 2069 1441 628.00 0.001302 0.82 0.2151726 0.00 0.0001 0.00
33 2099 1442 657.00 0.001302 0.86 0.2251089 0.00 0.0001 0.00
36 2354 1443 911.00 0.001302 1.19 0.3121374 0.00 0.0001 0.00
39 2432 1444 988.00 0.001302 1.29 0.33852
42 2587 1445 1142.00 0.001302 1.49 0.3912853
45 2632 1446 1186.00 0.001302 1.54 0.4063611
48 2902 1447 1455.00 0.001302 1.89 0.4985289
51 3089 1448 1641.00 0.001302 2.14 0.5622584
54 3238 1449 1789.00 0.001302 2.33 0.6129679
57 3460 1450 2010.00 0.001302 2.62 0.6886895
60 3529 1451 2078.00 0.001302 2.71 0.7119884  
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B.5. Histology images 
 
 




FIGURE B.5.1. Low leaker prototype valve, region 2 of thrombus originating in the 
hinge region. 40X magnification. 
 
 
FIGURE B.5.2. Low leaker prototype valve, region 2 of thrombus originating in the 
hinge region. 20X magnification. 
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FIGURE B.5.3. Low leaker prototype valve, region 2 of thrombus originating in the 
hinge region. 40X magnification. 
 
 
FIGURE B.5.4. Low leaker prototype valve, region 2 of thrombus originating in the 
















FIGURE B.5.5. 200 μm round orifice. 40X magnification. 
 
 
FIGURE B.5.6. 200 μm round orifice. 20X magnification. 
 
 





FIGURE B.5.8. Channel 1 thrombus. 20X . 
 
 
FIGURE B.5.9. Channel 3 upstream thrombus. 40X. 
 
 




FIGURE B.5.11. Low leaker thrombus, region 3A. 40X. 
 
 
FIGURE B.5.12. Low leaker thrombus, region 3B. 40X 
 
 




FIGURE B.5.14. Low leaker thrombus, region 2. 40X. 
 
 
FIGURE B.5.15. Low leaker thrombus, region 4. 10X 
 
 




FIGURE B.5.17. Low leaker thrombus, region 1. 4X 
 
 
FIGURE B.5.18. Low leaker thrombus, region 1. 40X 
 
 




FIGURE B.5.21. Low leaker thrombus, region 2-left. 40X 
 
 
FIGURE B.5.22. Low leaker thrombus, region 2. 10X 
 
 




FIGURE B.5.24. Low leaker thrombus, region 2-bottom right. 40X 
 
 
FIGURE B.5.25. Low leaker thrombus, region 2-bottom left. 40X. 
 
 




FIGURE B.5.27. Low leaker thrombus, region 3. 40X. 
 
 
FIGURE B.5.28. Low leaker thrombus, region 4. 10X 
 
 




FIGURE B.5.30. Low leaker thrombus, region 4-right. 40X. 
 
 
FIGURE B.5.31. Channel 3 thrombus-upstream. 10X 
 
 




FIGURE B.5.33. Channel 3 thrombus-downstream. 4X 
 
 
FIGURE B.5.34. Channel 3 thrombus-downstream, top. 40X. 
 
 




FIGURE B.5.36. Channel 1 thrombus. 20X magnification. 
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FIGURE B.5.37. Channel 3 upstream thrombus. 40X. 
 
 



















FIGURE B.5.39. Low leaker thrombus, region 3A. 40X. 
 
 
FIGURE B.5.40. Low leaker thrombus, region 3B. 40X 
 
 








FIGURE B.5.43. Low leaker thrombus, region 1. 40X 
 








FIGURE B.5.46. Low leaker thrombus, region 2. 20X. 
 
 




FIGURE B.5.48. Low leaker thrombus, region 4. 20X. 
 
 
FIGURE B.5.49. Channel 3 thrombus-upstream. 40X 
 
 
FIGURE B.5.50. Channel 3 thrombus-downstream. 40X. 
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FIGURE B.5.51. Low leaker prototype valve, region 2 of thrombus originating in the 
hinge region. 40X magnification. 
 
 
FIGURE B.5.52. Low leaker prototype valve, region 2 of thrombus originating in the 





















FIGURE B.5.54. 200 μm round orifice. 20X magnification. 
 
 














C.1. Velocity Vector Plots 
 
 
FIGURE C.1.1. Average velocity vector field downstream of the 400 μm round orifice. 




FIGURE C.1.2. Average velocity vector field downstream of the 400 μm round orifice. 
The pulse separation was 15 μs. Velocity in m/s is color coded according to the legend. 
 
 
FIGURE C.1.3. Average velocity vector field downstream of the 400 μm round orifice. 




FIGURE C.1.4. Average velocity vector field downstream of the 400 μm round orifice. 
The pulse separation was 15 μs. Velocity in m/s is color coded according to the legend. 
 
 
FIGURE C.1.5. Average velocity vector field downstream of the 400 μm round orifice. 




FIGURE C.1.6. Average velocity vector field upstream and downstream of the 400 μm 
round orifice. The pulse separation was 250 μs. Velocity in m/s is color coded according 
to the legend. 
 
 
FIGURE C.1.7. Average velocity vector field downstream of the 800 μm round orifice. 




FIGURE C.1.8. Average velocity vector field downstream of the 800 μm round orifice. 
The pulse separation was 10 μs. Velocity in m/s is color coded according to the legend. 
 
 
FIGURE C.1.9. Average velocity vector field downstream of the 800 μm round orifice 





FIGURE C.1.10. Average velocity vector field upstream and downstream of the 1200 μm 




FIGURE C.1.11. Average velocity vector field downstream of the 200 μm slit orifice. 




FIGURE C.1.12. Average velocity vector field downstream of Channel 4. The pulse 
separation was 10 μs. Velocity in m/s is color coded according to the legend. 
 
 
FIGURE C.1.13. Average velocity vector field downstream of Channel 8. The pulse 




C.1.14. Average velocity vector field downstream of Channel 8. The pulse separation was 
10 μs. Velocity in m/s is color coded according to the legend. 
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C.2. PReS Plots 
 
 
FIGURE C.2.1. Principal Reynolds stress (PReS) field for the 400 μm round orifice jet. 
Pulse separation was 15 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 
according to the legend. 
 
 
FIGURE C.2.2. Principal Reynolds stress (PReS) field for the 400 μm round orifice jet. 
Pulse separation was 15 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 




FIGURE C.2.3. Principal Reynolds stress (PReS) field for the 400 μm round orifice jet. 
Pulse separation was 15 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 
according to the legend. 
 
 
FIGURE C.2.4. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet. 
Pulse separation was 400 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 




FIGURE C.2.5. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet. 
Pulse separation was 200 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 
according to the legend. 
 
 
FIGURE C.2.6. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet. 
Pulse separation was 5 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 




FIGURE C.2.7. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet 
(1500 RPM). Pulse separation was 5 μs. PReS units are dyn/cm2. PRes magnitudes are 
color coded according to the legend. 
 
 
FIGURE C.2.8. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet. 
Pulse separation was 10 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 




FIGURE C.2.9. Principal Reynolds stress (PReS) field for the 800 μm round orifice jet. 
Pulse separation was 8 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 
according to the legend. 
 
 
FIGURE C.2.10. Principal Reynolds stress (PReS) field for the 1200 μm round orifice 
jet. Pulse separation was 10 μs. PReS units are dyn/cm2. PRes magnitudes are color 




FIGURE C.2.11. Principal Reynolds stress (PReS) field for the 1200 μm round orifice 
jet. Pulse separation was 75 μs. PReS units are dyn/cm2. PRes magnitudes are color 
coded according to the legend. 
 
 
FIGURE C.2.12. Principal Reynolds stress (PReS) field for the 200 μm slit orifice jet. 
Pulse separation was 5 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 




FIGURE C.2.13. Principal Reynolds stress (PReS) field for the Channel 8 jet. Pulse 
separation was 10 μs. PReS units are dyn/cm2. PRes magnitudes are color coded 
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